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Zusammenfassung  
Einleitung: Beschreibung der Technologie und der 
Vergleichstherapien 
Die Irreversible Elektroporation (IRE) ist ein nicht-thermisches ablatives Ver-
fahren, bei dem kurze, aber starke elektrische Felder mittels präzise platzier-
ter Nadeln und mit vom Computer gesteuerte Potentialdifferenzen zwischen 
diesen Nadeln erzeugt werden. Durch Ablation der Zellen mittels IRE sterben 
die Zellen einen apoptotischen Zelltod. Aufgrund des meist nicht-thermischen 
Effekts wird erwartet, dass die IRE zu weniger Schäden an angrenzenden 
Strukturen führt als andere thermische Ablationsansätze (Radiofrequenz-
ablation [RFA], Mikrowellenablation [MWA] und Kryoablation). So können 
Pankreas- und Lebertumore, die in der Nähe von großen Blutgefäßen oder an-
deren empfindlichen Strukturen wie Nerven und Gallenweg lokalisiert sind, 
ohne sie zu schädigen, entfernt werden. 
IRE kann perkutan, laparoskopisch oder im Rahmen einer offenen Operation 
(Laparotomie) durchgeführt werden. In allen Fällen werden mehrere Elekt-
roden um den Zieltumor gelegt, wobei manchmal auch eine Sonde in der Mitte 
platziert werden kann. Die Sonde wird unter Bildführung mittels Ultraschall 
(US) oder Computertomographie (CT) geführt. Der/die PatientIn benötigt 
eine Vollnarkose mit tiefer Sedierung und vollständiger Muskelentspannung, 
mit Herzsynchronisation während der Abgabe des Hochspannungsstroms. 
Das einzige kommerziell erhältliche IRE-Gerät ist das NanoKnife System® 
(AngioDynamics®). Dieses System hat das Zeichen Conformité Européenne 
(CE) für Zellmembran-Elektroporation und die Zulassung der US Food and 
Drug Administration (FDA) für die Weichgewebeablation. Die Zulassungen 
beziehen sich nicht auf spezifische Therapie oder Behandlung bestimmter 
Krankheiten.   
Zielgruppe und Komparatoren bei Bauchspeicheldrüsenkrebs und Leberkrebs 
Die Zielgruppe für IRE bei Bauchspeicheldrüsenkrebs sind PatientInnen mit 
inoperablen, lokal fortgeschrittenen Pankreastumoren. Die Standardtherapie 
für diese PatientInnen ist Chemotherapie mit oder ohne Strahlentherapie 
(Chemoradiotherapie [CRT]). Die Strahlentherapie (RT) wird typischerweise 
auch als palliative Option angeboten, da sie Schmerzen reduziert, aber keine 
positiven Auswirkungen auf das Überleben nachgewiesen wurden. 
Die Zielgruppe für IRE bei Leberkrebs sind PatientInnen mit inoperablem pri-
märem oder sekundärem Leberkrebs, die eine Kontraindikation zur Thermo-
ablation haben. Zu den häufigsten Behandlungsmöglichkeiten gehören die 
transarterielle Chemoembolisation (TACE), Multikinase-Inhibitoren wie So-
rafenib und Levatinib sowie die palliative und symptomatische Therapie. Ty-
pischerweise wird TACE für PatientInnen mit Erkrankungen im mittleren Sta-
dium angeboten, die die Leberfunktion erhalten haben, während Sorafenib als 
Standard der systemischen Erstlinientherapie für PatientInnen in fortge-
schrittenem Stadium und erhaltener Leberfunktion angesehen werden kann. 
PatientInnen, die an der Erkrankung im Endstadium leiden und nicht für eine 
Transplantation in Frage kommen, kommen möglicherweise nur für eine un-
terstützende symptomatische Behandlung in Frage. Die Anwendung von 
Strahlentherapie wurde auch in verschiedenen Stadien von Leberkrebs be-
richtet und wird speziell zur Schmerzlinderung bei PatientInnen mit Kno-
chenmetastasen empfohlen.  
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Gesundheitsproblem: Bauchspeicheldrüsenkrebs und Leberkrebs 
Bauchspeicheldrüsenkrebs ist eine der tödlichsten Krebsarten, mit mehr als 
458.918 neuen Fällen (2018), die weltweit geschätzt wurden. Der Krebs 
schreitet schnell voran und wird oft erst im fortgeschrittenen Stadium diag-
nostiziert. Es wird geschätzt, dass zum Zeitpunkt der Diagnose etwa 40% der 
Fälle mit lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (LAPC) und wei-
tere 40% mit Metastasierung diagnostiziert werden.  
Die Zielpopulation in dieser Bewertung umfasst PatientInnen, bei denen eine 
nicht metastasierte, aber inoperable Erkrankung aufgrund der Beteiligung 
des Zöliakie-Stammes oder der oberen mesenterialen Arterie diagnostiziert 
wurde, die nach den Richtlinien des National Comprehensive Cancer Network 
(NCCN) als LAPC oder nach den Kriterien des American Joint Committee on 
Cancer (AJCC) als Stufe III eingestuft werden. Wiederkehrende Erkrankungen 
werden ebenfalls berücksichtigt. 
Leberkrebs ist weltweit die zweithäufigste Todesursache durch Krebs. 2015 
wurden 850.000 neue Fälle diagnostiziert und 810.000 Todesfälle gezählt. 
Das Hepatozelluläre Karzinom (HCC) ist die häufigste Form von Leberkrebs 
und macht 90% aller primären Krebsarten der Leber aus. Neben primären Le-
bertumoren - in den meisten Fällen geht dem Auftreten von primärem Leber-
krebs eine Leberzirrhose voraus - sind Metastasen bei PatientInnen mit ext-
rahepatischer Neoplasie - oft ein kolorektales Adenokarzinom - eine häufige 
Ursache für die Erkrankung.  
Die Zielpopulation in dieser Bewertung umfasst PatientInnen mit inoperab-
lem (primärem oder sekundärem) Leberkrebs mit einer Kontraindikation für 
die thermische Ablation (wegen des Risikos von Kollateralschäden an Gallen, 
Gefäß- oder anderen Strukturen durch Wärmeeinwirkung). 
 
Methoden 
Im September 2018 wurde eine systematische Literaturrecherche in ver-
schiedenen Datenbanken durchgeführt:  Centre for Research and Dissemina-
tion (CRD) Database, Cochrane Library (Wiley), Embase (OVID), Medline 
(PubMed), Web of Science (Web of Knowledge) und Scopus (Stand Januar 
2019), gefolgt von einer manuellen Suche in der Referenzliste von relevanten 
Studien. In Guideline Datenbanken wurden relevante Leitlinien zur aktuelle 
Nutzung der Technologie IRE gesucht: Guidelines International Network 
[GIN]-Datenbank, Trip-Datenbank, PubMed Central [PMC], CMA Infobase und 
Google Scholar. Laufende klinische Studien und Forschungsprojekte wurden 
über Clinicaltrials.gov, das EU Clinical Registry und die International Clinical 
Trials Registry Platform (ICTRP) gefunden. 
Der einzige zum Zeitpunkt der Suche identifizierte Hersteller (AngioDyna-
mics®) wurde kontaktiert und gebeten, die Kurzfassung der Submissionsda-
tei auszufüllen und zu bestätigen, dass es sich bei dem Produkt um eine CE-
gekennzeichnete Technologie handelt und dass es sich um das einzige Pro-
dukt des Unternehmens handelt, das für diese Bewertung relevant ist. 
Das Autorenteam screente die Titel und Abstracts nach vordefinierten Krite-
rien, überprüfte die Volltexte der potenziell relevanten Artikel und schloss 
letztendlich auf Grundlage von Scoping-Fragen die relevanten Studien ein. Für 
die Bereiche klinische Wirksamkeit und Sicherheit wurden die Daten von 
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zwei AutorInnen unabhängig voneinander extrahiert und vom Ko-Autor auf 
Konsistenz und Genauigkeit überprüft. Diskrepanzen zwischen den AutorIn-
nen wurden durch Diskussion und Konsultation mit dem Ko-Autor bis zur Ei-
nigung gelöst. 
Das Risiko einer Verzerrung auf Studienebene wurde anhand der 20-Krite-
rien-Checkliste des Institute of Health Economics (IHE) für einarmige Studien 
(Fallserien) und des Risk of Bias in Nonrandomised Studies of Interventions 
(ROBINS-I) für nicht-randomisierte kontrollierte Studien (Non-RCTs) bewer-
tet. Für die technischen Merkmale der Technologie wurde kein Qualitätsbe-
wertungsinstrument verwendet, obwohl die Informationen durch Vergleich 
und Gegenüberstellung von Informationen aus verschiedenen Quellen (Her-
steller, Bibliographien, offizielle Webseiten und allgemeine Internetrecher-
chen) validiert wurden. Danach wurden die Informationen zusammengefasst. 
Die Qualität der Evidenz wurde nach dem GRADE-System (Grading of Recom-
mendations, Assessment, Development and Evaluation) bewertet und zusam-
mengefasst. Eine Metaanalyse war methodisch nicht möglich, da die Studien 
sehr unterschiedlich sind, unter anderem in Bezug auf Populationsmerkmale, 
Tumorgröße, Behandlungen vor, während und nach der IRE und Dauer der 
Nachbeobachtung. Dementsprechend wurde eine narrative Synthese der Da-
ten mit Hilfe von deskriptiven Statistiken durchgeführt. 
Zwei einzelne PatientInnen waren an der Bewertung beteiligt. Die PatientIn-
nen wurden durch die Abteilung für Patienten-/Bürgerpflegedienste (Servi-
cio de Atención ao Ciudadán e ao paciente) des Galizischen Gesundheitswe-
sens (SERGAS) identifiziert. PatientInnen mit Bauchspeicheldrüsen- oder Le-
berkrebs, die mit anderen Methoden behandelt wurden (da sie Erfahrungen 
mit der Krankheit und mit Behandlungsverfahren im Allgemeinen hatten) wa-
ren dazu eingeladen. 
 
Ergebnisse 
Verfügbare Evidenz 
Wirksamkeit 
Die systematische Literaturrecherche identifizierte 15 Beobachtungsstudien, 
die die Auswahlkriterien erfüllten, acht für Bauchspeicheldrüsenkrebs und 
sieben für Leberkrebs. Es wurden keine RCTs gefunden. Eine der Studien, die 
für Bauchspeicheldrüsenkrebs durchgeführt wurde, war ein (zweiarmiger) 
non-RCT, an dem 21 PatientInnen teilnahmen, die die Intervention IRE erhiel-
ten, mit einem medianen Follow-up von 8 Monaten.  Die 32 PatienInnten in 
der Kontrollgruppe erhielten eine Form von nicht-kurativem chirurgischem 
Eingriff (nur Laparotomie, nicht-radikuläre Resektion, Bypassoperation, 
Cholezystektomie oder perkutane Biopsie). Die restlichen sieben prospekti-
ven einarmigen Beobachtungsstudien umfassten 226 PatientInnen, die mit 
IRE behandelt wurden. Sechs von ihnen hatten eine mediane Nachbeobach-
tung von ≤12 Monaten. Die längste Nachbeobachtungszeit betrug 28 Monate. 
Für Leberkrebs wurden sieben prospektive einarmige Studien mit 151 Pati-
entInnen identifiziert: es wurden 220 mit IRE behandelten Läsionen behan-
delt. Die durchschnittliche Nachbeobachtungszeit betrug ≤18 Monate in fünf 
dieser Studien und das Maximum betrug 24 Monate. 
 
RoB-Bewertungen: 
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Sicherheit 
Bei Bauchspeicheldrüsenkrebs unterscheiden sich die eingeschlossenen Stu-
dien nicht von jenen zur Wirksamkeit; bei Leberkrebs wurde eine Studie nicht 
eingeschlossen, da keine Sicherheitsergebnisse gemeldet wurden.  
Klinische Wirksamkeit 
Bauchspeicheldrüsenkrebs 
Laut der einzigen Vergleichsstudie (non-RCT) unterschied sich das mediane 
Gesamtüberleben (OS) für PatientInnen nach IRE nicht signifikant zwischen 
Behandlungs- und Kontrollgruppe (10,03 versus 9,3 Monate; p = 0,053). Die 
Lebensqualität (QoL) nach IRE verringerte sich langsam, ohne aber statistisch 
signifikante Unterschiede zwischen den Gruppen zu zeigen. Nach der Defini-
tion des "Erfolgs des Verfahrens" im PICO (vgl. Hauptbericht) würden alle mit 
IRE behandelten PatientInnen als erfolglos behandelt definiert werden (die 
Größe des Tumors hat sich nach IRE nicht verändert). 
Das mediane Überleben nach IRE basierend auf Kaplan-Meier-Schätzungen 
lag in vier der einarmigen Studien zwischen 4,3 und 12 Monaten. Eine Studie 
berichtete von einem Überleben von 22,6 Monaten. Das Überleben nach 3 Mo-
naten betrug ≥90% in vier einarmigen Studien mit verfügbaren Daten. Nach 
6 Monaten lag die Überlebensrate zwischen 50% (95% Konfidenzintervall[CI] 
18.36, 75.32) und 100% (CI nicht angegeben). Nach 12 Monaten lag die Über-
lebensrate zwischen 20% (95% CI 3.09, 47.47) und 90% (95% CI 65.60, 
97.40). Die einzigen beiden Studien, die über 12 Monate hinaus berichteten, 
hatten Überlebensraten von 13,6% (95% CI 2.33, 34.71) nach 18 Monaten 
und 37% nach 24 Monaten. 
Nur drei Studien lieferten Daten zur Berechnung des OS ab dem Zeitpunkt der 
Diagnose. Der Median des OS in diesen Studien variierte zwischen 12,5 Mona-
ten und 17,5 Monaten. Die Überlebensrate nach 3 und 6 Monaten in den bei-
den Studien, für die diese Berechnung möglich war, betrug 100%. Die jeweili-
gen Raten betrugen 60% (95% CI 25.27, 82.72) und 79.2% (95% CI 56.98, 
90.75) nach 12 Monaten, 50% (95% CI 29.10, 67.76) und 50% (95% CI 18.36, 
75.32) nach 18 Monaten und 13.9% (95% CI 3.54, 31.14) und 30% (95% CI 
7.11, 57.79) nach 24 Monaten. 
Die drei Studien, die über das progressionsfreie Überleben (PFS) nach IRE be-
richteten, zeigten ein Median OS zwischen 3,2 Monaten und 15,4 Monaten. Die 
QoL wurde nur in zwei der einarmigen Studien berücksichtigt: in beiden Stu-
dien ging die QoL zurück.  
Leberkrebs 
Das mittlere Gesamtüberleben nach IRE wurde nur aus einer Studie berichtet 
und betrug 37,9 Monate (95% CI 30.28, 45.57). OS nach dem Zeitpunkt der 
Diagnose oder PFS wurde in den Leberkrebsstudien nicht berichtet. Der me-
diane TTP war nur in einer Studie verfügbar, d.h. 15,6 Monate. Laut dieser 
Studie betrug die mittlere Zeit bis zum lokalen Wiederauftreten 15,5 Monate. 
Das lokale rezidiv-freie Überleben nach 3 Monaten betrug 87,4% (CI nicht be-
richtet), 79,8% nach 6 Monaten und 74,8% nach 12 Monaten. Keine der Stu-
dien berichtete über QoL.  
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Sicherheit 
Bauchspeicheldrüsenkrebs 
Keine der Studien berichtete über interventionsbedingte Todesfälle (wäh-
rend der Intervention). Insgesamt erlebten 44 von 226 behandelten Patienten 
(19,5%) schwere Nebenwirkungen (AEs), obwohl mindestens 16 als nicht 
verfahrensbezogen eingestuft wurden. Die gesamte verfahrensbezogene Mor-
talität (Grad V) betrug in allen Studien 1,6% (4/247 Patienten). Die Todesur-
sachen waren Blutungen, Duodenal- und Gallengangsnekrosen sowie Pfort-
aderthrombosen. Die Häufigkeit von Komplikationen im Zusammenhang mit 
dem IRE-Verfahren des Grades III oder IV in den Studien, die relevante Daten 
lieferten, betrug 10,6% (Bereich 0-44%). Die Häufigkeit kleinerer (Grad I-II) 
Komplikationen in den Studien, die relevante Daten lieferten, betrug 32,7% 
(74/226). Die meisten der kleinen AEs waren gastrointestinale Probleme, In-
fektionen und andere wie Blutungen und Thrombosen. 
Leberkrebs 
Keine der Studien berichtete über interventionsspezifische Todesfälle. Die 
Häufigkeit der wichtigsten AEs betrug 8,7% (12/138; Bereich 0-28,6%). 
Keine berichtete über eine verfahrensbedingte Mortalität. Zu den wichtigsten 
AEs gehörten Hämothorax, Hämoperitoneum, Blutungen und Verengungen 
der Portalvene oder des Gallengangs. Die häufigsten kleinen AEs waren 
Schmerzen, Hämatome und Cholestasen. Arteriovenöse Shunts, unter ande-
rem Pneumothorax und Fistel, wurden ebenfalls berichtet. 
In einer Studie wurde von Nadel-Trakt-Seedings berichtet, wobei 30,8% 
(8/26) der Patienten ein regionales Rezidiv im Nadelkanal aufwiesen (bei Tu-
mor: 11/40).  
 
Organisatorische Aspekte 
IRE benötigt Fachleute, die bereits Erfahrungen mit der Technik gesammelt 
haben. Es liegen keine Informationen über die Kosten im Zusammenhang mit 
der Anschaffung und Einrichtung von IRE-Geräten vor, aber da IRE Anästhesie 
und radiologische und/oder chirurgische Operationsgeräte erfordert, gelten 
sie als ressourcenaufwändiger als andere ablative Methoden. 
 
Zukünftige Evidenz: laufende Studien 
Eine Suche nach laufenden Studien ergab 22 Studien im Bereich Bauchspei-
cheldrüsenkrebs, von denen die meisten aber einarmige Studien sind (Sta-
dium: Rekrutierung). Eine der Studien ist ein Patientenregister. Für Leber-
krebs wurden 16 Studien gefunden (mindestens acht: Rekrutierung), die 
meisten davon sind einarmige Studien und einige sind auch bereits abge-
schlossen: Es wurden keine entsprechenden Veröffentlichung gefunden. 
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Tabelle 1: Zusammenfassung der Ergebnisse für IRE: Bauchspeicheldrüsenkrebs 
Erfolg des Verfahrens 0 NA Nicht abschätzbar 53 (1) Sehr niedrig1234 Die Größe des Tumors hat sich nach der IRE in der Interven-
tionsgruppe nicht verändert. 
Gesamtüberleben 10.03 Monate 9.3 Monate HR = 0.54 
(p = 0.053) 
53 (1) Sehr niedrig1256 Das Gesamtüberleben war für IRE höher (aber nicht signifi-
kant). 
Gesamtüberleben nach 3 Monaten 90,48%  
(67.00, 97.53) 
NA Nicht abschätzbar 53 (1) Sehr niedrig1234  
Gesamtüberleben nach 6 Monaten 75.00%  
(49.81, 88.80) 
NA Nicht abschätzbar 53 (1) Sehr niedrig1234  
Gesamtüberleben nach 12 Monaten 47.62%  
(24.37, 67.71) 
NA Nicht abschätzbar 53 (1) Sehr niedrig1234  
Gesamtüberleben nach 18 Monaten 13.61%  
(2.33, 34.71) 
NA Nicht abschätzbar 53 (1) Sehr niedrig1234  
Gesamtüberleben nach 24 Monaten -- -- -- -- -- Nicht berichtetes Ergebnis 
Krebsspezifisches Überleben -- -- -- -- -- Nicht berichtetes Ergebnis 
Krankheitsfreies Überleben -- -- -- -- -- Nicht berichtetes Ergebnis 
Progressionsfreies Überleben -- -- -- -- -- Nicht berichtetes Ergebnis 
Zeit bis zum Wiederauftreten -- -- -- -- -- Nicht berichtetes Ergebnis 
Zeit bis zur Progression -- -- -- -- -- Nicht berichtetes Ergebnis 
Zeit bis zum lokalen Wiederauftreten -- -- -- -- -- Nicht berichtetes Ergebnis 
                                                                      
1 Das Risiko einer Verzerrung für diesen bestimmten Endpunkt wurde als sehr ernst eingestuft, aufgrund fehlender Randomisierung, weil die Patienten adjuvante Therapien erhielten, Informa-
tionen über die Patientenauswahl, Follow-up fehlten und Daten aus der Kontrolle unvollständig waren. 
2 Inkonsistenzen können nicht bewertet werden, da es nur eine Studie gibt. 
3 Die Indirektheit wurde mangels Vergleichsdaten als sehr schwerwiegend eingestuft. 
4 Die Ungenauigkeit wurde aufgrund des geringen Stichprobenumfangs als sehr schwerwiegend eingestuft und Unterschiede zwischen den Gruppen lassen sich nicht abschätzen. 
5 Die Indirektheit wurde als sehr schwerwiegend eingestuft, da es wichtige Fragen der Anwendbarkeit im Zusammenhang mit der Intervention (neoadjuvantes CHEMO und/oder CHEMO nach 
IRE) und dem Komparator (wenige Informationen über zusätzliche Behandlungen und Vorbehandlungen) gibt. 
6 Die Ungenauigkeit war aufgrund des geringen Stichprobenumfangs sehr gravierend, kein 95% CI verfügbar, p =0,053. 
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Gesundheitsbezogene Lebensqualität KPS ≥70 81% der 
Zeit nach IRE  
(IQR 65–98) 
KPS ≥70 74% der 
Zeit nach IRE  
(IQR 14-88) 
Nicht abschätzbar 
(p = 0.076) 
 Sehr niedrig1254  
Schmerzen -- -- -- -- -- Nicht berichtetes Ergebnis 
Tabelle 2: Zusammenfassung der Ergebnisse für IRE: Bauchspeicheldrüsenkrebs 
Ergebnis Erwartete absolute  
Effekte (95% CI) 
Relativer Effekt (95% CI) Anzahl der Teilnehmer 
(Studien) 
Qualität Anmerkungen 
Risiko mit IRE Risiko mit Kom-
parator 
  
Sicherheit 
Interventions-
spezifische  
Mortalität 
Vergleichend 0 NA Nicht abschätzbar 53 (1) Sehr niedrig1234 Keine interventionsspezifische  
Mortalität 
Einzelarm 0/226 (0%) - 226 (7) Sehr niedrig78910 Keine interventionsspezifische  
Mortalität 
Schwere- AEs Vergleichend - NA - - - Ergebnis nicht berichtet; AE nicht be-
wertet 
Einzelarm 44/26 (19.5%) - 226 (7) Sehr niedrig 791011  
                                                                      
7 Das Risiko einer Verzerrung wurde als sehr ernst eingestuft, da es nur einarmige Studien gibt, die Patienten verschiedene adjuvante Therapien erhielten, es mehrere Verzerrungen und man-
gelnde Informationen über die Patientenauswahl und -nachsorge gibt und die Daten unvollständig sind. 
8 Die Inkonsistenz für diesen bestimmten Endpunkt wurde als nicht schwerwiegend eingestuft, da keine Todesfälle aufgetreten sind. 
9 Die Indirektheit wurde wegen des Fehlens einer Kontrollgruppe und wichtiger Fragen der Übertragbarkeit im Zusammenhang mit der Intervention in den meisten Studien aufgrund unter-
schiedlicher Behandlungsstrategien und adjuvanter Behandlungen als sehr ernst eingestuft. 
10 Die Ungenauigkeit wurde als sehr schwerwiegend eingestuft, da der Stichprobenumfang gering ist und der Effekt nicht abgeschätzt werden kann. 
11 Inkonsistenz wurde als sehr schwerwiegend (sehr variabel) eingestuft. 
Abkürzungen: AE = Nebenwirkung; CHEMO = Chemotherapie; HR = Hazard Ratio; IQR = Interquartilbereich; IRE = irreversible Elektroporation; KPS = Karnofsky Leistungsstatus; NA = nicht 
verfügbar; QoL = Lebensqualität. 
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Geringfügige AEs Vergleichend - NA - - - Ergebnis nicht berichtet; AEs nicht be-
wertet 
Einzelarm 74/226 (32,7%) - 226 (7) Sehr niedrig711910  
 
 
Tabelle 3: Zusammenfassung der Ergebnisse für IRE: Leberkrebs 
Ergebnis Erwartete absolute  
Effekte (95% CI) 
Relativer Effekt 
(95% CI) 
Anzahl der Teilnehmer 
(Studien) 
Qualität Anmerkungen 
Risiko mit IRE   
Wirksamkeit     keine Vergleichsstudien 
Sicherheit      
Intervetions-spezifische  
Mortalität (Einzelarm) 
0/138 (0%) -- 138 (6) Sehr nie-
drig1213141516 
 
Schwere- AEs 
(Einzelarm) 
12/138 (8.7%) -- 138 (6) Sehr niedrig13417  
Geringfügige AEs 
(Einzelarm) 
41/124 (33.1%) -- 124 (5) Sehr niedrig1534  
                                                                      
12 Das Risiko einer Verzerrung wurde als sehr ernst eingestuft, da es nur einarmige Studien gibt und die Patienten verschiedene adjuvante Therapien erhielten, es gibt mehrere Verzerrungen 
und es mangelt an Informationen über den Patienten bzgl. Auswahl und Nachbereitung und es gibt unvollständige Daten. 
 
2Die Inkonsistenz für diesen bestimmten Endpunkt wurde als nicht schwerwiegend eingestuft, da keine Todesfälle aufgetreten sind. 
3 Die Indirektheit wurde als sehr schwerwiegend eingestuft, da es keine Kontrollgruppe gab und wichtige Aspekte der Anwendbarkeit im Zusammenhang mit der Intervention in den meisten 
Studien wegen der Unterschiede in den Behandlungsstrategien und den adjuvanten Behandlungen fehlten. 
4 Die Ungenauigkeit wurde als sehr schwerwiegend eingestuft, da der Stichprobenumfang gering ist und der Effekt nicht abgeschätzt werden kann. 
5 Inkonsistenz wurde als sehr schwerwiegend (sehr variabel) eingestuft. 
Abkürzungen: AE = unerwünschtes Ereignis, CI = Konfidenzintervall; IRE = irreversible Elektroporation. 
 
  
 
Diskussion 
Die Evidenz aus den eingeschlossenen Studien ist nicht konsistent hinsichtlich 
der Wirksamkeit von IRE bei der Erreichung einer vollständigen Ablation, und 
in vielen der Studien fehlen Informationen über den Erfolg dieser. Einige Au-
torInnen verweisen auf die Schwierigkeit, den ablativen Erfolg und das lokale 
Rezidiv mit herkömmlichen bildgebenden Verfahren zu beurteilen und führen 
die unterschiedlichen Ergebnisse auf die Merkmale der abgetragenen Tu-
more, frühere Behandlungen oder darauf zurück, wie das chirurgische oder 
IRE-Verfahren geplant und durchgeführt wurde. 
Die verfügbare Evidenz reicht nicht aus, um festzustellen, ob IRE die OS für 
PatientInnen mit Bauchspeicheldrüsen- oder Leberkrebs im Vergleich zur 
Standardversorgung wirksam verbessern würde. Für LAPC erfüllte nur eine 
qualitativ minderwertige, nicht-randomisierte Studie die Auswahlkriterien, 
und diese Studie ergab keinen Unterschied im mittleren OS, obwohl sie  
IRE mit nicht-kurativer Chirurgie verglich (10,03 Monate gegenüber 9,3 Mo-
nate; p = 0,053). 
Die prospektiven einarmigen Beobachtungsstudien zu LAPC lieferten nur we-
nige relevante Ergebnisdaten. Das relevante Ergebnis, Überleben ab dem Zeit-
punkt der Diagnose, wurde nur selten berichtet. Für die drei Studien, die über 
dieses Ergebnis berichten, lag OS zwischen 12,5 und 17,5 Monaten, was dem 
Überleben in anderen Studien entspricht. Es können aber keine Annahmen 
getroffen werden, da die Studien nicht vergleichbar sind. Es sei darauf hinge-
wiesen, dass die in die Studien einbezogenen PatientInnen vor oder gleichzei-
tig mit IRE mit verschiedenen Chemotherapien und/oder Chemoradiothera-
pien behandelt wurden, und es ist nicht bekannt, wie diese zum Überleben 
beigetragen haben könnten. 
Die Daten zu Lebertumoren sind noch geringer, da keine Vergleichsstudien 
identifiziert wurden und nur eine der einarmigen Studien Langzeitüberle-
bensdaten lieferte. 
Es ist bemerkenswert, dass, obwohl es eines der wichtigsten Ziele im Manage-
ment von lokal fortgeschrittenen Krebsarten ist, nur wenige Studien über QoL 
berichten. Die Ergebnisse der vorliegenden Studien, einschließlich des non-
RCTs, unterstützen die Annahme, dass IRE keine signifikanten Verbesserun-
gen in Bezug auf den Versorgungsstandard bringt. Im Gegenteil, es wurde ein 
Rückgang der QoL berichtet und eine Studie berichtete sogar von einem An-
stieg der Schmerzen. 
Insgesamt ist die Sicherheit von IRE ein Problem. Obwohl keine interventions-
bedingte Mortalität berichtet wurde, litten 1,6% der in LAPC-Studien rekru-
tierten PatientInnen an IRE-bezogenen AEs, die in den nächsten 30-90 Tagen 
zum Tod (Grad V) führten. Die Häufigkeit anderer schwerer IRE-bezogener 
Komplikationen war in mehreren der Studien ebenfalls relativ hoch. Aller-
dings war die Berichterstattung über AEs auch unter den untersuchten Stu-
dien sehr heterogen. Es wurden verschiedene Skalen für die Einstufung von 
AEs verwendet, es gibt keinen klaren Konsens über die Klassifizierung von 
IRE-bezogenen Komplikationen und Komplikationen wurden in den Studien 
unterschiedlich gezählt. 
Eine wichtige Einschränkung des vorliegenden systematischen Reviews be-
steht darin, dass es unmöglich ist, eine vergleichende Analyse durchzuführen, 
da keine vergleichenden Informationen vorliegen. Es besteht derzeit eine 
große Unsicherheit darüber, wie sich IRE im Vergleich zur Behandlung ohne 
IRE verhält und wie Unterschiede zwischen den Untergruppen die Ergebnisse 
beeinflussen könnten. Es wurde beobachtet, dass die Gesamthäufigkeit von 
IRE-bedingten schweren AEs in den Pankreasstudien, die perkutane IRE im 
Vergleich zur offenen Chirurgie verwendeten, höher war, obwohl, wie bereits 
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erwähnt, diese wenigen Studien im Hinblick auf andere Störfaktoren nicht 
vergleichbar sind. Dennoch könnte es wichtig sein, darauf hinzuweisen, dass 
einige AutorInnen berichteten, dass der perkutane Ansatz wegen abschre-
ckender Komplikationen aufgegeben wurde. 
Im Allgemeinen ist die Qualität der Evidenz für beide Indikationen sehr ge-
ring. Bis heute gibt es keine veröffentlichten RCTs und die einzige verglei-
chende LAPC-Studie, die aufgenommen wurde, ist eine kleine Studie, die IRE 
mit nicht-kurativer Chirurgie (Laparotomie, nicht-radikale Resektion, Biop-
sie) vergleicht und frühere oder gleichzeitige Behandlungen nicht berücksich-
tigt. Die einarmigen Studien, die zur Feststellung der Ergebnisse zur Wirksam-
keit und Sicherheit durchgeführt wurden, sind aufgrund ihrer geringen Größe, 
der kurzen Nachbeobachtungszeit und der stark ausgewählten Populationen, 
die verschiedene Arten von Behandlungen erhalten hatten, stark einge-
schränkt. Daten, die die Berechnung von OS, PFS und anderen kritischen Er-
gebnisse wie QoL ermöglichen, fehlten ebenfalls in vielen der Studien. Dies 
stellt ein wesentliches Hindernis dar, um Rückschlüsse auf das Potenzial von 
IRE zur Behandlung dieser Tumore zu ziehen. Dies war insbesondere bei Le-
berkrebs der Fall, bei dem die meisten Studien nur über ein lokales Rezidiv 
während der Nachbeobachtung berichteten. Zu den weiteren wichtigen Män-
geln gehören das Fehlen standardisierter Definitionen des Erfolgs, die unklare 
Klassifizierung von IRE-bezogenen Komplikationen und die unterschiedliche 
und mögliche Unterberichterstattung einiger Arten von AE.  
Auch die Übertragbarkeit der Ergebnisse ist sehr zweifelhaft. Wir beobachte-
ten, dass die Anwendung von IRE innerhalb des Behandlungsalgorithmus in 
allen Studien inkonsistent war, was zu Unsicherheiten bei der Anwendung 
dieser Technik in der Praxis führte. Während einige Studien IRE auf Patien-
tInnen beschränkten, die nicht auf eine Standardbehandlung ansprachen, 
wendeten andere diese Technik nur dann an, wenn die PatientInnen ungüns-
tige Überlebenschancen hatten oder wenn die Krankheit nach der vorherigen 
Chemotherapie-Behandlung nicht voranschritt. Das Behandlungsprotokoll 
variierte ebenfalls erheblich; einige Studien boten Chemotherapie vor IRE 
und andere Chemoradiotherapie oder Induktion Chemotherapie und Chemo-
radiotherapie vor IRE an, während einige Chemotherapie nach IRE verwen-
deten. Unterschiede wurden auch in Bezug auf die Anzahl der Ablationssit-
zungen, die bildgebenden Verfahren und die IRE-Technik festgestellt.  
Es ist von wesentlicher Bedeutung, dass angemessen konzipierte prospektive 
Vergleichsstudien durchgeführt werden, um die vergleichende Wirksamkeit 
und Sicherheit des IRE zu ermitteln. Im Idealfall handelt es sich um randomi-
sierte Studien, die auch eine Bewertung ermöglichen, ob zusätzliche Vorteile 
in Bezug auf Sicherheit, Überlebensmessungen, QoL und Schmerz beobachtet 
werden. 
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Conclusio 
Bauchspeicheldrüsenkrebs 
Es liegt keine ausreichende Evidenz vor, um festzustellen, ob IRE bei der Be-
handlung von inoperablem LAPC wirksamer oder mindestens so wirksam ist 
wie der konventionelle Standard der Versorgung (Chemotherapie, Chemora-
diotherapie oder Palliativtherapie). Es gibt keine ausreichenden Beweise, um 
festzustellen, ob IRE bei der Behandlung von inoperablem LAPC sicherer oder 
mindestens so sicher ist wie der konventionelle Standard der Versorgung 
(Chemotherapie, Chemoradiotherapie oder Palliativtherapie). 
Die vorliegenden Erkenntnisse lassen Zweifel an der Wirksamkeit von IRE für 
die vollständige Ablation von inoperablem LAPC aufkommen. Die vorliegen-
den Erkenntnisse lassen Zweifel an der Wirksamkeit von IRE als einzige lokale 
Behandlung von LAPC aufkommen. Derzeit ist unklar, ob IRE mit Chemothe-
rapie kombiniert werden muss und wenn ja, welche Therapien optimal sind. 
Es gibt Unsicherheiten bezüglich des Auftretens schwerer AEs, wenn IRE zur 
Behandlung von inoperablem LAPC eingesetzt wird. 
Leberkrebs 
Es fehlen Daten, um festzustellen, ob IRE bei der Behandlung von PatientIn-
nen mit primärem oder sekundärem, inoperablem Leberkrebs, der nicht für 
die thermische Ablation geeignet ist, effektiver oder mindestens so effektiv ist 
wie der konventionelle Standard der Versorgung (TACE, Sorafenib oder Palli-
ativtherapie). Es fehlen Belege dafür, ob IRE sicherer oder mindestens so si-
cher ist wie der konventionelle Versorgungsstandard (TACE, Sorafenib oder 
Palliativtherapie) für die Behandlung von PatientInnen mit primärem oder 
sekundärem inoperablem Leberkrebs, der nicht für die thermische Ablation 
geeignet ist. 
Die vorliegenden Erkenntnisse lassen Zweifel an der Wirksamkeit von IRE für 
die vollständige Ablation von primären oder sekundären inoperablen Leber-
tumoren aufkommen, die für die thermische Ablation nicht geeignet sind. Die 
vorliegenden Erkenntnisse lassen Zweifel an der Wirksamkeit von IRE als al-
leinige primäre lokale Behandlung von primären oder sekundären Lebertu-
moren aufkommen, die nicht für die thermische Ablation geeignet sind. 
Bei der Anwendung von IRE zur Behandlung von Lebertumoren, die nicht für 
die thermische Ablation geeignet sind, gibt es Unsicherheiten hinsichtlich des 
Auftretens von schweren AEs. 
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SUMMARY OF THE RELATIVE EFFECTIVENESS OF 
IRREVERSIBLE ELECTROPORATION
Scope
The scope can be found here: Scope.
Introduction
Description of technology and comparators
Irreversible electroporation (IRE) is a nonthermal ablative method involving the application of short 
high-voltage and low-frequency electric fields to create nanoscale pores in tissue, resulting in per-
meabilisation of cell membranes. This permeabilisation can become irreversible when the magni-
tude, duration and number of the electrical fields applied are above a certain threshold [1] (B0001). 
Because of the mostly nonthermal effect, it is alleged that IRE leads to less damage to adjacent 
structures in comparison to other thermal ablative approaches (radiofrequency ablation [RFA], mi-
crowave ablation [MWA] and cryoablation). This allows ablation of pancreatic and liver tumours that 
are localised close to major blood vessels or other sensitive structures such as nerves and the bile 
duct without causing them damage.
IRE can be performed percutaneously, laparoscopically or as part of open surgery (laparotomy) [2]. 
In all cases, the procedure involves placing multiple electrodes around the target tumour, although 
sometimes a probe can also be placed in the centre of the nodule. The probe is directed under image 
guidance via ultrasound (US) or computed tomography (CT). The patient requires general anaesthe-
sia with deep sedation and complete muscle relaxation, with cardiac synchronisation during delivery 
of the high-voltage current (B0001, B0009).
The only commercialised IRE device is the NanoKnife System® (AngioDynamics®). This system has 
the Conformité Européenne (CE) mark for cell membrane electroporation and US Food and Drug 
Administration (FDA) approval for soft tissue ablation. It has not received clearance for therapy or 
treatment of any specific disease or condition (B0003, A0020).
Comparators in pancreatic cancer
The intended population for IRE is patients diagnosed with unresectable locally advanced pancreatic 
tumours. The standard-of-care therapy for these patients is chemotherapy (CHEMO), with or without 
radiation therapy (chemoradiotherapy [CRT]). Radiotherapy (RT) is also typically offered as a pallia-
tive option as it reduces pain, but positive effects on survival have not been demonstrated (B0001).
Comparators in liver cancer
The intended population for IRE consists of patients with unresectable primary or secondary liver 
cancer who have a contraindication to thermal ablation. The most common treatment options include 
transarterial chemoembolisation (TACE), multikinase inhibitors such as sorafenib and levatinib, and 
palliative and symptomatic therapy. Typically, TACE is offered to patients with intermediate-stage 
disease who have preserved liver function, while sorafenib can be considered the standard first-line 
systemic therapy for patients with more advanced cancers and preserved liver function. Patients who 
have end-stage disease and are not candidates for a transplant might only be eligible for supportive 
palliative care and symptomatic treatment. The use of external beam RT has also been reported in 
different stages of liver cancer, and is specifically recommended for alleviating pain in patients with 
bone metastases (B0001).
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Health problem
Pancreatic cancer
Cancer of the pancreas is one of the most lethal cancer types, with more than 458,918 new cases 
estimated in 2018 worldwide [3] (A0002). The cancer progresses rapidly and is often diagnosed 
when it is at an advanced stage (A0004). It is estimated that at the time of diagnosis, approximately 
40% of cases are diagnosed with locally advanced pancreatic cancer (LAPC) and another 40% with 
metastatic disease [4] (A0023).
The target population in this assessment includes patients diagnosed with nonmetastasised but 
unresectable disease due to involvement of the coeliac trunk or superior mesenteric artery, classified 
as LAPC according to the National Comprehensive Cancer Network (NCCN) guidelines or as stage 
III by the American Joint Committee on Cancer (AJCC) criteria. Recurrent disease will also be con-
sidered (A0007).
Liver cancer
Liver cancer is the second most frequent cause of death from cancer worldwide [5].There were 
850,000 new cases diagnosed in 2015 and 810,000 deaths [6]. Estimates for Europe in 2018 showed 
a 5-year prevalence of 8.7% [3].
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 90% off all 
primary cancers of the liver. A more frequent cause of liver tumours besides primary liver tumours is 
metastases in patients with extrahepatic neoplasia, which is often a colorectal adenocarcinoma [7] 
(A0002). Some authors have reported hepatic metastases in as many as 40–50% of adult patients 
with extrahepatic primary tumours [8] (A0023). In most cases, the onset of primary liver cancer is 
preceded by cirrhosis of the liver (A0004).
The target population in this assessment includes patients diagnosed with unresectable (primary or 
secondary) liver cancer with a contraindication for thermal ablation (because of the risk of collateral 
damage to biliary, vascular or other structures due to the effect of heat) (A0007).
Methods
A systematic literature search was carried out on 26 September 2018 (and updated in January 2019) 
using the Centre for Research and Dissemination (CRD), Cochrane Library (Wiley), Embase (OVID), 
Medline (PubMed), Web of Science (Web of Knowledge) and Scopus. A manual search of the refer-
ence list of relevant studies was also undertaken to recover published studies that might have been 
missed by the search. Detailed tables on the search strategy are included in Appendix 1.
Guideline repositories were used to identify relevant guidelines for the current use of the technology 
(CUR) domain (Guidelines International Network [GIN] database, Trip database, PubMed Central 
[PMC], CMA Infobase and Google Scholar). Ongoing clinical trials and research projects were 
found through Clinicaltrials.gov, the EU Clinical Registry and the International Clinical Trials Registry 
Platform (ICTRP).
The only manufacturer identified at the time of the search (AngioDynamics®) was also contacted by 
the EUnetHTA Joint Action 3 WP4 Project Manager and asked to fill in the short version of the sub-
mission file and to confirm that the product is a CE marked technology and that it is the only product 
produced by the company that is relevant for this assessment.
The authoring team independently screened the titles and abstracts according to the predefined 
inclusion criteria. The full text of potentially relevant articles was read, and studies were included or 
excluded on the basis of scoping questions. For the clinical effectiveness (EFF) and safety (SAF) 
domains, data were extracted independently by two authors and double-checked regarding con-
sistency and accuracy by the co-author. Discrepancies between authors in relation to data were 
resolved through discussion and consultation with the co-author until agreement was reached.
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The risk of bias at the study level was assessed using the Institute of Health Economics (IHE) 
20-Criteria Checklist [9] for single-arm studies (case series) and Risk of Bias in Nonrandomised 
Studies of Interventions (ROBINS-I) for nonrandomised controlled trials (non-RCTs) [10]. No quality 
assessment tool was used for the technical characteristics of the technology (TEC) and CUR do-
mains, although information was validated by comparing and contrasting information from multiple 
sources (manufacturers, bibliography searches, official web pages and general Internet searches). 
Information was synthesised in a descriptive manner.
The quality of the body of evidence was assessed and synthesised according to the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) system. A meta-analysis or 
pooling of data was not methodologically possible because of the great variability between trials in 
terms of population characteristics, tumour size, treatments before, concomitant with and after IRE 
and length of follow-up, among other parameters. Accordingly, a narrative synthesis of the data is 
reported using descriptive statistics to summarise quantitative measures.
Two individual patients were involved in the assessment. Individual patients were identified through 
the Department of Patient/Citizen Care Services (Servicio de Atención ao Ciudadán e ao paciente) of 
the Galician Health Service (SERGAS). Participation was opened to patients with pancreatic or liver 
cancer who have undergone treatment with other ablative methods (as experiences with the disease 
and ablative methods will generally be shared).
Results
Available evidence
Effectiveness
The systematic literature search identified 15 observational studies that met the eligibility criteria, 
eight for pancreatic cancer and seven for liver cancer. No RCTs were found. One of the studies 
included for pancreatic cancer was a non-RCT that included 21 patients receiving the intervention, 
with median follow-up of 8.19 months [11]. The 32 patients in the control group received some type of 
noncurative surgery (laparotomy, nonradical resection, bypass surgery, cholecystectomy or percuta-
neous biopsy only). The remaining seven prospective single-arm observational studies enrolled 226 
patients treated with IRE. Six of these had median follow-up of ≤12 months. The longest follow-up 
was 28.1 months.
For liver cancer, seven prospective single-arm trials were included involving 151 patients with 220 
IRE-treated lesions. The mean follow-up was ≤18 months in five of these studies and the maximum 
recorded was 24 months.
Summary-of-findings tables (GRADE approach) are presented in Tables 1 and 2. For the EFF do-
main, only comparative trial data are included.
Safety
For pancreatic cancer, articles included in the SAF domain do not differ from those for the EFF 
domain. For liver cancer, one study [12] was not included as safety outcomes were not reported.
Clinical effectiveness
Pancreatic cancer
According to the only comparative study [11], the median overall survival (OS) for patients after 
IRE did not differ significantly between the treatment and control group (10.03 versus 9.3 months; 
p = 0.053) (D0001). The quality of life (QoL) after IRE declined slowly, without statistically significant 
differences between groups (D0013). According to the definition of “success of the procedure” in the 
PICO (P: patient, problem or population; I: intervention; C: comparison, control or comparator; O: 
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
13Version 1.4, 18 May 2019
outcome) question, all patients treated with IRE would be defined as unsuccessfully treated (the size 
of the tumour did not change after IRE).
The median survival after IRE based on Kaplan-Meier estimations ranged from 4.3 to 12 months in 
four of the single-arm trials [13–16]. One study reported survival of 22.6 months [17]. The survival 
at 3 months was ≥90% in the four single-arm studies [14,15,17,18] with data available (D0001). At 6 
months, the survival rate ranged from 50% (95% confidence interval [CI] 18.36, 75.32) [15] to 100% 
(CI not provided) [17]. At 12 months the survival rate ranged from 20% (95% CI 3.09, 47.47) [15] to 
90% (95% CI 65.60, 97.40) [17,18]. The only two studies reporting beyond 12 months had survival 
rates of 13.6% (95% CI 2.33, 34.71) at 18 months [11] and 37% at 24 months [17].
Only three studies provided data to calculate OS from the time of diagnosis [14–16]. The median OS 
in these studies varied from 12.5 months to 17.5 months. The survival rate at 3 and 6 months in the 
two studies for which this calculation was possible [14,15] was 100%. The respective rates were 60% 
(95% CI 25.27, 82.72) and 79.2% (95% CI 56.98, 90.75) at 12 months, 50% (95% CI 29.10, 67.76) 
and 50% (95% CI 18.36, 75.32) at 18 months, and 13.9% (95% CI 3.54, 31.14) and 30% (95% CI 
7.11, 57.79) at 24 months.
The three studies that reported on progression-free survival (PFS) after IRE showed median OS 
between 3.2 months and 15.4 months [14,16,17] (D0001).
Of the seven single-arm studies, only one provided information regarding the actual success of the 
procedure (according to the PICO definition for this assessment), which was 96% [19]. One study 
reported time to progression (TTP) [14], which was 3.3 months (95% CI 2.30, 6.38). The median time 
to local recurrence varied from 6.8 months to 12 months [13,14,16] (D0006).
QoL was only considered in two of the single-arm studies. In the study by Scheffer et al. [16] some 
QoL items declined after IRE. QoL also declined in the study by Paiella et al. [15]: the median pre-
operative QoL score of 58.3 declines to 37.5 at 2 weeks and 33.33 at 3 months after IRE (D0013).
Liver cancer
The mean OS after IRE was only available from one study [20], which was 37.9 months (95% CI 
30.28, 45.57). OS from the time of diagnosis or PFS was not reported in the liver cancer studies 
(D0001).
The outcome “success of the procedure” according to the PICO question was not available in any 
of the studies, although incomplete definitions of success were provided in five studies [21–25]. The 
median TTP was only available in one study [25], which was 15.6 months. According to this study, 
the mean time to local recurrence was 15.5 months. Local recurrence-free survival at 3 months was 
87.4% (CI not reported), 79.8% at 6 months and 74.8% at 12 months (D0006).
None of the studies reported QoL. However, two provided information on postprocedural pain as a 
complication (D0013).
Safety
Pancreatic cancer
None of the studies reported intervention-specific deaths (during the intervention). In total, 44 out of 
226 treated patients (19.5%) experienced major adverse events (AEs) although at least 16 were not 
considered procedure-related by the authors. The overall procedure-related mortality (grade V AE) 
was 1.6% (4/247 patients) among all studies. The causes of death were haemorrhage, duodenal and 
bile duct necrosis and portal vein thrombosis. The frequency of grade III or IV IRE procedure-related 
complications in the studies that provided relevant data was 10.6% (range 0–44%). For patients who 
underwent IRE for primary control, the frequency was 5.6% (6/107) for open surgery (>90% of cases) 
and 20.3% (14/69) for the percutaneous approach (C0008).
The frequency of minor (grade I–II) complications in the studies that provided relevant data was 
32.7% (74/226). The frequency of procedure-related AE was 13.1% (14/107) among open surgery 
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cases and 31.9% (22/69) among percutaneous IRE cases. Most of the minor AEs were gastrointes-
tinal problems, infection and others such as bleeding and thrombosis (C0008).
Liver cancer
None of the studies reported intervention-specific deaths. The overall frequency of major AEs was 
8.7% (12/138; range 0–28.6%). None reported procedure-related mortality. Major AEs included hae-
mothorax, haemoperitoneum, bleeding and stricture of the portal vein or bile duct. The most common 
minor AEs were pain, haematomas and cholestasis. Arteriovenous shunts, pneumothorax and fistu-
la, among others, were also reported (C0008).
Needle-tract seeding was reported in one study [22], with 30.8% (8/26) of patients experiencing 
regional recurrence in the needle tract (by tumour: 11/40). Granata et al. [24] reported that two minor 
AEs occurred along the needle tract (C0008).
Organisational aspects
IRE requires professionals who have acquired previous experience with the technique [26] (G0003). 
No information exists regarding costs related to IRE equipment acquisition and set up (G0006), 
but given that IRE requires anaesthesia and radiological and/or surgical operating equipment, it is 
deemed costlier in terms of resources than other ablative methods [5] (G0007).
Upcoming evidence
A search for ongoing studies identified 22 trials in the pancreatic cancer setting, most of which are 
single-arm trials that are still recruiting patients. One of the studies is a patient registry. For liver 
cancer, 16 trials were found, of which at least eight are still recruiting. Most of these are single-arm 
trials and some are finished, but no publication was found.
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Table 1. Summary-of-findings table for IRE: Pancreatic cancer
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI)
Number of 
participants  
(studies)
Quality Comments
Risk with IRE Risk with 
comparator
Effectiveness (comparative trials)
Success of the procedure 0 NA Not estimable 53 (1) Very low1,2,3,4 The size of the tumour did not change 
after IRE in the intervention group
Overall survival 10.03 months 9.3 months HR = 0.54 
(p = 0.053)
53 (1) Very low1,2,5,6 Overall survival was higher (but not 
significantly) for IRE
Overall survival at 3 months 90.48% (67.00, 97.53) NA Not estimable 53 (1) Very low1,2,3,4
Overall survival at 6 months 75.00% (49.81, 88.80) NA Not estimable 53 (1) Very low1,2,3,4
Overall survival at 12 months 47.62% (24.37, 67.71) NA Not estimable 53 (1) Very low1,2,3,4
Overall survival at 18 months 13.61% (2.33, 34.71) NA Not estimable 53 (1) Very low1,2,3,4
Overall survival at 24 months -- -- -- -- -- Outcome not reported
Cancer-specific survival -- -- -- -- -- Outcome not reported
Disease-free survival -- -- -- -- -- Outcome not reported
Progression-free survival -- -- -- -- -- Outcome not reported
Time to recurrence -- -- -- -- -- Outcome not reported
Time to progression -- -- -- -- -- Outcome not reported
Time to local recurrence -- -- -- -- -- Outcome not reported
Health-related quality of life KPS ≥70 81% of the 
time after IRE (IQR 
65–98)
KPS ≥70 74% of the 
time after IRE (IQR 
14-88)
Not estimable 
(p = 0.076)
53 (1) Very low1,2,5,4 
Pain  -- -- -- -- -- Outcome not reported
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Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI)
Number of 
participants  
(studies)
Quality Comments
Risk with IRE Risk with 
comparator
Safety 
Intervention-
specific mortality
Comparative 0 NA Not estimable 53 (1) Very low1,2,3,4 No intervention-specific mortality
Single arm 0/226 (0%) – 226 (7) Very low7,8,9,10 No intervention-specific mortality
Major AEs Comparative – NA – -- -- Outcome not reported; AE not graded
Single arm 44/226 (19.5%) – 226 (7) Very low7,11,9,10
Minor AEs Comparative – NA – -- -- Outcome not reported; AEs not graded
Single arm 74/226 (32.7%) – 226 (7) Very low7,11,9,10
1 The risk of bias for this particular endpoint was categorised as very serious because of the lack of randomisation, patients received adjuvant therapies, lack of information on patient selection, follow-up 
and incomplete data from the control.
2 Inconsistency cannot be assessed because there is only one study.
3 Indirectness was categorised as very serious owing to the lack of comparative data.
4 Imprecision was categorised as very serious owing to the small sample size and differences between groups cannot be estimated.
5 Indirectness was categorised as very serious because there are important applicability issues related to the intervention (neoadjuvant CHEMO and/or CHEMO after IRE) and comparator (few informa-
tion regarding additional treatments and pretreatments).
6 Imprecision was very serious due to small sample size, no 95% CI available, p = 0.053.
7 The risk of bias was categorised as very serious because there are only single-arm studies, patients received different adjuvant therapies, there are several biases and a lack of information on patient 
selection and follow-up and there are incomplete data.
8 Inconsistency for this particular endpoint was categorised as not serious because no deaths occurred.
9 Indirectness was categorised as very serious because of the lack of control group and important applicability issues related to the intervention in most studies owing to differences in treatment strategies 
and adjuvant treatments.
10 Imprecision was categorised as very serious because the sample size is small and the effect cannot be estimated.
11 Inconsistency was categorised as very serious (highly variable).
Abbreviations: AE  =  adverse event; CHEMO = chemotherapy; HR = hazard ratio; IQR = interquartile range; IRE = irreversible electroporation; KPS = Karnofsky performance status; NA = not available; 
QoL = quality of life.
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Table 2. Summary-of-findings table for IRE: Liver cancer
Outcome Anticipated absolute 
effects (95% CI)
Relative effect 
(95% CI)
Number of participants 
(studies)
Quality Comments
Risk with IRE
Effectiveness No comparative trials 
Safety 
Intervention specific mortality (single arm) 0/138 (0%) – 138 (6) Very low1,2,3,4
Major AEs (single arm) 12/138 (8.7%) – 138 (6) Very low1,5,3,4
Minor AEs (single arm) 41/124 (33.1%) – 124 (5) Very low1,5,3,4
1 The risk of bias was categorised as very serious because there are only single-arm studies, patients received different adjuvant therapies, there are several biases and a lack of information on patient 
selection and follow-up and there are incomplete data.
2 Inconsistency for this particular endpoint was categorised as not serious because no deaths occurred.
3 Indirectness was categorised as very serious owing to the lack of a control group and important applicability issues related to the intervention in most studies because of differences in treatment 
strategies and adjuvant treatments.
4 Imprecision was categorised as very serious because the sample size is small and the effect cannot be estimated.
5 Inconsistency was categorised as very serious (highly variable).
Abbreviations: AE = adverse event, CI = confidence interval; IRE = irreversible electroporation.
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Discussion
Evidence from the studies included is not consistent regarding the effectiveness of IRE in achiev-
ing complete ablation, and information regarding success is lacking in many of the studies. Some 
authors refer to the difficulty in assessing ablative success and local recurrence using conventional 
imaging modalities [19,20,24], and attribute the different results to characteristics of the tumours 
ablated, prior treatments or to how the surgical or IRE procedure was planned and performed [17].
The evidence available is insufficient to establish if IRE would be effective in improving OS for pa-
tients with pancreatic or liver cancer when compared to the standard of care. For LAPC, only one 
low-quality nonrandomised trial [11] met the eligibility criteria and this trial found no difference in mean 
OS, despite comparing IRE to noncurative surgery (10.03 months versus 9.3 months; p = 0.053).
The prospective single-arm observational trials on LAPC provided few relevant outcome data. The 
critical effectiveness-related survival outcome would be OS from the time of diagnosis. For the three 
studies reporting on this outcome, OS ranged from 12.5 to 17.5 months, which is in the OS range 
found in the latest CHEMO trials [27], but no assumptions can be made given that the studies lack 
comparability. It should be noted that the patients included in the trials were treated with different 
CHEMO and/or CRT regimens before or concurrent with IRE, and it is not known how these might 
have contributed to OS or control rates.
Data regarding liver tumours are even more limited, as no comparative trials have been identified 
and only one of the single-arm studies provided long-term survival data [20].
It is noteworthy that despite being one of the most relevant goals in the management of locally 
advanced cancers, few studies report on QoL. The results from these studies, including the one non-
RCT [11], do not support significant improvements with respect to standard of care. On the contrary, 
they found a decrease in QoL [15,16] and one study reported increases in pain scores [16].
Overall, the safety of IRE is a concern. Although no intervention-specific mortality was reported, 
1.6% of the patients recruited in LAPC studies suffered from IRE-related AEs that led to death (grade 
V) during the next 30–90 days. The frequency of other severe IRE-related complications was also 
relatively high in several of the trials [13,16,25]. However, the reporting of AEs was also very hetero-
geneous among the studies included. Different scales for grading AEs were used, there is no clear 
consensus regarding the classification of IRE-related complication and complications were counted 
differently among studies.
An important limitation of the present systematic review is that it is the impossible to carry out a 
comparative analysis to assess how the tumour location and size and the approach could affect SAF 
outcomes. There is currently great uncertainty regarding how IRE compares to treatment without 
IRE and how differences between subgroups could influence results. We observed that the overall 
frequency of IRE-related severe AEs was higher in the pancreatic studies that used percutaneous 
IRE in comparison to open surgery, although as already noted, these few studies are not comparable 
in terms of other confounding factors. Nonetheless, it might be important to note that some authors 
reported that the percutaneous approach was abandoned because of discouraging complications 
[11].
In general, the quality of the evidence is very low for both indications. To date, there are no published 
RCTs and the only comparative LAPC trial that was included is a small propensity-matched trial that 
compares IRE to noncurative surgery (laparotomy, nonradical resection, biopsy) and does not take 
into account previous or concurrent treatments [11]. The single-arm trials included to ascertain EFF 
or SAF outcomes are greatly limited by their small size, short follow-up period and highly selected 
populations that had received different types of treatments. Data allowing calculating OS, PFS and 
other critical measures of EFF such as QoL were also missing in many of the trials. This constitutes 
an important impediment to drawing any conclusions regarding the potential of IRE for treating these 
tumours. This was especially noticeable for liver cancer, for which most trials only reported on local 
recurrence during follow-up. Among other important shortcomings are the lack of standardised defi-
nitions regarding success, the unclear classification of IRE-related complications and different and 
possible underreporting of some types of AE.
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The applicability of the EFF and SAF results is also very doubtful. We observed that application of 
IRE within the treatment algorithm was inconsistent across studies, raising uncertainties regarding 
the use of this technique in real practice. For example, while some studies restricted IRE to patients 
unresponsive to standard treatment [15], others only applied this technique when patients had fa-
vourable survival characteristics [14] or when the disease did not progress after previous CHEMO 
treatment [17]. The treatment protocol also varied substantially; some studies offered CHEMO before 
IRE and others CRT or induction CHEMO and CRT before IRE, while several used CHEMO after 
IRE. Differences were also noted regarding the number of ablative sessions, the imaging modalities 
and IRE technique, with no formal consensus regarding the considerations that should be taken into 
account to identify tumours for which IRE might be more beneficial.
It is essential that appropriately designed prospective comparative trials are carried out to determine 
the comparative effectiveness and safety of IRE. Ideally, these would be randomised trials that would 
also allow evaluation of whether additional benefits are observed in terms of safety, survival mea-
sures, QoL and pain.
Conclusion
Pancreatic cancer
There is insufficient evidence to establish whether IRE is more effective than, or at least as effective 
as, the conventional standard of care (CHEMO, CRT or palliative therapy) for the treatment of unre-
sectable LAPC.
There is insufficient evidence to establish whether IRE is safer than, or at least as safe as, the 
conventional standard of care (CHEMO, CRT or palliative therapy) for the treatment of unresectable 
LAPC.
The existing evidence raises doubts regarding the efficacy of IRE for achieving complete ablation of 
unresectable LAPC.
The existing evidence raises doubts regarding the efficacy of IRE as a sole primary local treatment 
for LAPC. Currently, it is unclear whether IRE needs to be combined with CHEMO and, if so, which 
regimens are optimal.
There are uncertainties regarding the occurrence of severe AEs when IRE is used for the treatment 
of unresectable LAPC.
Liver cancer
There is a lack of data to establish whether IRE is more effective than, or at least as effective as, the 
conventional standard of care (TACE, sorafenib or palliative therapy) for the treatment of patients 
with primary or secondary unresectable liver cancer that is not suitable for thermal ablation.
There is a lack of evidence to establish whether IRE is safer than, or at least as safe as, the con-
ventional standard of care (TACE, sorafenib or palliative therapy) for the treatment of patients with 
primary or secondary unresectable liver cancer that is not suitable for thermal ablation.
The existing evidence raises doubts regarding the efficacy of IRE for achieving complete ablation of 
primary or secondary unresectable liver tumours that are not suitable for thermal ablation.
The existing evidence raises doubts regarding the efficacy of IRE as a sole primary local treatment 
for primary or secondary liver tumours that are not suitable for thermal ablation.
There are uncertainties regarding the occurrence of severe AEs when IRE is used for the treatment 
of liver tumours that are not suitable for thermal ablation.
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1  SCOPE
Description Project scope
Population The diseases of interest are:
• Pancreatic neoplasm. MeSH terms: C04.588.274.761, C04.588.322.475, 
C06.301.761, C06.689.667, C19.344.421; malignant neoplasm of pancreas 
International Classification of Diseases (ICD)-10: C25
• Liver neoplasms. MeSH terms: C04.588.274.623, C06.301.623, C06.552.697; 
malignant neoplasm of liver ICD-10: C22; malignant neoplasm metastasis in liver 
ICD-10: C78-7
The target populations are:
• Patients with histologically proven unresectable LAPC/stage III.
The following subgroups will be considered:
◊ Patients who have already received CHEMO and/or RT after which the tumour did 
not progress
◊ Patients who have already received CHEMO and/or RT after which the tumour 
becomes resectable; IRE is applied for margin accentuation
◊ Patients who have not received CHEMO or RT
• Patients with unresectable primary or secondary liver cancer and a contraindication 
for thermal ablation
The following subgroups will be considered:
◊ Patients with primary liver cancer
◊ Patients with secondary liver cancer, differentiated by origin/histology
The intended use of the technology is as an ablative treatment.
Rationale: The population was defined according to:
• European guidelines (European Society for Medical Oncology [ESMO] clinical 
practice guideline for the diagnosis, treatment and follow-up of cancer of the 
pancreas [27]; European Association for the Study of the Liver [EASL] clinical 
practice guideline on management of hepatocellular carcinoma [5]).
• American guidelines: NCCN clinical practice guidelines in oncology on pancreatic 
adenocarcinoma and hepatobiliary cancers [28,29]
• AJCC cancer staging manual for pancreas and hepatobiliary cancers [30]
Intervention • Tumour resection by IRE using the NanoKnife System, with the following 
subanalyses considered, depending on the approach: percutaneous, laparoscopic or 
open surgery
• MeSH: Electroporation E05.200.500.454, E05.242.448, E05.301.500
• Manufacturers:
◊ NanoKnife (Company: AngioDynamics, USA)
Comparison •  Pancreatic cancer
 – Standard of care therapy:
◊ CHEMO
◊ RT
◊ CRT
◊ Palliative care
◊ No treatment (watchful waiting)
• Liver cancer
 – Standard of care therapy:
◊ Chemoembolisation
◊ Kinase inhibitor: sorafenib or others
◊ RT
◊ Palliative care
◊ No treatment (watchful waiting)
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Description Project scope
Rationale: Standard therapy was established according to:
• European guidelines: ESMO clinical practice guideline on the diagnosis, treatment 
and follow-up for cancer of the pancreas [27]; EASL clinical practice guidelines on the 
management of hepatocellular carcinoma [5,31]
• NICE guideline on pancreatic cancer in adults: diagnosis and management [32]
• American Society of Clinical Oncology clinical practice guideline on locally advanced, 
unresectable pancreatic cancer 2016 [33]
• EUnetHTA guideline on comparators and comparisons: criteria for the choice of the 
most appropriate comparator(s) [34]
Outcomes EFF-related:
• Success of the procedure (defined as the ability to complete the IRE procedure as 
planned and the absence of any residual tumour on imaging)
• OS (at 3, 6, 12, 18 and 24 months)
• Cancer-specific survival
• Disease-free survival
• PFS
• Time to recurrence
• Time to progression: radiological progression via CT scan or magnetic resonance 
imaging (MRI) at 6 weeks and 3, 6, 12, 18 and 24 months
• Time to local recurrence: local radiological progression at 6 weeks and 3, 6, 12, 18 
and 24 months
• Health-related QoL (measured via European Organisation for Research and 
Treatment of Cancer [EORTC] Quality of Life Questionnaires [QLQs] C30 andPAN26, 
Functional Assessment of Cancer Therapy hepatic [FACT-Hep], EuroQol – five 
dimensions [EQ-5D] or other questionnaires at baseline and at 6 weeks and 3, 6 and 
12 months after IRE)
• Pain
SAF-related:
• Procedure-related complications (e.g., needle-tract seeding)
• Adverse events: type, graded using the Common Terminology Criteria for Adverse 
Events (CTCAE), Dindo-Clavien classification, Society of Interventional Radiology 
(SIR) grading system or others
• Intervention-specific mortality
Rationale:
The outcomes were chosen on the basis of the following guides:
• Design and endpoints of clinical trials in hepatocellular carcinoma [35]
• Guidelines for time-to-event and endpoint definitions in trial for pancreatic 
cancer: Definition for the Assessment of Time-to-event Endpoints in CANcer trials 
(DATECAN) [36].
• EUnetHTA guidelines on endpoints used in relative effectiveness assessments: 
clinical endpoints, safety and health-related QoL and utility measures [37–39]
Study design EFF: RCTs, prospective non-RCTs and single-arm prospective studies with at least ten 
patients
SAF: RCTs, prospective non-RCT and single-arm prospective studies with at least ten 
patients
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2 METHODS AND EVIDENCE INCLUDED
2.1 Assessment team
Description of the distribution of responsibilities and the workload between authors and co-authors:
Avalia-t, as author:
• Developed the first draft of the EUnetHTA project plan and amended the project plan following 
comments from the co-author, dedicated reviewers and external experts.
• Performed the literature search and study selection.
• Conducted the assessment (data extraction, analysis, risk-of-bias assessment of the referenc-
es selected, synthesis and interpretation of findings).
• Checked assessment elements; filled in the checklist regarding potential ethical (ETH), or-
ganisational (ORG), social (SOC) and legal (LEG) aspects of the HTA Core Model® for Rapid 
Relative Effectiveness Assessment (REA).
• Sent the first draft to the dedicated reviewers, compiled feedback, answered comments and 
made changes according to the reviewers’ comments.
• Sent the second draft to the external experts, compiled feedback provided as answers to the 
reviewers and was responsible for making the corresponding changes.
• Sent the second draft to the manufacturer for fact checking, compiled feedback and made 
changes.
• Prepared the final assessment and wrote a final summary of the assessment.
LBI, as co-author:
• Collaborated in the development of the EUnetHTA project plan.
• Collaborated in the literature selection.
• Checked and approved all the steps (e.g., data extraction, assessment of the risk of bias and 
the quality of the body-of-evidence assessment) and provided methodological support.
• Reviewed the first and second draft assessments, proposed amendments where necessary 
(performed additional manual searches when needed) and provided written feedback.
• Collaborated on elaboration of the conclusions, which were discussed and agreed on.
VASPVT, NIPN and SNHTA as dedicated reviewers:
• Reviewed and discussed the EUnetHTA project plan (scoping meeting).
• Reviewed and provided comments on the first draft assessment.
• Guaranteed quality assurance.
• Reviewed and agreed on the conclusions.
2.2 Source of assessment elements
Assessment elements for the TEC, health problem, CUR, EFF and SAF domains were selected 
according to the HTA Core Model Application for Rapid REAs (4.2). The checklist for potential ETH, 
ORG, patient, SOC and LEG aspects was used to ascertain if these domains were relevant for 
assessment. For the purpose of the report, critical issues were defined in accordance with the ORG 
aspects of the HTA Core Model Application for Medical and Surgical Interventions (3.0).
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General questions referring to selected issues were translated into actual research questions (an-
swerable questions). Some research questions were grouped and answered together: the questions 
were listed below each other and the answer was provided subsequently.
2.3 Search
A systematic literature search was carried out on 26 September 2018 (and updated in January 
2019) to identify primary studies fulfilling the inclusion criteria to address the EFF and SAF domain 
elements. Search terms related to IRE and NanoKnife were used in combination with terms related 
to liver and pancreatic cancer. The bibliographic research was restricted to studies written in English, 
Spanish, Portuguese, French or Italian. No time restrictions were applied. Detailed tables on the 
search strategy are included in Appendix 1.
Information retrieval was carried out in accordance with EUnetHTA guidelines [40,41]. The following 
sources of information were used in the search:
• CRD
• Cochrane Library (Wiley)
• Embase (OVID)
• Medline (PubMed)
• Web of Science (Web of Knowledge)
• Scopus
A manual search of the reference list in relevant articles was also undertaken to recover published 
studies that might have been missed by the search. In addition, the following clinical trial databases 
were searched to identify ongoing studies:
• Clinicaltrials.gov
• ICTRP
• EU Clinical Registry
Guideline repositories were used to identify relevant guidelines for the CUR domain (GIN database, 
Trip database, PMC, CMA Infobase and Google Scholar). In addition, we searched the GLOBOCAN 
database for estimates of incidence and mortality for pancreatic and liver cancer and carried out 
a general Internet search to identify other possible publications relevant to symptoms, the natural 
course of the diseases and other issues.
Information for the TEC domain came mainly from the previous systematic literature search and the 
manufacturer’s EUnetHTA submission file, although we also carried out a general Internet search 
and reviewed the manufacturer’s website pages to compare data.
The only manufacturer identified at the time of the search (AngioDynamics) was contacted by the 
EUnetHTA Joint Action 3 WP4 Project Manager. The short version of the submission file was sent 
to the manufacturer on 16 October 2018. They were encouraged to complete sections 1, 2, 3 and 
4. The submission file was received on 14 November 2018. The manufacturer also answered the 
following points:
• Confirmation that the product is a CE marked technology and that it is the only product pro-
duced by the company that is relevant for this assessment.
• If they were aware of any other CE marked products that would be relevant for this assessment.
• To send the instructions for use and the CE certification document for the product.
• To send unpublished but nonconfidential (studies, etc.) data on the product. This ensured that 
no key information was missed.
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2.4 Study selection
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en
ti
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ca
ti
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n Additional records identified
through other sources
(n = 0)
Records identified through
database searching
(n = 1880)
Records after duplicates removed
(n = 833)
Records screened
(n = 833)
Full-text articles assessed
for eligibility
(n = 43)
Studies included in qualitative synthesis 
(n = 15)
Pancreatic cancer:
Prospective non-RCT (propensity score-
matched analysis) (n = 1)
Single-arm prospective studies (n = 7)
Liver cancer:
Single-arm prospective studies (n = 7)
Studies included in quantitative
synthesis (meta-analysis)
(n = 0)
Records excluded
(n = 790)
Full-text articles excluded,
with reasons 
(n = 28)
Exclusion criteria:
• Other study design (n = 14)
• Other population (n = 10)
• Fewer than 10 patients (n = 3)
• Patients included in
  a previous study (n = 1)
Figure 1: Flow chart for study inclusion
A total of 1880 abstracts were retrieved via the bibliographic search. After removing duplicates, 833 
abstracts remained for screening. The authoring team independently screened the titles and ab-
stracts according to the predefined inclusion criteria specified in the Scope. The following publica-
tion types were excluded: case reports, letters, congress presentations and editorials. A total of 43 
articles were selected for full-text examination. When the same institution had published sequential 
studies, the study with the largest number of cases was chosen to avoid overlap. Disagreements 
were resolved via consensus.
Twenty-eight articles were excluded for the following reasons: 14 studies had another study design 
(13 retrospective analyses and 1 letter to the editor), ten papers had a study population that differed 
from the predefined PICO question, three studies had fewer than ten patients and one study had 
duplicated patients (Figure 1).
2.5 Data extraction and analyses
Data were extracted independently by the two authors and double-checked regarding consistency and 
accuracy by the co-author. A predefined data extraction form was used for this purpose (Tables A2, 
A3 and A4 in Appendix 1). Discrepancies between authors in relation to data were resolved through 
discussion and consultation with the co-author until agreement was reached. The main investigators 
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for two of the trials [15,20] were contacted in relation to data discrepancies. Inconsistencies were 
resolved in only one of these two cases [20].
For each individual study, the following information was recorded:
• Study characteristics (author, centre, funding, conflicts of interest, trial registration number, 
study design, data collection period, inclusion and exclusion criteria)
• Population characteristics (number of participants, age, gender, clinical stage, tumour type 
and location, tumour size, treatments before the intervention, simultaneous treatments and 
treatments after the intervention)
• Intervention and control characteristics (device, approach, imaging guidance, IRE intention, 
comparator, hospital stay and length of follow-up)
• Outcomes:
◊ EFF endpoints: success of the procedure, OS (after diagnosis and after IRE), cancer-spe-
cific survival, disease-free survival, PFS, time to recurrence, time to progression, time to 
local recurrence, health-related QoL and pain
◊ SAF endpoints: procedure-related complications, AEs and intervention-specific mortality
A meta-analysis or pooling of data was not methodologically possible owing to the great variability 
between trials in terms of population characteristics, tumour size, treatments before, concomitant 
with and after IRE and length of follow-up, among other parameters. Accordingly, a narrative data 
synthesis using descriptive statistics to summarise quantitative measures is reported.
The proposed subanalyses by approach (open surgery, laparoscopy or percutaneous) or the treat-
ment received (CHEMO and/or RT) or by intention for IRE (ablation or margin accentuation) were not 
possible for any of the questions because of the lack of direct comparative data and the impossibility 
of aggregate analysis given the great variability among the studies included.
Continuous variables are presented either as the mean with standard deviation (SD) and/or the 
median with the interquartile range (IQR) or range. Categorical variables are reported as frequencies 
or percentages. Whenever possible, data reported for different measures were transformed into a 
common statistical or descriptive format.
For cases in which the authors did not report survival outcomes but did provide individual data, 
Kaplan-Meier analysis was performed for each study as part of the assessment [14,15,18,20]. In 
five cases [11,13,16,17,19], additional data were requested from investigators to estimate survival 
outcomes. This information was only obtained for two of the trials [11,17]. In calculating survival and 
recurrence/progression rates, only successfully treated patients were considered.
AEs were categorised as grade I, II, III, IV or V classes 1, 2, 3 and 4 according to the CTCAE, Dindo-
Clavien classification, SIR or other grading system. Grades III, IV and IV correspond to major AEs 
and grades II and I to minor AEs. When AEs or complications were not graded, they were recorded 
in tables as “other adverse events/complications”. Whenever possible, the number of patients who 
experienced AEs was provided. IRE-related and non–IRE-related AEs were recorded. When the 
article did not provide this information, AE were classified as IRE-related.
Data were grouped and tabulated in accordance with guidance on narrative synthesis from 
the UK Economic and Social Research Council (ESRC) [42] and the Cochrane Consumers and 
Communication Review Group guidelines on data synthesis and analysis [43].
2.6 Quality rating
Quality assessment of studies included for the EFF and the SAF domains was carried out in accor-
dance with EUnetHTA guidelines [41]. Risk of bias at the study level was assessed using the IHE 
20-Criteria Checklist [9] for single-arm studies (case series) and ROBINS-I for non-RCTs [10].
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The quality of the body of evidence was assessed using GRADE. The author team performed the 
risk-of-bias assessment and the GRADE assessment independently. Disagreements were resolved 
via consensus.
No quality assessment tool was used for the TEC and CUR domains, although information was 
validated by comparing and contrasting information from multiple sources (manufacturers, bibliogra-
phy searches, official web pages and general Internet searches). Information was synthesised in a 
descriptive manner.
Multiple sources were also used to validate individual, possibly biased, sources of information for the 
assessment of ORG issues. A descriptive analysis was performed.
2.7 Patient involvement
The current assessment involved a patient representative recruited via a patient organisation, as well 
as two individual patients. The Spanish Group of Patients with Cancer (GEPAC; Grupo Español de 
Pacientes con Cáncer) was contacted to involve a patient representative during the scoping phase. 
The president and founder of GEPAC acted as the patient representative and was responsible for 
reviewing the preliminary PICO question and the draft project plan.
Individual patients were identified through the Department of Patient/Citizen Care Services (Servicio 
de Atención ao Ciudadán e ao paciente) of the Galician Health Service (SERGAS). They were re-
sponsible for preliminary contact with a hepatobiliary surgery clinician who arranged meetings with 
patients. As IRE is not performed in our setting, participation was open to patients with pancreatic 
or liver cancer who had undergone treatment with other ablative methods, as experiences with the 
disease and ablative methods will generally be shared. Two semi-structured interviews were con-
ducted with two patients who had suffered from liver cancer and had undergone MWA. The clinician 
considered that interviewing LAPC patients would not be possible given their poor health status. 
The schedule of questions for the interview was based on the non-medicine template of the Health 
Technology Assessment International patient group [44], with questions related to key topics selected 
and redefined according to the intervention. Questions that were asked in the interview are shown in 
Appendix 1. The 1-hour face-to-face meeting was conducted by the main author after receiving ap-
propriate training. The meeting was held in Santiago de Compostela Hospital and was recorded and 
transcribed. Patient-relevant endpoints were extracted by one author (from Avalia-t) and checked by 
a second author (from Avalia-t). No formal data analysis method was used given the simple structure 
of the interview. No ethical approval was needed. Patients were asked to sign an informed consent 
form. Relevant results were incorporated in the assessment element domains as appropriate.
2.8 Description of the evidence used
Pancreatic cancer
Evidence for the EFF and SAF domains for pancreatic cancer comes from one prospective non-RCT 
(propensity score-matched analysis) and seven prospective single-arm trials. Table 3 summarises 
the main characteristics of the studies included.
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
27Version 1.4, 18 May 2019
Table 3. Main characteristics of studies included for pancreatic cancer
Author and 
year
Study type Number 
of IRE 
patients
Intervention(s) Main  
endpoints
Included in 
EFF and/or 
SAF domain
Huang 2018 
[17]
Prospective 
single-arm 
study
70 Open IRE and 
laparoscopic IRE
Success of the 
procedure, OS, PFS, 
complications
EFF and SAF
Scheffer 2017 
[16]
Prospective 
single-arm 
study
25 Percutaneous 
IRE
OS, PFS, time to local 
progression, pain, QoL, 
complications
EFF and SAF
Mansson 2016 
[14]
Prospective 
single-arm 
study 
24 Percutaneous 
IRE
OS, time to local 
recurrence, 
complications
EFF and SAF
Lambert 2016 
[11]
Prospective 
non-RCT 
(propensity 
score matched 
analysis) 
21 Percutaneous 
and open IRE
OS, QoL, 
complications
EFF and SAF
Kluger 2016 
[13]
Prospective 
single-arm 
study 
50 NR OS, time to local 
recurrence, 
complications
EFF and SAF
Paiella 2015 
[15]
Prospective 
single-arm 
study
10 Open IRE OS, QoL, 
complications
EFF and SAF
Belfiore 2015 
[18]
Prospective 
single-arm 
study
20 Percutaneous 
IRE
OS, complications EFF and SAF
Martin 2012 
[19]
Prospective 
single-arm 
study
27 Open and 
percutaneous 
IRE
Success of 
the procedure, 
complications
EFF and SAF
Abbreviations: EFF = effectiveness; IRE = irreversible electroporation; NR = not reported; OS = overall survival; QoL = quality 
of life; PFS = progression-free survival; RCT = randomised controlled trial; SAF = safety.
Sources: [11,13–19].
According to GRADE, the quality of evidence was very low for EFF and SAF outcomes (Tables A10 
and A11 in Appendix 1), as most of the evidence is from highly biased, small, single-arm trials with 
serious issues regarding inconsistency and indirectness (Table A8 in Appendix 1). The only compar-
ative trial that was included for LAPC is a small propensity-matched trial that compares IRE to non-
curative surgery [11]. As shown in Table A7 (Appendix 1) the risk of bias for this trial was classified 
as critical because of the high potential for confounding arising from the unclear patient selection and 
the possible imbalance between the intervention and control groups in terms of adjuvant treatments 
and co-interventions.
Liver cancer
Evidence for the EFF and SAF domains for liver cancer comes from seven prospective single-arm 
trials (Table 4).
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Table 4. Main characteristics of studies included for liver cancer
Author and 
year
Study 
type
Number 
of IRE 
patients
Intervention(s) Main  
endpoints
Included in 
EFF and/or 
SAF domain
Fruhling 2017 
[20]
Prospective 
single-arm 
study
30 Percutaneous 
IRE
Local recurrence, 
complications
EFF and SAF
Distelmaier 
2017 [22]
Prospective 
single-arm 
study
29 Percutaneous 
IRE
Success of the 
procedure, local 
recurrence, complications
EFF and SAF
Niessen 2016 
[25]
Prospective 
single-arm 
study
34 Percutaneous 
IRE
Success of the 
procedure, time to 
local recurrence, 
complications
EFF and SAF
Granata 2016 
[24]
Prospective 
single-arm 
study
20 Percutaneous 
IRE
Success of the 
procedure, complications
EFF and SAF
Eller 2015 
[23]
Prospective 
single-arm 
study
14 Percutaneous 
IRE
Local recurrence, 
complications
EFF and SAF
Eisele 2014 
[12]
Prospective 
single-arm 
study
13 Percutaneous, 
laparoscopic and 
open IRE
Success of the 
procedure, local 
recurrence
EFF
Cheung 2013 
[21]
Prospective 
single-arm 
study 
11 Percutaneous 
IRE
Success of the 
procedure, local 
recurrence, complications
EFF and SAF
Abbreviations: EFF = effectiveness; IRE = irreversible electroporation; SAF = safety.
Sources: [12,20–25].
According to GRADE, the quality of evidence for liver cancer was also very low for EFF and SAF 
outcomes (Table A12 in Appendix 1) as the evidence comes from seven small, single-arm trials that 
show a critical risk of bias and serious concerns regarding inconsistency and indirectness. The pa-
tient selection criteria are unclear in most of the studies, and many studies lack information regarding 
co-interventions and follow-up losses (Table A9 in Appendix 1).
2.9 Deviations from project plan
With regard to efficacy outcomes, PFS was added.
With regard to the standard of care in liver cancer, CHEMO was deleted.
With regard to the LAPC population, “primary or recurrent” was deleted to avoid confusion. This 
change does not affect the study population.
Two external experts failed to provide comments.
The patient representative from GEPAC reviewed the PICO question but failed to provide comments 
on the project plan.
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF 
TECHNOLOGY (TEC)
3.1 Research questions
Element ID Research question
B0001
What is irreversible electroporation (IRE) ablation [with a percutaneous, 
laparoscopic or open surgical approach]?
B0002 What is the claimed benefit of IRE in relation to the comparators?
B0003 What is the phase of development and implementation of IRE?
B0004 Who administers IRE? In what context and level of care is IRE provided?
B0008 What kind of special premises are needed to use IRE?
B0009 What equipment and supplies are needed to use IRE?
A0020 For what indications has IRE received marketing authorisation or a CE mark?
A0021 What is the reimbursement status for IRE?
3.2 Results
Features of the technology and comparators
[B0001] What is irreversible electroporation (IRE) ablation [with a percutaneous, laparoscopic 
or open surgical approach]?
IRE is a nonthermal ablative method involving application of short high-voltage and low-frequency 
electric fields to create nanoscale pores in tissue, resulting in permeabilisation of cell membranes. 
The permeabilisation can become irreversible when the magnitude, duration and number of the 
electrical fields applied are above a certain threshold [1]. While the mechanism of cell death caused 
by IRE is not exactly known, it is believed that it is due in part to the formation of permanent pores 
(nanopores), as this permeabilisation can lead to disruption of homeostasis and consequently induc-
tion of apoptosis.
It is alleged that IRE causes less damage to adjacent structures than other thermal ablative ap-
proaches (RFA, MWA and cryoablation). Thus, IRE would allow ablation of tumours that are localised 
close to major blood vessels or other sensitive structures such as nerves and the bile duct, maintain-
ing them intact. However, while it is not a thermal-based ablation technique, IRE can create thermal 
energy [45], and this thermal effect can also contribute in a lesser way to induction of cell death due 
to necrosis [46]. It is also believed that IRE avoids one of the limitations of other techniques that can 
lead to incomplete ablation: loss of heat (in RFA or MWA) or cold (in cryoablation) through the blood 
flow, which is known as the “heat sink effect”.
IRE can be performed percutaneously, laparoscopically or via open surgery [2]. In all cases, the 
procedure involves placing multiple electrodes around the target lesion, although sometimes a probe 
can also be placed in the centre of the nodule. The probe number and placement configuration can 
depend on the location, size and shape of the target, commonly varying from two to six per lesion in 
the studies included. The probe is directed under image guidance via US or CT. The patient requires 
general anaesthesia with deep sedation and complete muscle relaxation, with cardiac synchronisa-
tion during delivery of the high-voltage current.
According to the literature, the percutaneous approach appears to be the preferred method given the 
potentially fewer complications. However, the laparoscopic and open surgery approaches could have 
the advantages of allowing visualisation and determination of the extent of the tumour, and allow 
additional resections and procedures to be carried out if required [12,19]. For pancreatic cancer, 
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these approaches also have the advantage of allowing the needles to be positioned parallel to the 
mesenteric vessels, which is the preferred strategy for mesenteric involvement [47]. The decision 
regarding the best approach is commonly taken by a multidisciplinary team (surgeons, radiologists, 
oncologists and gastroenterologist) on the basis of CT measurements before the procedure, but 
further investigations are recommended to differentiate the patients who might be best treated by 
each approach [2]. For example, it has been shown that some comorbidities such as gastric varices 
could be a contraindication for ablation using the percutaneous approach [48].
Marketed products
The only commercialised IRE device is the NanoKnife System (AngioDynamics, Qeensbury, NY, 
USA). This system has a CE mark for cell membrane electroporation and FDA approval for soft-tissue 
ablation. It has not received clearance for therapy or treatment of any specific disease or condition.
One of the components of the NanoKnife System is the NanoKnife generator (Figure 2): a reusable, 
nonsterile low-energy direct current generator consisting of an LCD display, a console keyboard, a 
power unit and cord and a double footswitch. The unit includes software that generates a two-dimen-
sional representation of the ablation zone (according to the company EUnetHTA submission file) [26].
Figure 2. NanoKnife generator
1, LCD display; 2, console keyboard; 3, power unit and cord; 4, double footswitch
Single-use electrodes are connected to the generator. The NanoKnife System has six probes out-
puts, so users can connect up to six NanoKnife electrode probes at one time; however, only one pair 
of NanoKnife electrode probes can be operated at a time.
The probes are 15 cm or 25 cm in length and 19 gauge in diameter and are covered in a retractable 
insulation sheath, which allows adjustment of the active tip length. The probe components are la-
belled in Figure 3.
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Figure 3. NanoKnife electrode probe components
1, Active electrode, with length adjustable in 0.5-cm increments from 0 cm to 4 cm; 2, thumb slide; 
3, insulation sleeve; 4, 19-gauge needle with depth markers and an echogenic needle tip; 5, 10-
foot connection cable
There are two types of probe: an activation probe (blue in colour; Figure 4) and the standard sin-
gle-electrode probe (white in colour; Figure 5). The blue single-electrode activation probe is required 
to activate the generator, which will allow other standard single-electrode probes to function with it. 
Only one single-electrode activation probe is required to activate the generator, but a minimum of two 
probes (blue and white) are required to execute a procedure. Depending on the size of the soft tissue 
area to be ablated, a maximum of six probes can be used in a procedure.
 
Figure 4. NanoKnife single-electrode activation probe
 
Figure 5. NanoKnife single-electrode standard probe
The generator can deliver between 100 V and 3000 V of energy in 90–100 pulses, with a maximum 
pulse length of 100 ms [49]. Table 5 outlines the main features of the intervention.
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Table 5. Features of the intervention
Technology
Name NanoKnife System
Manufacturer AngioDynamics, 603 Queensbury Avenue Queensbury, NY 12804, USA
Reference codes Device Description Product Code (UPN 
or catalogue #)
NanoKnife generator 20300101 (v 2.2)
H787203003010 (v 3)
IRE probe spacer H787204003015
NanoKnife single-electrode probe, RFID activation, 15 cm H787204001030
NanoKnife single-electrode probe, 15 cm H787204001040
NanoKnife single-electrode probe, RFID activation, 25 cm H787204001050
NanoKnife single-electrode probe, 25 cm H787204001060
Class/GMDN code • Council Directive 93/42/EEC concerning medical devices: class II b
• FDA classification: class II
• GMDN: irreversible electroporation system
Mechanism of action The device applies high-voltage direct current to pairs of electrodes that are 
inserted into the body, bracketing the target tissue to be ablated. The electric field 
acts as a physical stimulus, inducing holes in cell membranes and resulting in loss 
of homeostasis and subsequent cell death. The mechanism that causes permanent 
cell damage is referred to as irreversible electroporation.
Mode of 
administration 
Percutaneous, laparoscopic or laparotomy (open surgical) approaches
Abbreviations: FDA = Food and Drug Administration; GMDN = Global Medical Device Nomenclature; IRE = irreversible elec-
troporation; RFID = radiofrequency identification; UPN = universal product number.
Source: [26].
Comparators in pancreatic cancer: What is the standard-of-care therapy?
The intended population for IRE is patients diagnosed with unresectable locally advanced pancreatic 
tumours. Despite the great advances in molecular approaches, outcomes for this population are very 
poor. The standard-of-care therapy for these patients, and thus the main comparator for our analysis, 
is CHEMO with or without RT (CRT). While the appropriate treatment has to be determined individ-
ually on the basis of performance status, gemcitabine has been the standard treatment for many 
years. The effectiveness of other chemotherapies, such as FOLFIRINOX (fluorouracil, leucovorin, 
irinotecan and oxaliplatin), is still being studied. RT is also typically offered as a palliative option to 
reduce pain. Other palliative measures might also be required to relieve symptoms such as severe 
pain. Complications such as biliary and/or duodenal obstruction may also need to be resolved, in 
addition to nutritional support [50].
For some patients who have completed or stopped CHEMO because of severe AEs, a waiting period 
can be advised, known as watchful waiting (WW). WW consists of closely watching but not giving 
treatment unless symptoms appear or change. WW is intended to minimise treatment-related toxicity 
and can also be adopted when the risks of treatment are greater than the possible benefits. WW is 
more frequent for cancers that grow slowly or for cystic lesions of the pancreas [51].
Comparators in liver cancer: What is the standard-of-care therapy?
The intended population for IRE includes patients with unresectable primary or secondary liver can-
cer who have a contraindication for thermal ablation. There are currently multiple treatment options 
for these patients, but none is highly effective. The most common treatments, and thus possible 
comparators, are TACE, multikinase inhibitors such as sorafenib and levatinib, palliative therapy and 
symptomatic therapy.
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Typically, TACE is offered to patients with intermediate-stage disease and preserved liver function, 
while sorafenib can be considered the standard first-line systemic therapy for patients with more ad-
vanced cancers and preserved liver function. As in pancreatic cancer, a WW period can be advised. 
Patients who have end-stage disease and are not candidates for a transplant might only be eligible 
for supportive palliative care and symptomatic treatment. The use of external beam RT has also 
been reported in different stages of liver cancer, and is specifically recommended to alleviate pain in 
patients with bone metastases.
[B0002] What is the claimed benefit of IRE in relation to the comparators?
Owing to its mostly nonthermal effect, IRE allows ablation of tumours localised close to major blood 
vessels or other sensitive structures. These tumours are considered unresectable [46] given the 
potential for damage to critical structures and the prognosis with existing treatments is very poor. 
Another possible advantage of IRE could be its potential for avoiding the serious toxic side effects 
related to the systemic treatments commonly used for advanced pancreatic and hepatic tumours 
(CHEMO, multikinase inhibitors, TACE and other systemic therapies). While most of the common 
toxicities include mild to moderate AEs, such as nausea, vomiting, diarrhoea, fatigue, loss of appetite 
and anaemia, some might lead to life-threatening events. In the case of sorafenib, cardiovascular 
events, arterial thromboembolic events, haemorrhage complications and renal toxicity could be fatal 
[52].
[B0003] What is the phase of development and implementation of IRE?
The technology underlying IRE, electroporation, has been in use since the 1960s [53]. It was ini-
tially used to introduce macromolecules, such as anticancer drugs, into the cell membrane, and the 
subsequent cell death was considered a side effect. However, in 2005 Davalos demonstrated the 
usefulness of IRE as an ablative method, ablating liver tissue without thermal effects. The first human 
experience with IRE was described in 2011 by Pech [54], who assessed IRE in renal cell carcinoma.
The only commercial system is the NanoKnife System, which has been available on the market 
since 2006. The system received FDA 510K clearance for surgical ablation of soft tissue in 2006 
[55] and a CE mark for cell membrane electroporation in 2010. According to company information 
[26], the NanoKnife System is currently marketed in 38 countries and territories, including Austria, 
Belgium, Denmark, England, France, Germany, Italy and Spain. Since 2017, it seems to be used in 
more than 135 unique hospitals or cancer centres in the USA (>5450 procedures). No data on its 
implementation in Europe were found, apart from the fact that NanoKnife procedures are reimbursed 
in Germany for these two cancers.
Since its approval, IRE has been used in tumours in different locations, such as liver, lung, pancreas, 
kidney and prostate [56]. There are currently several ongoing trials of IRE in additional tumours.
[B0004] Who administers IRE? In what context and level of care is IRE provided?
IRE is intended to be used in a tertiary care centre, either within an interventional radiology suite or 
in an operating room, depending on the guidance method required (open or laparoscopic placement 
versus imaging-guided percutaneous placement). The decision regarding eligibility for IRE should 
be taken by a multidisciplinary disease management team that should include surgical oncologists, 
medical oncologists, radiation oncologists, anaesthesiologists, interventional radiologists, gastroen-
terologists and pathologists [26].
Users of the NanoKnife System will include surgeons and interventional radiologists. Nurses, ra-
diology technicians, clinical specialists (depending on hospital guidelines) and other general clinical 
staff assist with the procedure. Primary and extended users may operate the user interface to control 
the NanoKnife generator and associated peripherals, including physical procedure set-up (which 
may include manoeuvring equipment and devices, connecting electrodes, placing electrocardiogram 
[ECG] connections, connecting to the power supply, etc.), establishing procedure protocols, monitor-
ing procedure progress and stopping procedures under the supervision and direction of the primary 
treating physician.
The team should have previous experience with ablative techniques and a minimum of previous 
procedures with IRE is recommended [26]. For ablation of the pancreas, a physician with extensive 
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thermal ablation experience is required (minimum of 50 cases of RFA, MWA or cryoablation in the 
liver, lung or kidney), as well as a minimum of five IRE procedures on solid organs that have greater 
degrees of tolerance, such as the liver and kidney [19].
[B0008] What kind of special premises are needed to use IRE?
[B0009] What equipment and supplies are needed to use IRE?
Before the procedure, the size and form of the tumour must be assessed to determine the number of 
probes that are needed, usually via CT or US. These imaging modalities are also used to guide the 
insertion of IRE electrodes (to ensure appropriate treatment planning and that electrodes are parallel 
to each other, otherwise incomplete ablation may occur). After the procedure, imaging techniques 
are also used to evaluate the extent of the ablated area, commonly using CT, US or MRI [49]. In 
some cases, functional positron emission tomography (PET) is used.
IRE is intended to be used with standard anaesthetic, radiological and surgical operating equipment. 
It is performed under general anaesthesia and it is important to administer a neuromuscular blocking 
agent because uncontrolled muscle contractions could occur. To reduce the risk of inducing cardiac 
arrhythmias, an ECG synchronisation device should be coupled to the IRE system [57] to ensure 
that pulses are delivered during the refractory cardiac period to prevent dysrhythmias [58]. Besides, 
it is recommended to connect the patient to an external defibrillator to intervene in case of ventricular 
arrhythmias.
The length of hospital stay will depend on the patient’s general condition and the approach that has 
been used. A laparotomy approach (open surgery) usually requires a longer hospital stay, while 
a percutaneous approach should lead to a shorter stay. Globally, it has been reported that some 
patients return home the same day or the following morning, while in other studies the stay is longer 
than 2 weeks.
[A0020] For what indications has IRE received marketing authorisation or a CE mark?
The NanoKnife System has received a CE mark for cell membrane electroporation but has not been 
approved for the treatment of any specific disease or condition. In the USA, it has received FDA ap-
proval for surgical ablation of soft tissue and in early 2018 the NanoKnife System received expedited 
access pathway designation for the treatment of stage III pancreatic cancer. The expedited access 
pathway is designed to accelerate the approval process for medical devices to treat conditions for 
which no alternatives are available.
The IRE system has been used to treat various organs, including liver, pancreas, prostate, kidney, 
lung, pelvis and lymph nodes, with different levels of evidence available for each organ. With regard 
to the pancreas and liver, most patients are offered NanoKnife IRE for local ablation of primary or 
secondary tumours that are not resectable or suitable for thermal ablation because of proximity (<0.5 
cm) to major hepatic or portal vein branches or bile duct structures [59].
Contraindications for the technique are as follows [26,47]:
• Ablation of lesions in the thoracic area in the presence of implanted cardiac pacemakers or 
defibrillators
• Ablation of lesions in the vicinity of implanted electronic devices or implanted devices with 
metal parts
• Ablation of lesions of the eyes, including the eyelids
• A patient history of epilepsy or cardiac arrhythmia
• Recent history of myocardial infarction
[A0021] What is the reimbursement status of IRE?
To the best of our knowledge, IRE reimbursement for pancreas and liver cancer is only available in 
Germany. Detailed information on the reimbursement status/recommendations for IRE is included in 
Table A15 in Appendix 2.
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4 HEALTH PROBLEM AND CURRENT USE OF THE 
TECHNOLOGY (CUR)
4.1 Research questions
Element ID Research question
A0002 What is pancreatic cancer? What is liver cancer (primary or secondary)?
A0004
What is the natural course of the pancreatic cancer?
What is the natural course of the liver cancer (primary or secondary)?
A0005
What are the symptoms and the burden of disease for patients with pancreatic 
cancer?
What are the symptoms and the burden of disease for patients with liver cancer 
(primary or secondary)?
A0024
How is pancreatic cancer currently diagnosed according to published guidelines 
and in practice?
How is liver cancer (primary or secondary) currently diagnosed according to 
published guidelines and in practice?
A0025
How is pancreatic cancer currently managed according to published guidelines 
and in practice?
How is liver cancer (primary or secondary) currently managed according to 
published guidelines and in practice?
A0007
What is unresectable locally advanced pancreatic cancer (LAPC)?
What is unresectable liver cancer (primary or secondary) for which thermal 
ablation is contraindicated?
A0023
How many patients belong to the unresecatble LAPC) group?
How many patients belong to the unresectable liver cancer (primary or secondary) 
contraindicated for thermal ablation group?
A0011 How much is IRE utilised?
4.2 Results
Overview of the disease or health condition
[A0002] What is pancreatic cancer?
Cancer of the pancreas is one the most lethal cancer types, with more than 330,000 new cases 
diagnosed in 2012 and approximately the same number of deaths worldwide [60]. For 2018, the 
estimated incidence increased to 458,918 new cases [3]. In Europe, pancreatic cancer is the fourth 
most fatal cancer among both men and women [61].
Pancreatic cancer may arise in the exocrine or endocrine parenchyma, but the exocrine parenchyma 
is the most common site. Most often, these tumours begin to develop in the pancreatic ducts, so they 
are called ductal adenocarcinomas [27]. The head of the pancreas is the most common location of 
tumours. Male sex and age 60–80 years are two risk factors for pancreatic cancer.
What is liver cancer (primary or secondary)?
Liver cancer is the second most frequent cause of death from cancer worldwide [5].There were 
850,000 new cases diagnosed in 2015 and 810,000 deaths [6]. Estimations for Europe in 2018 
showed a 5-year prevalence of 8.7% [3].
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HCC is the most common type of liver cancer, accounting for 90% off all cancers of the liver. This 
type of cancer begins in hepatocytes. The incidence of HCC increases progressively with age and is 
higher among males. However, HCC incidence varies by geographic areas, and is highest in Asian 
and African countries and moderate in Europe and Latin America. This difference is because of 
variation in the prevalence of associated risk factors [62]. A much less common cancer is intrahepatic 
cholangiocarcinoma, which begins in intrahepatic bile ducts [63]. Apart from primary hepatic cancer, 
a more frequent cause of liver tumours besides primary tumours is metastases in patients with 
extrahepatic neoplasia, which is often a colorectal adenocarcinoma [7]. Metastases from breast and 
lung cancer are also common [64].
[A0004] What is the natural course of the pancreatic cancer?
Most pancreatic cancers are caused by mutations that occur sporadically, and only 10% of cases 
are associated with hereditary syndromes. Most pancreatic cancers originate in the ductal epithelium 
and grow through different grades of preinvasive pancreatic intraepithelial neoplasia (pANin) to fully 
invasive cancer [65]. This histological progression is accompanied by consecutive genetic mutations. 
There are four major driver genes for pancreatic cancer: KRAS, CDKN2A, TP53 and SMAD4 [66]. 
From a genetic perspective, pancreatic cancer is a complex and heterogeneous disease [65] and 
approximately 63 mutations are estimated to be involved [67].
Pancreatic cancer progresses rapidly and is often diagnosed when it is at an advanced stage. In 
contrast to other types of cancer, the prognosis has not improved in recent years. The overall 5-year 
survival is approximately 5% (65). Therefore, in most cases therapeutic measures will be focused on 
relieving symptoms and prolonging survival as much as possible.
What is the natural course of the liver cancer (primary or secondary)?
In most cases, the onset of primary liver cancer is preceded by cirrhosis of the liver [5]. The liver 
tissue slowly changes to the detriment of normal hepatocytes, and becomes fibrous and scarred [68]. 
Among the most common risk factors are viral hepatitis (B or C), chronic alcohol intake and other 
metabolic diseases such as haemochromatosis, α
1
-antitrypsin deficiency and nonalcoholic fatty liver 
disease [5].
Approximately one-third of cirrhotic patients will develop HCC [5]. The prognosis for this type of 
tumour depends on the degree of liver dysfunction and the tumour extent. In many cases, when 
symptoms appear the cancer is already at an advanced stage. If the diagnosis is made at an early 
state, the estimated 5-year survival is approximately 28% [69].
The natural course of secondary liver cancer depends on the origin of the neoplasm.
Effects of the disease or health condition
[A0005] What are the symptoms and the burden of disease for patients with pancreatic cancer?
In the early stages of pancreatic cancer there are usually no symptoms to raise suspicion of the 
disease. Symptoms usually appear when the cancer is already at an advanced stage and there 
are metastases in distant organs. The symptoms depend on the area of the pancreas in which the 
tumour is located as well as the stage of the disease [65].
Obstructive cholestasis due to compression of the common bile duct is common in cancers located in 
the head of the pancreas. Tumours located in the body and tail of the pancreas do not have a specific 
symptomatology, which normally leads to later diagnosis. Some of the most common symptoms 
are weight loss, jaundice, abdominal pain, bloating, floating stools, dyspepsia, nausea, vomiting, 
pruritus, lethargy and in some cases pancreatitis [27]. Recent-onset non-insulin-dependent diabetes 
is also relatively common [70–72].
What are the symptoms and the burden of disease for patients with liver cancer (primary or 
secondary)?
In liver cancer, symptoms commonly appear when the cancer is at an advanced stage. Some of the 
frequent symptoms are loss of appetite, weight loss, nausea or vomiting, pain in the abdomen and 
jaundice, among others [73].
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In cirrhotic patients, a liver tumour may be suspected if the symptomatology gets worse, although the 
cancer is commonly diagnosed during radiological and serological surveillance testing.
Current clinical management of the disease or health condition
[A0024] How is pancreatic cancer currently diagnosed according to published guidelines and 
in practice?
When a pancreatic tumour is suspected, diagnostic imaging tests should be performed to provide 
information about the size of the tumour and the disease burden. Serum biomarkers CA 19-9 and 
CEA lack sensitivity as single tests for diagnosing malignancy [27,32,50,74]. CT is considered the im-
aging technique of choice for diagnosis and staging [27,32,74]. A CT scan can confirm the presence 
of a pancreatic tumour and guide the surgical approach, as it identifies the location of the tumour in 
relation to the mesenteric artery, celiac axis, superior mesenteric vein and portal vein [65].
Endoscopic US can also be used to provide complementary information [27,32,50]. This technique 
has the advantage of allowing biopsy of pancreatic tissue and lymph nodes to check for distant 
metastasis [27], which is indicated when there is high suspicion of pancreatic cancer but CT imag-
ing is inconclusive, or when cytological or histological pancreatic samples are required. The NICE 
guideline also proposes offering fluorodeoxyglucose PET/CT when the diagnosis is not clear [32]. 
Less commonly, clinicians may sometimes find it necessary to perform MRI or magnetic resonance 
cholangiopancreatography, for example in cases of allergy to CT contrast medium or for patients 
with cystic lesions [27,29,32]. Endoscopic retrograde cholangiopancreatography could be useful in 
evaluating biliary anatomy but has on added diagnostic value over CT or MRI [27].
How is liver cancer (primary or secondary) currently diagnosed according to published guide-
lines and in practice?
Liver cancer diagnosis is based on imaging tests [5]. Patients with chronic liver disease should be 
entered into screening programs and undergo US every 6 months. When a nodule larger than 1 cm 
is found, additional contrast-enhanced tests (mainly CT or MRI) should be performed to confirm the 
existence of the tumour. Further confirmation using other invasive tests is not required because of 
the typical hallmarks of HCC: a combination of hypervascularity in the late arterial phase and wash-
out on portal venous and/or delayed phases, which reflects the vascular derangement that occurs 
during hepatocarcinogenesis. In cases of doubt, a biopsy should be performed [5]. For any mass 
found that is <1 cm, the patient should be followed up every 4 months during the first year and then 
every 6 months.
Nodules found in noncirrhotic patients should be confirmed by liver biopsy (as the presence of the 
hallmarks may not be HCC-specific). Noncirrhotic patients are usually diagnosed at a more advanced 
disease stage as they are not included in screening programs.
[A0025] How is pancreatic cancer currently managed according to published guidelines and 
in practice?
Clinical staging
Staging of pancreatic cancer is the first step in deciding on the best treatment option. The AJCC 
TNM system is often used for pancreatic cancer staging [75]. Three categories are considered in this 
classification: the size and location of the primary tumour (T), the adjacent lymph nodes (N) and the 
presence or absence of metastasis (M). In pancreatic cancer, the local extent, which may involve 
surrounding vessels, is taken into account. Using this classification, stages I, II, III and IV can be 
identified. The TNM classification nomenclature is presented in Table 6.
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Table 6. TNM staging of pancreatic tumours
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1
T2
Tumour limited to the pancreas, ≤2 cm in diameter
Tumour limited to the pancreas, >2 cm in diameter
T3 Tumour extends beyond the pancreas but without involvement of the celiac axis or the superior 
mesenteric artery
T4 Tumour involves the celiac axis or the superior mesenteric artery (unresectable primary tumour)
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node(s) metastasis
N1 Regional lymph node(s) metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1-3 N1 M0
Stage III T4 any N M0
Stage IV Any T any N M1
Source: AJCC cancer staging manual [75].
The AJCC staging system is used to assess the clinical prognosis and generate patient survival data 
according to the disease stage. However, the NCCN consensus guidelines [29] define a staging 
system for treatment purposes that is based on whether the tumour is considered operable or not 
(depending on tumour location within the pancreas and arterial or venous involvement). According 
to this system, based on the American Hepato-Pancreatico-Biliary Association consensus report, a 
tumour is considered resectable if it can be completely removed with negative margins. The catego-
ries are as follows:
• Resectable (localised disease, includes stages I and II)
• Unresectable:
◊ Borderline resectable: tumour abutment or <180° contact around the circumference of the 
superior mesenteric artery or coeliac arteries, or a short segment of hepatic artery or the 
superior mesenteric vein, pulmonary vein or confluence of these veins
◊ Locally advanced (stage III): tumour encasement of >180° of the circumference of the supe-
rior mesenteric artery or coeliac arteries, any unreconstructable venous involvement
◊ Metastatic (stage IV)
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Resectability as defined according to the NCCN guidelines is presented in Table 7.
Table 7. Definition of resectability according to NCCN guidelines
Resectability
status
Arterial Venous
Resectable No arterial contact (CA, SMA or CHA) No tumour contact with the SMV or 
PV or <180° contact without vein 
contour irregularity
Borderline
resectable
Pancreatic head/uncinated process
• Solid tumour with CHA without extension coeliac 
axis or hepatic artery bifurcation allowing for 
safe and complete resection and reconstruction
• Solid tumour contact with the SMA <180
• Presence of variant arterial anatomy (e.g. 
accessory right hepatic artery) and the presence 
and degree of tumour contact should be noted if 
present as if may affect surgical planning
Pancreatic body/tail
• Solid tumour contact with the CA of 180°
• Solid tumour contact with the CA of 180° without 
involvement of the aorta and with an intact and 
uninvolved gastroduodenal artery (some prefer 
these criteria to be in the unresectable category)
• Solid tumour contact with the SMV 
or PV or >180° contact without vein 
contour irregularity or thrombosis 
of the vein, but with suitable 
vessels proximal and distal to the 
site of involvement to allow safe 
and compete resection and vein 
reconstruction
• Solid tumour contact with the IVC
Unresectable Distant metastases
• Pancreatic head/uncinated process
• Solid tumour contact with SMA of >180°
• Solid tumour contact with CA of >180°
• Solid tumour contact with the first jejunal SMA 
branch
Body and tail
• Solid tumour contact with SMA and CA
• Solid tumour contact with CA and aorta
Pancreatic head/uncinated process
• Unreconstructable SMV/PV due to 
tumour involvement or occlusion 
(can be due to tumour or bland 
thrombus)
• Contact with the most proximal 
draining jejunal branch into SMV
Body and tail
• Unreconstructable SMV/PV due to 
tumour involvement or occlusion 
(can be due to tumour or bland 
thrombus)
Abbreviations: CA = coeliac axis; CHA = common hepatic artery; IVC = inferior vena cava; PV = portal vein; SMA = superior 
mesenteric artery; SMV = superior mesenteric vein.
Source: National Comprehensive Cancer Network guidelines [29].
Treatment of pancreatic cancer
Treatment of pancreatic cancer should be managed by a multidisciplinary team that includes sur-
geons, medical and radiation oncologists, radiologists, gastroenterologists, nutritionists, pain spe-
cialists and palliative care specialists. There are different possibilities according to the disease stage, 
the tumour location, whether main vascular structures and/or nerves are affected and the general 
health status of the patient.
Open surgery is the standard of care and the only curative option for pancreatic cancer [27,32].
Surgical candidates can be divided into patients with clearly resectable cancer at diagnosis and pa-
tients with borderline resectable cancer. Existing guidelines recommend that patients with resectable 
disease should be treated with immediate surgery followed by adjuvant therapy to decrease the risk of 
metastasis [27,29,32,50]. The ESMO and Spanish Society of Medical Oncology (SEOM) guidelines 
recommend adjuvant treatment with either with F-fluorouracil/folinic acid or gemcitabine [27,50]. The 
NICE guideline recommends gemcitabine plus capecitabine, and gemcitabine for those who are not 
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able to tolerate a combined treatment. Most guidelines agree that CRT should be considered only in 
the clinical trial setting, as controversial results have been obtained in previous studies [27,32,50].
While it is considered that surgery should not be the initial approach for patients with borderline 
resectable cancer, there is no clear consensus regarding the use of neoadjuvant CHEMO outside 
of clinical trials [27,29,32,50,74]. According to the ESMO guideline, the best option for patients not 
included in a trial appears to be CHEMO (gemcitabine or FOLFORINOX) followed by CRT before 
surgery.
Regardless of treatment, survival for patients with nonresectable cancer or LAPC is low, at <1 year in 
older studies and approximately 15–16 months in recent trials [27]. According to existing European 
guidelines, the preferred treatment for advanced cases is CHEMO [27,32,50,74]. The ESMO, SEOM 
and Belgian Health Care Knowledge Centre guidelines recommend gemcitabine as monotherapy 
[27,50,74]. According to SEOM, FOLFIRINOX or gemcitabine/albumin-bound paclitaxel could be 
a valid alternative, while NICE recommends combination CHEMO, with gemcitabine for those who 
cannot tolerate this treatment. SEOM also recommends CRT for selected patients after stabilisa-
tion of the CHEMO response or induction consolidation. The only radiosensitiser recommended is 
capecitabine [27,32]. American guidelines [33,76] also recommend combination regimens and pro-
pose that CRT/stereotactic body RT may be offered as an alternative when there is a response or 
stable disease after 6 months of induction therapy. In all cases, these treatments should be accom-
panied by the recommended strategies for relief of pain and symptom burden, which might include 
palliative RT, as well as other medication.
Ablative techniques such as IRE and other thermal techniques are not considered standard of care 
for patients with pancreatic tumours.
Pain control or relief from biliary and/or duodenal obstruction is frequently needed in LAPC and 
metastatic cancer. CHEMO is only recommended when the patient’s performance status is good 
enough. In general, gemcitabine is considered as the first option, and can be combined with other 
chemotherapies, depending on the patient’s performance status.
A summary of treatments in pancreatic cancer according to stage is presented in Figure 6.
Diagnosis of
pancreatic
carcinoma
Bordeline
resectable
pancreatic cancer
Resectable
pancreatic
cancer
Bordeline
resectable
pancreatic cancer
Locally
advanced
pancreatic cancer
Metastasic
pancreatic
cancer
Surgery
Neoadjuvant
Chemotherapy
+/– RT
Chemotherapy
Chemotherapy
and/or best
supportive care
Surgical
exploration
Figure 6. Treatment of pancreatic cancer
Abbreviations: RT = radiotherapy.
Source: Adapted from ESMO guidelines [27].
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
41Version 1.4, 18 May 2019
How is liver cancer (primary or secondary) currently managed according to published guide-
lines and in practice?
Once the presence of a liver neoplasm has been confirmed, the disease extent should be investigat-
ed and the prognosis evaluated to define the best management strategy. To this end, different stag-
ing systems have been developed. One of these is the TNM, which is the standard staging system 
in oncology. According to this classification there are four main T stages (T1–T4) with subcategories 
as shown in Table 8.
Table 8. TNM staging of liver cancer
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Solitary tumour without vascular invasion
T2 Solitary tumour with vascular invasion or multiple tumours (none >5 cm)
T3a Multiple tumours >5 cm
T3b Single tumour or multiple tumours of any size involving a major branch of the portal vein or 
hepatic vein
T4 Tumour(s) with direct invasion of adjacent organs other than the gallbladder or perforation 
of the visceral peritoneum
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA T3a N0 M0
Stage IIIB T3b N0 M0
Stage IIIC T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T N1 M1
Source: AJCC cancer staging manual (75).
The TNM classification, which is widely used for other types of cancer, has several limitations for 
HCCs [77,78]. First, pathological information is required to classify patients and this is not always 
available. Second, the TNM system does not allow classification according to liver functional status 
or health status or evaluation of a patient’s prognosis. European guidelines recommend that staging 
should include assessment of tumour extent, as well as liver function, portal pressure and clinical 
performance status [5,31].
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The EASL and ESMO guidelines, as well as many other guidelines of national HCC associations 
(Spain, Italy), endorse the Barcelona Clinic Liver Cancer (BCLC) [79] classification for HCC staging. 
This classification has been externally validated and has the advantage of being a dynamic system 
that allows the entry of new treatments shown to improve patient survival. The BCLC classification 
considers tumour status, liver function and health performance status, along with treatment-depen-
dent variables. Liver function is assessed via the Child-Pugh class, which takes into account ascites, 
encephalopathy, serum albumin, bilirubin and prothrombin time; each parameter is scored from 1 to 
3, with 3 indicating the most severe damage. Three categories are then defined (A, B or C) according 
to the total score. Health performance status is assessed using the Eastern Cooperative Oncology 
Group (ECOG) scheme, which has five categories according to the patient’s ability to care for them-
selves, daily activity and physical ability [80].
The BCLC classification has five stages (0, A, B, C and D) with therapeutic options recommended 
for each (Figure 7).
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liver transplantation
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Figure 7. BCLC classification of liver cancer
Abbreviations: ECOG = Eastern Cooperative Oncology Group; PS = performance status.
Source: BCLC classification [79].
Treatment of hepatocarcinoma cancers
HCC patients should be treated by multidisciplinary teams that include hepatologists, radiologists, 
surgeons, pathologists and oncologists. In general, the treatment choice for HCC depends on the 
degree of hepatic involvement, the size and distribution of the tumour, the vascular involvement and 
the general health status of the patient.
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According to current guidelines [5,28,31,81–85], liver resection (LR) represents the treatment of 
choice for small early-stage tumours in noncirrhotic patients and in cirrhotic patients with single 
nodules with preserved liver function and no evidence of portal hypertension (Child Pugh A–B; BCLC 
stage 0 and A). There is no proof of any additional benefit with neoadjuvant or adjuvant systemic 
therapies.
Liver transplantation (LT) is recommended for early-stage disease in noncirrhotic and cirrhotic pa-
tients who meet the Milan criteria (solitary lesion of <5 cm or 2–3 nodules <3 cm, without vascular 
invasion or extrahepatic dissemination) [5,31,81–85].
Among ablative techniques, RFA is considered the first-line treatment for patients with a contra-
indicated to LR or LT because of associated disease. RFA can also constitute an alternative to 
surgery for noncirrhotic patients with very early-stage disease (solitary nodules <2 cm) [5,31,81–85]. 
While awaiting LT, patients could also be offered resection, local ablation or TACE. The estimated 
5-year survival for patients treated with LR, LT or RFA is 70–90% for those diagnosed with very ear-
ly-stage disease (BCLC 0) and 50–70% for those presenting with early-stage disease (BCLC A) [31]. 
Although there is no consensus on extending the criteria for surgery, several guidelines propose that 
the suitability for LR or LT should also be assessed for patients with intermediate-stage tumours that 
can be downgraded to meet the corresponding criteria, given that surgery is the only curative option 
[5,83,84]. Selected patients with larger or multinodular tumours or advanced compensated liver fail-
ure can also be treated with RFA, but the response rate for these tumours is much lower. According 
to the Dutch guideline, RFA can be also be used for larger tumours provided the Child Pugh score 
is <8 [81]. The EASL guideline states that IRE can be considered as a novel form of ablation that is 
currently not recommended over thermal ablation techniques as it requires general anaesthesia and 
deep muscular blockage, making it more demanding and costly. Other ablative treatments under 
investigation are laser ablation and cryoablation [5].
Currently, TACE is the first-line treatment for cirrhotic patients with intermediate-stage tumours that 
do not meet the Milan criteria [5,81–85] or those with asymptomatic multinodular tumours without 
macroscopic vascular invasion or extrahepatic spread (BCCL B). TACE involves infusion of a cy-
totoxic agent, followed by arterial occlusion with embolising agents, most often Gelfoam particles. 
Although TACE is the only potential strategy with clinical benefits, the median patient survival is just 
approximately 20 months [5,31]. Side effects include those due to the chemoembolisation agent 
used, commonly doxorubicin, in addition to those due to the intra-arterial procedure, which can in-
clude pain, fever, hepatic decompensation and in rare case infarction of organs other than the liver 
[5,84].Serious complications can occur in 3–5% of patients treated [84]. Some studies seem to have 
shown that doxorubicin-eluting beads might result in fewer systemic side effects and some guidelines 
recommend these over conventional TACE [81]. Although there are multiple ongoing trials assessing 
other locoregional treatments such as transcatheter arterial radioembolisation and external RT, these 
are not recommended in most guidelines given the lack of comparative evidence.
Although it is acknowledged that there is currently no effective treatment for advanced-stage cancer 
(BCCL C), sorafenib is commonly recommended for patients with compensated cirrhotic disease 
and good performance status [5,31,81–85]. An Italian position paper recommends sorafenib only 
for patients who are not candidates for surgery or locoregional treatments (ablation, TACE) or when 
TACE has failed [83]. A randomised trial has shown that sorafenib can increase median survival 
from approximately 8 to 10 months. Best supportive care is recommended for patients with heavily 
impaired liver function or poor performance status (BCLC C) and for patients who experience pro-
gression or are intolerant to sorafenib. For example, patients who might have bone metastases might 
benefit from palliative RT. CHEMO is currently not recommended.
Target population
[A0007] What is unresectable locally advanced pancreatic cancer (LAPC)?
Regarding pancreatic cancer, the target population in this assessment is:
• Patients diagnosed with nonmetastatic but unresectable disease due to involvement of the 
coeliac trunk or superior mesenteric artery, classified as LAPC according to the NCCN guide-
lines or as stage III according to the AJCC criteria. Recurrent cancers will also be considered.
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The following subgroups will be considered:
◊ Patients who have already received CHEMO and/or RT and the tumour does not progress
◊ Patients who have already received CHEMO and/or RT and the tumour becomes resect-
able; IRE is applied for margin accentuation
◊ Patients who have not received CHEMO or RT
What is unresectable liver cancer (primary or secondary) for which thermal ablation is 
contraindicated?
Regarding liver cancer, the target population in this assessment is:
• Patients diagnosed with unresectable (primary or secondary) liver cancer for which thermal 
ablation is contraindicated because of the risk of collateral damage to biliary, vascular or struc-
tures due to the effect of heat.
The following subgroups will be considered:
◊ Patients with primary liver cancer
◊ Patients with secondary liver cancer, differentiated by origin/histology
[A0023] How many patients belong to the unresectable LAPC?
The global incidence of pancreatic cancer is increasing, with more than 330,000 new cases diag-
nosed in 2012 [60]. For 2018, the estimated incidence was 458,918 new cases [3], and 18.8 new 
cases per 100,000 individuals in Europe, with the highest incidence in Western Europe [86].
Estimating exactly how many patients have LAPC and could therefore benefit from IRE is not easy. It 
is estimated that at the time of diagnosis, approximately 40% of patients have metastatic disease and 
another 40% have LAPC (stage III) [4]. According to these data, we could estimate that more than 
180,000 cases of LAPC would be diagnosed each year worldwide. According to a systematic review, 
approximately one-third of patients who are diagnosed with LAPC may show resectable disease 
after neoadjuvant therapy [87].
How many patients belong to the unresectable liver cancer (primary or secondary) contrain-
dicated for thermal ablation group?
The incidence of primary liver cancer is increasing. In 2012, there were 782,000 new cases world-
wide [60]. The estimated incidence for 2018 in Europe is 12.4 new cases per 100,000 individuals, 
with the highest estimates for Southern and Western Europe [86]. Secondary liver tumours are even 
more frequent than primary liver cancer but the incidence is unknown. Some authors have reported 
hepatic metastases in as many as 40–50% of adult patients with extrahepatic primary tumours [8].
[A0011] How much is IRE utilised?
According to the manufacturer, more than 135 unique hospitals or cancer centres have performed 
NanoKnife procedures in the USA since 2017. The NanoKnife System has been used in >5450 
procedures since being introduced to the US market in 2007.
No information regarding the extent of IRE utilisation in the European Union was found.
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5 CLINICAL EFFECTIVENESS (EFF)
5.1 Research questions
Element ID Research question
D0001 What is the expected beneficial effect of IRE on mortality?
D0005
How does IRE affect the symptoms and findings (severity, frequency) of pancreatic 
cancer?
How does IRE affect the symptoms and findings (severity, frequency) of liver 
cancer (primary or secondary)?
D0006
How does IRE affect the progression (or recurrence) of pancreatic cancer?
How does IRE affect the progression (or recurrence) of liver cancer (primary or 
secondary)?
D0011 What is the effect of IRE on patients’ body functions?
D0012 How does IRE affect general health-related quality of life?
D0013 What is the effect of IRE on disease-specific quality of life?
D0017 Were patients satisfied with the technology?
5.2 Results
The critical outcomes for evaluating effectiveness were OS, cancer-specific survival, disease-free 
survival, PFS, time to progression, time to recurrence, time to local recurrence, QoL and pain, as 
these reflect the main endpoints of the treatment.
Pancreatic cancer
Included studies
The systematic literature search was restricted to randomised and nonrandomised clinical trials and 
prospective observational studies. A total of eight studies met our eligibility criteria. No RCTs were 
found. One of the studies included was a non-RCT trial (propensity score matched) [11]. The rest 
of the studies were considered to have a prospective single-arm design, although the information 
provided was uncertain in three cases [14,17,19]. Characteristics of the studies included and the 
results are presented in Tables A2 and A3 in Appendix 1.
The studies included were published between 2012 and 2018 and originated from the Czech 
Republic (n = 1), Netherlands (n = 1), Sweden (n = 1), USA (n = 2), Italy (n = 2) and East Asia coun-
tries (Taiwan, Singapore, Korea and China). All but two [17,19] described single-centre experiences. 
Safety/procedural complications or feasibility were reported as the main objective in five of these 
studies [11,13,15–17]. Efficacy outcomes included control of disease, local progression, event-free 
survival, PFS, OS and alleviation of pain.
Patient characteristics
Overall, the studies included provided results for 247 IRE-treated patients. The study sample size 
studies ranged from 10 to 70 patients.
The non-RCT [11] included 21 patients with AJCC stage III disease who were treated with IRE. These 
patients were compared with 32 patients who underwent some type of noncurative surgery, including 
exploratory laparotomy, non-radical resection, bypass surgery, cholecystectomy or percutaneous 
biopsy only. All of the patients had a good performance status (Karnofsky performance status [KPS] 
≥80). The mean age of subjects was 68 years in the IRE group and 65.2 years in the control group 
(p = 0.22). Females accounted for 52.4% of the IRE group and 31.3% of the control group (p = 0.10). 
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In both groups, most of the tumours were adenocarcinomas (76% vs 69%) located in the head of 
the pancreas (81% vs 75%). All tumours were ≤6.5 cm. In the IRE group, neoadjuvant CHEMO 
was given to 23.8% of the patients and 33.3% received CHEMO after IRE. Some patients from the 
control group received CHEMO (percentage not reported). The median follow-up for patients was 
8.19 months (range 1.25–26.8).
The seven prospective single-arm observational studies enrolled 226 patients treated with IRE. The 
median age ranged between 61 and 70 years (Huang et al. [17] did not report age information). All 
of the patients were estimated to have biopsy/histologically confirmed LAPC defined according to 
the NCCN or AJCC TNM system. With the exception of Kluger et al. [13], studies included only pa-
tients with unresectable disease before CHEMO/CRT. The majority suffered from adenocarcinomas 
located in the head of the pancreas. Tumour size ranged from ≤3 cm to 6.5 cm. Patients with severe 
disease and those who were completely disabled were commonly excluded [11,13,14,16]. Mansson 
et al. [14] restricted inclusion to individuals with expected survival of ≥3 months. In the study by 
Martin et al. [19] all patients had advanced pain previous to IRE.
Most of the patients received CHEMO and/or CRT before IRE, and CHEMO was also offered to 
some of the subjects after IRE in several trials [11,14,15,17,18] using different treatment regimens 
and schemes. In two of the studies, patients who experienced downstaging received surgery [13,18]. 
In the study by Huang et al. [17], only patients who did not experience disease progression after 
CHEMO were included. Scheffer et al. [16] excluded subjects who could be successfully downstaged 
to resectable tumour and Paiella et al. [15] considered only those who did not respond to standard 
treatments.
Two of the studies declared a conflict of interest [16,19].
Procedure
IRE was performed using the NanoKnife System in all cases. The approach was open surgery in 
four of the trials (≥90% of patients) [11,15,17,19] and percutaneous in three studies [14,16,18]; infor-
mation was lacking in one study [13]. Overall, open surgery was used in 120 procedures (48.6%), a 
percutaneous approach in 72 (29.1%) and a laparoscopic approach in five (2.0%). Image guidance 
was carried out using US in four studies and CT in two.
In most cases, IRE was performed with an ablative intent using CT or US guidance. In two studies, 
IRE was offered for either margin accentuation or primary control [13,19]. Kluger et al. [13] treated 
three patients with a second IRE procedure. The number of needles used for IRE varied from two to 
six (mean 3–4). The median procedure duration in the studies that mainly used open surgery varied 
from 79 to 165 minutes [11,15,17,19]. The duration for the percutaneous approach was not reported, 
except for two patients included in the study by Lambert et al. (26 minutes) [11].
In three of the studies, additional procedures were also performed at the time of IRE, including 
gastrojejunostomy, double bypass, cholecystectomy, gastroenteroanastomosis and hepaticojejunos-
tomy [11,13,19].
Follow-up
Seven of the eight studies had median follow-up of ≤12 months. The longest follow-up was 28.1 
months [17] and the shortest was 3 months [19].
Liver cancer
Studies included
The systematic search was restricted to randomised and nonrandomised clinical trials and prospec-
tive observational studies. No RCTs were found. A total of seven prospective single-arm studies 
met our eligibility criteria. The characteristics of the studies included and the results are presented 
in Table A3 in Appendix 1. The trials were single-centre experiences in Sweden (n = 1), Germany 
(n = 4), Italy (n = 1) and Australia (n = 1). The studies were published between 2013 and 2017. Six 
trials reported on EFF and SAF outcomes and one on only EFF outcomes.
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Patient characteristics
The seven studies enrolled 151 patients with 220 IRE-treated lesions. The study sample size varied 
from 11 to 34 patients (mean 20.57 ± 8.84). The mean age of patients ranged from 59.4 to 70 
years. Females represented 30% of the population. All of the patients treated had unresectable liver 
tumours not suitable for thermal ablation (RFA, MWA or cryoablation) because they were located 
near major hepatic or portal vessels, bile duct structures or peripheral important structures. All of the 
patients had fewer than three malignant lesions, which were commonly ≤3 cm. Two studies restricted 
inclusion to primary HCC tumours [21,24]; the rest included primary and secondary tumours, mainly 
colorectal liver metastases. Another two restricted inclusion to patients with good performance status 
[20,24]. All of the patients included in the two studies that treated only primary tumours had chronic 
liver disease of Child-Pugh class A [24] and Child-Pugh classes A and B [21]. Apart from Niessen 
et al. [25], who included patients with Child-Pugh class A, B and C disease, none of the studies 
provided information regarding liver function. Tumour stage for primary HCC was only provided in 
one study (stage A, BCLC classification) [24].
Four studies [12,20,23,25] reported that patients had received several treatments before IRE, includ-
ing surgical treatments, systematic therapy, RFA/MWA, brachytherapy, RT and TACE, among others.
Only Cheung et al. [21] declared a potential conflict of interest: the research equipment was received 
from AngioDynamics.
Procedure
The NanoKnife System was used in all cases. In six of the seven studies, IRE was performed via a 
percutaneous approach. Overall, the percutaneous approach was used in 145 patients (96%), the 
laparoscopic approach in four (2.6%) and open surgery in two (1.3%).
In all studies, IRE was used with an ablative intent and CT or US was used for imaging guidance. 
The number of needles used varied from two to six. The mean duration reported for percutaneous 
procedures varied from 1 to 5 hours. Eisele et al. [12] reported a mean procedure time of 4 hours for 
an open approach and 2.58 hours for a laparoscopic approach.
Follow-up
The mean follow-up was <18 months in four studies [12,23–25]. The shortest follow-up was in the 
study by Granata et al. [24] at 6 months. The longest follow-up times were in the studies by Fruhling 
et al. [20] (median 22.3 months, range 2.5–55.6) and Distelmaier et al. [22] (mean 24 ± 7 months).
EUnetHTA Joint Action 3 WP4 48Version 1.4, 18 May 2019
Irreversible electroporation for the treatment of liver and pancreatic cancer
Table 9. Evidence used in effectiveness domain in pancreatic cancer (comparative studies)
Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of 
patients
Median 
FU, mo
(range)
Adjuvant 
treatments
Irreversible 
electroporation 
approach
Success 
of the 
procedure
Overall survival 
(95% CI)
Progression 
Free 
Survival
(95% CI)
Time to Recurrence
(95% CI)
Health- 
related 
quality of life 
and painProgression
Local 
recurrence
Lambert, 2016, 
Czech Republic 
[11]
Prospective non-
RCT (propensity 
score-matched 
analysis)
2012–2014
Stage III 
LAPC 
21 8.19 
(1.25–
26.84)1
CHEMO before 
IRE: 23.8% 
(n = 5)
CHEMO after 
IRE: 33.3% 
(n = 7)
Open surgery: 
90.5% (n = 19)
Percutaneous: 
9.5% (n = 2)
–
(tumour size 
did not change 
after IRE)
Median 10.03 mo 
(5.26, 15.39)1
• 3 mo: 90.48 
(67.00, 97.53)1
• 6 mo: 75.00 
(49.81, 88.80)1
• 12 mo: 47.62 
(24.37, 67.71)1
• 18 mo: 13.61 
(2.33, 34.71)1
-- --
[P: 42.1% (not 
FU reported)]
-- KPS ≥70 81% 
of the time 
after IRE (IQR 
65–98)
Matched 
cohort: 
stage III 
LAPC
32 -- Patients who had 
undergone some 
type of surgery 
or percutaneous 
biopsy only, 
with or without 
CHEMO
NA NA Median 9.3 mo -- -- -- KPS ≥70 74% 
of the time after 
surgery (IQR 
14–88)
HR: 0.54 
(p = 0.053)
p = 0.076
Outcomes refer to the time from IRE to the event of interest. When they refer to the time after diagnosis, this is indicated in the text.
1 Calculated using individual data provided by the author.
Abbreviations: CHEMO = chemotherapy; CI =  confidence interval; FU =  follow-up; HR = hazard ratio; IQR =  interquartile range; IRE =  irreversible electroporation; KPS = Karnofsky performance status; 
LAPC = locally advanced pancreatic cancer; mo = months; NA = not applicable; P = progression; RCT = randomised controlled trial.
Source: [11].
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Table 10. Evidence used in effectiveness domain in pancreatic cancer (single-arm studies)
Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of
patients
FU Adjuvant 
treatments
IRE approach Success 
of the 
procedure
Overall survival
(95% CI)
Progression 
Free Survival
 (95% CI)
Time to Recurrence
(95% CI)
Health-related 
quality of life and 
pain
Progression
Local 
recurrence
Huang, 2018, 
China [17]
Prospective 
multicentre single-
arm study
2012–2015
Stage 
III LAPC 
(AJCC)
70 Median 
28.1 mo
CHEMO/CRT 
before and 
after IRE: 100% 
(n = 70)
Open surgery: 
92.9% (n = 65)
Laparoscopic: 
7.1% (n = 5)
–
[complete 
ablation 
100% (90 d 
after IRE)]1
Median 22.6 mo (19.60–
25.60, range 6.6–52.3)2
• 3 mo: 100%
• 6 mo: 100%
• 12 mo: 90%
• 24 mo: 37%
Median 15.4 mo 
(range 5.3–52.3)
–
[DP: 34.2% 
(median FU 28.1 
m)]
–
[LR: 8.6% 
(median FU 
28.1 m)]
–
Scheffer, 2017, 
Netherlands [16]
Prospective 
single-arm study
2014–2015
LAPC 
(NCCN)
25 Median 
12 mo 
(IQR 
7–16)
CHEMO before 
IRE:100% 
(n = 25)
Percutaneous: 
100% (n = 25)
–
[IRE 
procedure 
100% 
successful]
After IRE: median 11 mo 
(9–13)
After diagnosis: 17 mo 
(10–24)
After IRE: 
median 8 mo 
(4–12)
After diagnosis: 
15 mo (10–20)
– Median 12 m 
(8, 16)
EORTC QLQ-C30 and 
PAN26
• 6 w:reduced 
appetite (p = 0.048)
• 3 mo: diminished 
general functioning 
(p = 0.040)
• 6 mo: diminished 
general functioning 
(p = 0.028)
• 6 mo: increased 
feeling of weak 
arms and/or legs 
(p = 0.031) and 
indigestion problems 
(p = 0.007)
Pain
• 1 d: median 2 (range 
0–5)
• 6 w: impact of pain 
on gait (p = .016), 
normal work 
(p = 039), and daily 
activities (p = 0.023)
• 6 mo: pain 
increased and more 
difficult to treat 
with analgesics 
(p = 0.039)
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Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of
patients
FU Adjuvant 
treatments
IRE approach Success 
of the 
procedure
Overall survival
(95% CI)
Progression 
Free Survival
 (95% CI)
Time to Recurrence
(95% CI)
Health-related 
quality of life and 
pain
Progression
Local 
recurrence
Mansson, 2016, 
Sweden [14]
Prospective 
single-arm study
Data collection 
period not 
reported
LAPC 
(equivalent 
to NCCN)
24 Median 
6.96 mo 
(range 
1.12–
18.75)
CHEMO + CRT 
before IRE: 
29.2% (n = 7)
RT alone before 
IRE: 12.5% 
(n = 3)
CHEMO alone 
before IRE: 
8.3% (n = 14)
CHEMO after 
IRE: 58.3% 
(n = 14)
Percutaneous: 
100% (n = 24)
– Median 8.95 mo (6.79–
11.11)3
• 3 mo: 95.83% (73.92, 
99.40)
• 6 mo: 58.33% (36.45, 
74.99)
• 12 mo: 29.55% (12.45, 
48.99)
After diagnosis: 17.5 mo 
(13.18–21.83)
Median 3.19 mo 
(2.14–6.18)3
• 3 mo: 
58.33% 
(36.45, 
74.99)
• 6 mo: 
33.33% 
(15.90, 1.87)
TTP: median 
3.32 mo (2.30–
6.38)3
Median 6.81 
mo (4.87–
8.78) 3
[LR: 58.3%]
–
Kluger, 2016, 
USA [13]
Prospective 
single-arm study
October 2012 
onwards
LAPC 
(NCCN)
Ablation
-- -- -- Median 7.71 mo (6.03–12.0) -- -- --
Margin accentuation 
-- -- -- -- -- -- --
Total 
50 Median 
8.69 mo 
(IQR: 
0.26-
16.26)
CHEMO before 
IRE: 92% 
(n = 46)
RT before IRE: 
78% (n = 39)
-- -- Median 12.03 mo (7.71–
23.12)
-- –
[P: 58% (FU 8.69 
mo)]
Median 8.6 
mo (5.51–not 
reached)
[LR: 11% (FU 
8.69 mo)]
--
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Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of
patients
FU Adjuvant 
treatments
IRE approach Success 
of the 
procedure
Overall survival
(95% CI)
Progression 
Free Survival
 (95% CI)
Time to Recurrence
(95% CI)
Health-related 
quality of life and 
pain
Progression
Local 
recurrence
Paiella, 2015, 
Italy [15]
Prospective 
single-arm study
June 2011–
December 2011
LAPC 
(equivalent 
to NCCN)
10 Median 
7.6 mo
CHEMO before 
IRE: 100% 
(n = 10)
RT before IRE: 
40% (n = 4)
CHEMO after 
IRE: 30% (n = 3)
Open surgery: 
100% (n = 10)
–
[IRE 
procedure 
100% 
successful]
Median 4.3 m (2.9–10.1) 
[mean 7.5 mo (24.95–
10.03)]3
• 3 mo: 90% 
(47.30, 98.53)
• 6 mo: 50% 
(18.36, 75.32)
• 12 mo: 20% 
(3.09, 47.47)
After diagnosis: median 12.5 
mo (8.5–24.1) [mean 16.79 
mo (12.40–21.18)] 3
– – – EORTC QLQ c30/
PAN26:
Preoperatively: 58.3
• 2 w: 37.5
• 3 mo: 33.5
KPS:
Baseline: 100
• 30 d: 80
• 60 d: 77.5
• 90 d: 70
Pain (VAS):
Baseline: 0.5
• 30 d: 3
• 60 d: 4
• 90 d: 1
Belfiore, 2015, 
Italy [18]
Prospective 
single-arm study
April 2013–June 
2014
LAPC 
(NCCN)
20 Mean 
8.55 mo 
(range 
3–14)3
100% CHEMO 
after IRE 
(n = 20)
Percutaneous: 
100% (n = 20)
–
[IRE 
procedure 
100% 
successful]
Mean 12.95 mo (11.57–
14.33)
• 3 m: 95% (69.5, 99.3)3
• 6 mo: 90% (65.6, 97.4)3
• 12 mo: 90% (65.6, 
97.4)3
– –
[P 10% (FU 8.55 
mo)]
–
[LR 10% (FU 
6 mo)]
–
Martin, 2012, 
USA [19]
Prospective 
single-arm study
December 2009–
March 2011
Stage 
III LAPC 
(AJCC)
27 90 d CHEMO and/or 
RT before IRE: 
85% (n = 23)
Open surgery: 
96.3% (n = 26)
Percutaneous: 
3.7% (n = 1)
96.3% (90-d 
after IRE) 
[1 patient 
died]4
–
[after FU of 90 d: 100%]
– – – Pain before IRE: 5 
points (range 3–9)
Outcomes refer to the time from IRE to the event of interest. When they refer to the time after diagnosis, this is indicated in the text.
1 Success of the procedure defined as “complete ablation”, with no residual contrast-enhanced tumour on dynamic imaging after 3 months.
2 Data provided by the author.
3 Calculated using individual data provided in the article.
4 Success of the procedure defined as the ability to deliver the planned therapy in the operative room and no evidence of residual tumour at 3 months.
Abbreviations: AJCC = American Joint Committee on Cancer; CHEMO = chemotherapy; CI = confidence interval; CRT = chemoradiotherapy; d = days; DP = distant progression; FU =  follow-up; EORTCQLQ = European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; IQR = interquartile range; IRE = irreversible electroporation; KPS = Karnofsky performance score; LAPC = locally advanced pancreatic cancer; 
LR = local recurrence; mo = months; NCCN = National Comprehensive Cancer Network; P = progression; PFS = progression-free survival; RT = radiotherapy; TTP = time to progression; VAS = visual analogue scale; w = weeks.
Sources: [13–19].
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Table 11. Evidence used in effectiveness domain in liver cancer
Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of 
patients
FU Tumour type IRE 
approach
Success 
of the 
procedure
(95% CI)
Overall 
survival
(95% CI)
PFS (95% 
CI)
Time to Recurrence
(95% CI)
Health- 
related 
quality 
of life 
and pain
Progression Local recurrence
Fruhling, 2017, 
Sweden [20]
Prospective 
single-arm study
September 2011–
September 2014
– 30 Median 
22.3 mo 
(range 
2.5–55.6)
• PT: HCC (21.1%, n = 8)
• ST: CRLM (60.5%, n = 23), other 
(18.4%, n = 7)
Percutaneous 
100% (n = 30)
– [Mean 37.92 mo 
(30.28–45.57)]1
• 3 mo: 96.67% 
(78.61, 99.52)1
• 6 mo: 96.67% 
(78.61, 99.52)1
• 12 mo: 89.76% 
(71.51, 96.58)1
• 18 mo: 69.05% 
(48.93, 82.54)1
• 24 mo: 65.21% 
(44.92, 79.58)1
– – –
% LR:
 3 m  6 m
All 
tumours  21.1% 34.2%
CRLM 26.1% 47.8%
HCC 0% 0%
Other 28.6% 28.6%
–
Distelmaier, 
2017, Germany 
[22]
Prospective 
single-arm study
February 2012–
June 2015
– 29 Mean 24 
mo (SD 7)
29 pts, 43 Ts:
• PT: HCC (2 pts, 4 Ts)
• ST: breast (4 pts, 4 Ts), 
colorectal (13 pts, 21 Ts), 
cholangiocellular (2 pts, 
4 Ts), pancreas (2 pts, 2 
Ts), melanoma (1 pt, 1 T), 
mesothelioma (1 pt, 1 T), 
oesophageal (2 pts, 2 Ts), renal 
(1 pt, 3 Ts), gastrointestinal 
stroma (1 pt, 1 T)
Percutaneous 
100% (n = 29)
–
[90% (79, 
98) by pt at 1 
d after IRE; 
93% (85, 100) 
by T] 2
– – –
[DP 17.2% at 
mean FU of 
24 mo]
–
LR + RR by pt: 10/26 
(38% (95% CI 20, 59) at 
mean FU of 24 mo)
LR by pt: 7.7% (2/26)
RR by pt: 30.8% (8/26) 
[seeding along the 
needle tract]
–
Niessen, 2016, 
Germany [25]
Prospective 
single-arm study
December 2011–
June 2013
– 34 Median 
13.9 mo 
(range 
1.8–19.5)
34 pts, 65 Ts:
• PT: HCC: 15 pts, 33 Ts
• ST: colorectal (12 pts, 22 
Ts), cholangiocellular (4 pts, 
5 Ts), testicular (1 pt, 2 Ts), 
neuroendocrine (2 pts, 3 Ts)
Percutaneous 
100% (n = 34)
–
[95.4% by T 6 
w after IRE] 3
– – TTP: median 
15.6 mo
By T: mean 15.5 mo
LR-free survival:
• 3 mo: 87.4%
• 6 mo: 79.8%
• 12 mo: 74.8%
–
Granata, 2016, 
Italy [24]
Prospective 
single-arm study
January 2012–
July 2013
Stage A 
(BCLC 
classification)
20 6 mo 24 PTs: well-differentiated HCC 
(83.3%), moderately differentiated 
nodule (12.5%), poorly 
differentiated lesion (4.17%)
Percutaneous 
100% (n = 20)
–
[91.7% by T 1 
mo after IRE]4
–
[100% after 6 
mo of FU]
– – – –
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Author, year, 
country, study 
characteristics
Tumour 
stage
Number 
of 
patients
FU Tumour type IRE 
approach
Success 
of the 
procedure
(95% CI)
Overall 
survival
(95% CI)
PFS (95% 
CI)
Time to Recurrence
(95% CI)
Health- 
related 
quality 
of life 
and pain
Progression Local recurrence
Eller, 2015, 
Germany [23]
Prospective 
single-arm study
Data collection 
period not 
reported
– 14 Mean 
388 d 
(SD 160; 
range 
120–594) 
[among 
10 
patients 
without 
LR]
14 pts, 18 Ts:
• PT (21.4%): HCC
• ST (78.6%), neuroendocrine 
(1/14), squamous cell (1/14), 
colorectal (9/14)
Percutaneous 
100% (n = 14)
–
[86% 1 d after 
IRE] 5
– – –
[P 50% at 
mean FU of 
388 d]
–
[LR 17% at mean FU of 
388 d]
–
Eisele, 2014, 
Germany [12]
Prospective 
single-arm study
Data collection 
period not 
reported
– 13 Median 8 
mo (range 
3–12)
14 Ts:
• PT: HCC (5 pts, 5 Ts, 35.7%), 
intrahepatic recurrent 
cholangiocarcinoma (2 pts, 2 Ts, 
14.3%)
• ST: colorectal liver metastases 
(6 pts, 7 Ts, 42.9%)
Percutaneous 
53.8% (n = 7)
Laparoscopic 
30.8% (n = 4)
Open surgery 
15.4% (n = 2)
–
[76.9%] 6
Percutaneous 
57.1%, 
laparoscopic 
100%, open 
surgery 100%
100%
(100% at 3 mo, 
60 and 12 mo)
– –
[P 20% at 
mean FU of 
8 mo]
– –
Cheung, 2013, 
Australia [21]
Prospective 
single-arm study
November 2008–
December 2009
– 11 Mean 18 
mo (SD 
4; range 
14–24)
18 T: HCC (100%) Percutaneous 
100% (154 
procedures)
–
[54.5% (1st 
and 2nd IRE) 
after 6 mo 7; 
72% by T]
– – –
[mean time 
to DP 14 mo 
(SD 6)]
–
[LR 0% at mean FU of 
18 m]
-
Outcomes refer to the time from IRE to the event of interest. When they refer to the time after diagnosis, this is indicated in the text.
1 Calculated using individual data provided in the article.
2 Successful ablation defined as no residual tumour and the ablation zone covered the target tumour with an adequate safety margin.
3 Technical success defined as successful delivery of all planned pulses to the target volume as calculated by the IRE generator and complete tumour coverage (assessed via computed tomography or magnetic resonance 
imaging 6 weeks after ablation).
4 Defined as a “complete response”: disappearance of any enhancement in all target lesions.
5 Defined as total inclusion in the devascularised area in the initial postinterventional computed tomography scan performed the first day after IRE.
6 No definition provided.
7 No residual tumour or recurrence at or directly adjacent to the treated location following up to two IRE ablations.
Abbreviations: BCLC = Barcelona Clinic Liver Cancer; CRLM = colorectal liver metastases; d = day; DP = distant progression; FU = follow-up; HCC = hepatocellular carcinoma; IRE = irreversible electroporation; LR = local 
recurrence; mo = months; pt = patient; P = progression; PFS = progression free survival; PT = primary tumour; RR = regional recurrence; SD = standard deviation; ST = secondary tumour; T = tumour; TTP = time to 
progression; w = weeks.
Sources: [12,20–25].
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Mortality
[D0001] What is the expected beneficial effect of IRE on mortality?
Pancreatic cancer
Overall survival
• Overall survival after IRE
The comparative trial [11] reported median survival of 10.03 months (95% CI 5.26, 15.39) in the IRE 
group and 9.3 months in the control group; the difference between the groups was not significant 
(hazard ratio 0.54, p = 0.053). The survival probability calculated from data provided by the authors 
was 90.5% (95% CI 67.00, 97.53) at 3 months, 75% (95% CI 49.81, 88.80) at 6 months, 47.6% (95% 
CI 24.37, 67.71) at 12 months and 13.6% (95% CI 2.33, 34.71) at 18 months. These data were not 
available for the control group.
The median survival after IRE according to Kaplan-Meier estimation ranged from 4.3 to 12 months 
in four of the single-arm trials [13–16]. One study provided only the mean survival, which was 12.95 
months [18]. One study reported survival of 22.6 months [17]. In this trial, survival was significantly 
longer for patients treated with TS-1 CHEMO (28.7 months) than for those who received gemcitabine 
(13.2 months). There was no information for one study [19]. Median survival was significantly higher 
in the margin extension group than in the primary treatment group (p = 0.01; data not provided) in 
one of the studies [13].
OS at specified time points after IRE (3, 6, 12 and 24) was not reported in individual studies but 
could be calculated from data given in the publication or provided by the contact author. The OS at 3 
months was available from four studies [14,15,17,18] and ranged from 90% to 100%. The OS ranged 
from 50% (95% CI 18.36, 75.32) [15] to 100% (CI not provided) [17] at 6 months and from 20% (95% 
CI 3.09, 47.47) [15] to 90% [17,18] at 12 months. In the only study reporting beyond 12 months, OS 
was 37% at 24 months [17].
• Overall survival from the time of diagnosis
The median OS from the time of diagnosis could only be obtained in three studies [14–16] and varied 
from 12.5 to 17.5 months. Survival at 3 and 6 months was 100% in two of these studies [14,15]. At 
12 months it was 60% (95% CI 25.27, 82.72) and 79.17% (95% CI 56.98, 90.75). At 18 months, it 
was 50% (95% CI 29.10, 67.76; 18.36, 75.32) and at 24 months, 13.89% (95% CI 3.54, 31.14) and 
30% (95% CI 7.11, 57.79).
Cancer-specific survival
Cancer-specific survival was not reported.
Disease-free survival
Disease-free survival was not reported.
Progression-free survival
In the three studies that reported PFS after IRE (defined as the time from intervention to either 
radiological progression or death) the median PFS was 15.4 months (95% CI 10, 20) [17], 8 months 
(95% CI 4, 12) [16] and 3.19 months (95% CI 2.14, 6.18) [14]. Kaplan Meier analysis of the individual 
data for the last study gave PFS of 58.33% (95% CI 36.45, 74.99) at 3 months and 33.33% (95% 
CI 15.90, 51.87) at 6 months. In the only study reporting PFS after diagnosis, median PFS was 15 
months (95% CI 10, 20) [16].
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Liver cancer
Overall survival after IRE
The mean OS after IRE in the only study with data available for calculation [20] was 37.92 months 
(95% CI 30.28, 45.57). OS was 96.67% (95% CI 78.61, 99.52) at 3 months, 96.67% (95% CI 78.61, 
99.52) at 6 months, 89.76% (95% CI 71.51, 96.58) at 12 months, 69.05% (95% CI 48.93, 82.54) at 
18 months and 65.21% (95% CI 44.92, 79.58) at 24 months.
Overall survival after diagnosis
No data were available for calculating OS after diagnosis.
Cancer-specific survival
Cancer-specific survival was not reported.
Progression-free survival
PFS was not reported in the liver cancer studies.
Morbidity
[D0005] How does IRE affect the symptoms and findings (severity, frequency) of pancreatic 
cancer? How does IRE affect the symptoms and findings (severity, frequency) of liver cancer 
(primary or secondary)?
Evidence is lacking regarding the effect on symptoms and findings.
[D0006] How does IRE affect the progression (or recurrence) of pancreatic cancer? How does 
IRE affect the progression (or recurrence) of liver cancer (primary or secondary)?
Pancreatic cancer
Success of the procedure
Success of the procedure as defined in the PICO question was the ability to complete the IRE proce-
dure as planned and the absence of any residual tumour. According to this definition, for all patients 
treated with IRE in the only comparative study [11] the treatment would be defined as unsuccessful. 
The authors explained that the size of the tumour did not change after IRE (39 ± 10 mm vs 39 ± 14 
mm; p = 0.65). Only in five patients did the tumour decrease in size by >10 mm.
One of the single-arm trials reported success as defined by the PICO question [19], which was 
96.3%. This study defined ablation success as the ability to deliver the planned therapy in the opera-
tive room and no residual tumour at 3 months. Another study partly defined success [17]; the authors 
assessed complete ablation of the tumour at 90 days after IRE, defined as no residual contrast-en-
hanced tumour on dynamic imaging, which was reported as 100%. Three studies assessed only the 
technical success of the procedure [15,16,18].
Time to progression after IRE
Time to progression (local recurrence + distant progression) was only available in one study [14], 
reported as 3.32 months (95% CI 2.30, 6.38).
Time to local recurrence after IRE
The median time to local recurrence was 12 months (95% CI 8, 16) in the study by Scheffer et al. 
[16], 6.81 months (95% CI 4.87, 8.78) in the study by Mansson et al. [14] and 8.6 months (95% CI 
5.51, not reached) in the study by Kluger et al. [13].
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
56Version 1.4, 18 May 2019
Liver cancer
The outcome “success of the procedure”, as considered in the PICO question was not available in 
any of the studies, although incomplete definitions of success were provided in five studies [21–25], 
with assessments carried out at different time points. One study [22] assessed success the day 
after IRE and reported that complete ablation, defined as no residual tumour and complete tumour 
coverage with an adequate safety margin, was achieved in 90% of the subjects (93% by tumour). 
Another study [21] reported an ablation success per tumour of 72%, considering cases that showed 
no residual or recurrent disease at or directly adjacent to the ablation site after two treatments and at 
least 6 months of follow-up; the per-patient rate of success was 54.5%. Granata et al. [24] observed a 
complete response in 91.7% of patients at 1 month according to the metastatic Response Evaluation 
Criteria in Solid Tumours scheme (disappearance of any enhancement in all target lesions). Niessen 
et al. [25] assessed successful delivery of all planned pulses to the target volume as calculated by 
the IRE generator and complete tumour coverage (via CT and/MRI performed 6 weeks after abla-
tion), reported as 95.4%. Eller et al. [23] reported the technical success of the procedure as 86% 
(defined as total inclusion in the devascularised area in the initial postinterventional CT performed 
the first day after IRE). In the study by Eisele et al. [12] ablation success of 76.9% was reported but 
no definition was provided. Fruhling et al. [20] did not provide results.
Time to progression after IRE
The time to progression was available only in one study [25], which included patients undergoing 
percutaneous IRE, for whom the median time to progression was 15.6 months. Two studies provided 
the percentage of patients who experienced progression during follow-up. In the first study [23], 50% 
of patients experienced progression after mean follow-up of 12.8 months. In the second study [12], 
progression was observed in 20% of patients after median follow-up of 8 months.
Time to local recurrence after IRE
The mean time to local recurrence (15.5 months) was only available in one study [25]. Local recur-
rence–free survival at 3 months was 87.4% (no CI reported), 79.8% at 6 months and 74.8% at 12 
months. While not providing the time to local recurrence, one study [20] reported that 21% of the 
patients had a local recurrence at 3 months and 34.2% at 6 months, with corresponding colorectal 
cancer liver metastasis rates of 26.1% and 47.8%. There were no local recurrences at either time 
point for HCC (p = 0.084, colorectal cancer liver metastases vs HCC).
Another study [23] reported that 17% of patients experienced a local recurrence after mean follow-up 
of 12.8 months. Distelmaier et al. [22] observed a local recurrence rate of 7.7% after mean follow-up 
of 24 months, with regional recurrences in 30.8% of patients due to needle-tract seeding. Cheung et 
al. [21] did not observe any local recurrence during the mean 18 months of follow-up.
[D0011] What is the effect of IRE on patients’ body functions?
No evidence was found to answer this research question.
Health-related QoL
[D0012] How does IRE affect general health-related quality of life?
[D0013] What is the effect of IRE on disease-specific quality of life?
Pancreatic cancer
The study with a comparator group [11] analysed functional status in terms of KPS using a scale 
from 0 (death) to 100 (normal life) at each clinical visit. The results showed that functional status after 
IRE slowly declined. KPS was ≥70 81% (IQR 65–98%) of the time after IRE, compared to 74% (IQR 
14–88%) of the time after surgery in the control group; the difference was not statistically significant. 
A sharp decline occurred approximately 8 weeks before death in the IRE group (no data available 
for the control group).
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In the study by Scheffer et al. [16], patients completed two QoL questionnaires (QLQ-C30 and QLQ-
PAN26) and a pain registration form (with a visual analogue score ranging from 0 to 10) at each visit. 
The questionnaire response was 100% before IRE but varied after IRE: 80% of patients completed 
the questionnaires 6 weeks after IRE, 88% at 3 months and 85% at 6 months. Compared with 
baseline, patients had reduced appetite at 6 weeks (p = 0.048) and diminished general functioning 
at 3 months (p = 0.04) and 6 months (p = 0.028). At 6 months they also had an increased feeling of 
weak arms and/or legs (p = 0.031) and indigestion problems (p = 0.007). Patients reported moderate 
pain after IRE, with a median visual analogue scale score of 2 (range 0–5). Compared with baseline, 
23% of the pain items deteriorated after 6 weeks: impact of pain in gait (p = 0.016), normal work 
(p = 0.039) and daily activities (p = 0.023). After 6 months, the pain was more difficult to treat with 
analgesics (p = 0.039). The rest of the items did not change significantly.
Only one more study provided QoL data [15] and used the Italian versions of QLQ-C30 and QLQ-
PAN26. Performance status was evaluated using the Karnofsky score. According to the question-
naires, the median QoL score was 58.3 preoperatively, and declined to 37.5 at 2 weeks and 33.33 at 
3 months after IRE. The median baseline KPS recorded was 100 and was 80, 77.5 and 70 at 30, 60 
and 90 days after IRE, respectively.
Liver cancer
None of the studies reported QoL, although two provided information on postprocedural pain as a 
complication.
Satisfaction
[D0017] Were patients satisfied with the technology?
No evidence was identified to answer this research question.
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6 SAFETY (SAF)
6.1 Research questions
Element ID Research question
C0008 How safe is IRE?
C0002 Are the harms related to dosage or frequency of applying IRE?
C0004
How does the frequency or severity of harms change over the time or in different 
settings?
C0005
What are the susceptible patient groups that are more likely to be harmed through 
the use of IRE?
B0010 What kind of data/records and/or registry is needed to monitor the use of IRE?
6.2 Results
The critical outcomes used to evaluate the evidence were intervention-specific mortality and major 
AEs. Minor AEs were considered to be important.
Studies included
Pancreatic cancer
The study inclusion criteria for assessing SAF did not differ from those used for assessing EFF and 
the same articles were included for both domains. The characteristics of the studies included and 
the results are described in the previous section and presented in Tables A2 and A3 in Appendix 1.
AEs were reported and graded in all of the studies included, except the non-RCT [11]. The Clavien-
Dindo grading system was used in three studies [13,14,17] and CTCAE in two studies [15,16]. Two 
of the trials did not report on the grading system used [18,19]. Another two reported exclusively on 
the number of events and did not provide the number of events per patient [15,16].
Three studies recorded AEs at 90 days [13,16,19] and one reported AEs at 30 days [14]. The timing 
was not available in four studies [11,15,17,18]. Classification of IRE-related complications was miss-
ing [11,16–18] or unclear [13–15,19] in the studies included.
Liver cancer
The study inclusion criteria for assessing SAF did not differ from those used for assessing EFF. All 
but one of the studies were included, as AEs were not reported in one study [12]. Characteristics 
of the studies and the results are described in the previous section and presented in Table A4 in 
Appendix 1.
All of the liver cancer studies provided AEs per patient graded according to severity, although two did 
not provide information regarding the grading system [21,24]. The SIR grading system was used in 
three studies [20,22,25] and the CTCAE in one study [23]. One study [20] reported immediate and 
periprocedural (within 30 days) AE. Another study also classified the complications according to time 
of occurrence (immediate, periprocedural or delayed) [22]. The rest did not provide this information. 
The classification of IRE related or no IRE related complications was missing in most of the studies 
[20,22,23,25].
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
59Version 1.4, 18 May 2019
Patient safety
[C0008] How safe is IRE?
Pancreatic cancer
Intervention-specific mortality
None of the studies reported intervention-specific deaths (during the intervention).
Major adverse events
Among seven studies grading AEs, all but one [18] reported some type of major AEs (grade III, IV or 
V). In total, 44 out of 226 patients (19.47%) experienced major AEs, although at least 16 were not 
considered procedure-related by the authors. In some cases, the same patient experienced several 
AEs.
The overall procedure-related mortality was 1.62% (4/247 patients) among all the studies. Kluger et 
al. [13] reported that six of the 50 patients enrolled (12%) died within 90 days after the procedure 
(median 26 days, range 8–42); five of these deaths occurred in the primary treatment group (17.3%) 
and one in the margin extension group (4.2%). They considered that only three of the six deaths were 
procedure-related. The causes of death were cardiopulmonary arrest, duodenal and bile duct necro-
sis, multisystem organ failure caused by placement of a vena cava stent for symptomatic stenosis 
and an angiogram embolisation of the gastroduodenal artery, portal vein thrombosis and intraperito-
neal haemorrhage. One cause of death was not reported. The study did not specify whether these 
interventions were performed via open surgery or a percutaneous approach. In the study by Martin et 
al. [19], one of the 27 patients (3.7%) treated with IRE (open surgery 90.5%; percutaneous approach 
9.5%) died due to progression of a portal vein thrombosis. It is unknown if this patient was in the open 
surgery or percutaneous group.
The mean frequency of grade III or IV IRE procedure-related complications for the studies that pro-
vided relevant data was 10.62% (range 0–44%). The frequency was 5.61% (6/107) for patients 
undergoing IRE mainly for primary control via open surgery (>90% of cases) and 20.29% (14/69) 
for those undergoing percutaneous IRE. The overall frequency of AEs in the open surgery group, 
including other non-IRE related 30-90 day severe AEs was 12.15% (13/107). Kluger et al. [13] found 
no significant difference in the incidence of severe AEs based on tumour location (head, 31%; body, 
15%; p = 0.49), tumour size (≤3 cm, 26%; >3 cm, 21%; p = 0.53), approach (caudad–cephalad, 23%; 
anterioposterior, 26%; p = 0.81) or when IRE was used as a primary treatment versus for margin 
extension (24% vs 25%; p = 0.59).
The procedure-related complications recorded in the open surgery studies were pseudoaneurysm 
bleeding (n = 1), duodenal leaks (n = 2), pancreatic and internal fistula (n = 2) and intraabdominal 
abscess (n = 2). The most common severe AEs found for the percutaneous group were biliary ob-
struction (n = 3) and pancreatitis (n = 3). Others included cholangitis and biloma (n = 1), mesenteric 
vein thrombosis (n = 1), mesenteric artery stenosis (n = 1), bleeding from an ulcer (n = 1), haematem-
esis due to a duodenal wall ulcer (n = 1) and gastrointestinal AEs (vomiting, loss of appetite). Kluger 
et al. [13] (no approach reported) described three cases of delayed gastric emptying and three deep 
surgery infections, among others. The comparative trial [11] did not grade the procedure-related 
complications but reported that the percutaneous approach was abandoned after two cases given 
the high rate of complications (biliary peritonitis, cholangitis, liver abscesses and pancreatic fistula). 
The frequency of complications in the open surgery group was 15.8%.
Minor adverse events
In total, 74 of 226 patients (32.74%) experienced minor AEs, including those related and unrelated to 
IRE. The overall frequency of minor AEs was 24.30% (26/107) for the open surgery group and 50.7% 
(35/69) for the percutaneous group.
Overall, the frequency of minor (grades I and II) IRE procedure-related complications among 
the studies that provided relevant data was 21.7% (49/226). One study [16] counted all compli-
cations separately and complications such as pneumonia, nausea and vomiting were considered 
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procedure-related .The percentage of minor complications in the studies varied from 0% to 48%. The 
frequency was 13% (14/107) in the open surgery group and 31.9% (22/69) in the percutaneous IRE 
group.
The IRE-related minor AEs reported included infection (n = 5), abdominal pain (n = 3), diarrhoea 
(n = 2), vomiting (n = 2), portal vein thrombosis (n = 2), pancreatitis (n = 2), hepatitis (n = 1), ascites 
accumulation (n = 1) and gastrointestinal bleeding (n = 1). Minor AEs not related to IRE included 
wound infections, deep venous thrombosis, abdominal back pain and haematological complications, 
among others.
Liver cancer
Intervention-specific mortality
No intervention-specific deaths occurred in any of the studies.
Major adverse events
Overall, the frequency of major AEs was 8.70% (12/138), and ranged from 0% to 28.6% among the 
studies included. None reported procedure-related mortality.
Niessen et al. [25] reported six grade III complications (four abscesses, one intraperitoneal bleeding 
and one partial thrombosis of the portal vein) and Eller et al. [23] observed three grade III AEs (two 
haemothorax and one haemoperitoneum) and one grade IV AE (severe bleeding requiring surgery). 
Fruhling et al. [20] reported one bile duct dilatation and stricture of the portal vein and bile duct, but 
did not assign a grade.
Minor adverse events
The recording of minor complications was variable among the studies and not all recorded pain as 
an AE or used the same considerations concerning its classification. Cheung et al. [21] included all 
cases of pain as AEs, while Fruhling et al. [20] only considered patients who required morphine. The 
frequency of minor complications would be 33.1% (41/124) according to the first classification and 
28.2% (35/124) in the latter case. This percentage could be underestimated given that the study 
by Eller et al. [23] did not report on minor complications, although the authors stated that pain was 
sufficiently controlled.
The minor complications included pain (n  =  14), haematoma (n  =  9), urinary retention (n  =  4), 
cholestasis (n = 5), pneumothorax (n = 2), arteriovenous shunt (n = 2), arterioportal fistula (n = 1), in-
fection (n = 1), increased blood pressure (n = 1), tachycardia (n = 1) and shortness of breath (n = 1). 
The four patients who developed transient urinary retention had a history of prostatic hypertrophy 
[21] and the authors believed that these complications could be related to the opioid analgesia rather 
than the hepatic-ablation per se.
No comparisons can be made based on approach as all patients were treated with percutaneous 
IRE. Niessen et al. [25] reported no association between the complications found in their study 
(haematoma and pneumothorax) and histological type, location or previous CHEMO.
Other adverse events/complications
Needle-tract seeding was observed by Distelmaier et al. [22], with 30.8% of patients (8/26) experi-
encing regional recurrence in the needle tract (by tumour: 11/40). Granata et al. [24] found two minor 
AEs along the needle tract: one peripheral arteriovenous shunt and one segmental dilatation of the 
intrahepatic biliary ducts.
[C0002] Are the harms related to dosage or frequency of applying IRE?
No evidence was found relating either the dosage or frequency to the harms associated with the 
treatment.
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[C0004] How does the frequency or severity of harms change over the time or in different 
settings?
No evidence was found to answer this question.
[C0005] What are the susceptible patient groups that are more likely to be harmed through 
the use of IRE?
No evidence was found to answer this research question.
[B0010] What kind of data/records and/or registry is needed to monitor the use of IRE?
No evidence was identified to answer this research question.
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Table 12. Frequency and severity of adverse events in pancreatic cancer (comparative studies)
Author, year, country, 
study characteristics, 
AE grading system 
Intervention
Intervention 
mortality
Complications/adverse events
Major Minor
Not graded Total
Grade V Grade IV Grade III Grade II Grade I
Lambert, 2016, Czech 
Republic [11]
Prospective non-RCT 
(propensity score-matched 
analysis), 2012–2014, AEs 
not graded
IRE 0 0 -- -- -- -- 5 pts:
• Open surgery: bleeding (1), peripancreatic 
abscess (1), fistula and abscess (1)
• Percutaneous: biliary peritonitis, cholangitis, liver 
abscess (1) and pancreatic fistula (1)
[Other changes 1–2 mo after IRE (28): peripancreatic oe-
dema (9), pancreatic or peripancreatic necrosis (6), peri-
pancreatic or suprameso-colic inflammatory infiltrate (4), 
enlarged lymph nodes (4), carcinosis with ascites (4), exten-
sion of the tumour into the liver (1)]
5 pts (out 
of 21 
treated)
Propensity-
matched 
cohort: 
noncurative 
surgery
-- -- -- -- -- -- -- --
Abbreviations: IRE = irreversible electroporation; m = months; p = patients; RCT = randomized controlled trial.
Sources: [11]
EUnetHTA Joint Action 3 WP4 63Version 1.4, 18 May 2019
Irreversible electroporation for the treatment of liver and pancreatic cancer
Table 13. Frequency and severity of adverse events in pancreatic cancer (single-arm studies)
Author, year, 
country, study 
characteristics, 
grading system
Intervention-
specific 
mortality
Complications/adverse events
Major Minor Not graded Total
Grade V Grade IV Grade III Grade II Grade I
Huang, 2018, 
China [17]
Prospective 
multicentre single-
arm study, 2012–
2015, Clavien-
Dindo classification
0 0 0 3 pts (3 AEs): 
pseudoaneurysm 
bleeding (1), pancreatic 
fistula (1), intraabdominal 
abscess (1)
13 pts (27 AEs): acute hepatitis, ascites 
accumulation, gastrointestinal bleeding 
and ileus
30 AEs (in 70 treated 
pts)
Scheffer, 2017, 
Netherlands [16]a
Prospective single-
arm study, 2014–
2015, CTCAE (90 d 
after IRE)
0 0 2: pancreatitis 
(1 pt), bleeding 
from duodenal 
ulcer adjacent 
to the ablation 
zone (1 pt)
9: pancreatitis (2 pts), 
biliary obstruction (3 pts), 
cholangitis and biloma 
(1 pts), high-grade SMA 
stenosis (1 pt), vomiting 
(1 pt), loss of appetite or 
reduced intake (1 pt) 
12: abscess (1 pt), pneumonia (1 pt), 
nausea (1 pt), vomiting (2 pts), diarrhoea 
(2 pts), gastroparesis (2 pts), abdominal 
pain (3 pts)
7 pts: irregular 
vessel narrowing 
[immediately after 
procedure]
23 AEs in 10 pts (out 
of 25 treated pts)
Mansson, 2016, 
Sweden [14]
Prospective single-
arm study, data 
collection period 
not reported, 
Clavien-Dindo (30 d 
after IRE)
0 • Related to IRE: 0
• Not related to IRE: 
pneumonia (1 pt)
0 3: thrombosis with 
bleeding (1 pt), 
gastroenteroanastomosis 
(1 pt), bleeding from a 
prior ulcer (1 pt)
8 pts: infection, 
pancreatitis, portal vein 
thrombosis
Not related to 
IRE: 13 pts
1 pt :bleeding 
[before discharge]
24 pts (100%)
[11/24 (45.8%) 
considered IRE related 
complications]
Kluger, 2016, USA 
[13]
Prospective single-
arm study, October 
2012 onwards, 
Clavien-Dindo (90 d 
after IRE)
0 (first dead at 
8 d)
6 pts (4 at 30 d):
• Not related to IRE: 3 pts
• IRE related: duodenal 
and bile duct necrosis 
(1), gastrointestinal 
bleeding (1) and 
intraperitoneal 
haemorrhage (1)
10 pts (9 at 30 d) [4 IRE-related] 8 p 5 p 29 AEs (in 50 treated 
pts)
[7 (44%) major 
complications due to 
IRE]
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Author, year, 
country, study 
characteristics, 
grading system
Intervention-
specific 
mortality
Complications/adverse events
Major Minor Not graded Total
Grade V Grade IV Grade III Grade II Grade I
Paiella, 2015, Italy 
[15]a
Prospective single-
arm study, June 
2011–December 
2011, MedDRA 
classification 
system, graded 
according to 
CTCAE
0 Not related to IRE
Sepsis: 1 pt
• Related to IRE: pancreatic abscess and 
internal fistula (1 pt)
• Non related to IRE: pulmonary embolism 
(1 pt), systemic candidiasis (1 pt), 
pneumonia: (1 pt)
Not related to IRE (9): abdominal and 
back pain (5 pt), portal vein thrombosis 
(present before IRE, 1 pt), onset of 
ulcerative colitis (1 pt), peripheral 
oedema (1 pt), wound infection (1 pt)
1 pt: transient 
hypertensive 
episode
14 AEs (in 10 treated 
pts)
[1 considered a 
procedure-related 
complication]
Belfiore, 2015, 
Italy [18]
Prospective single-
arm study, April 
2013– June 2014, 
no grading system 
stated
0 0 0 0 2: transient amylase increase in serum 
(1 pt), mild ascites (1 pt)
 2 AE (over 20 patients) 
[only immediate after 
treatment]
Martin, 2012, USA 
[19] b
Prospective 
single-arm study, 
December 2009–
March 2011, no 
grading system 
stated (90 d after 
IRE)
0 Portal vein thrombosis: 
1 pt
Bile leak: 1 pt • Related to IRE: bile 
leak (1 pt)
• Not related to IRE: 
pulmonary (2 pts), 
renal failure (1 pt), 
ascites (1 pt)
• Related to IRE: 
portal vein 
thrombosis (1 pt)
• Not related to IRE (8 
AEs): haematologic 
AE (2), ileus (1), 
deep venous 
thrombosis (2), 
wound infection (3)
Haematologic 
AE: 1 pt
17 AEs in 9/27 pts 
(33%)
Possible IRE-related 
complications in 4 pts
a Data are the number of complications.
b Data are the number of complications. Five patients experienced major adverse events and four patients experienced minor adverse events.
Abbreviations: AE = adverse events; CTCAE = Common Terminology Criteria for Adverse Events; d = days; IRE = irreversible electroporation; MedDRA = Medical Dictionary for Regulatory Activities; pt = patient; 
SMA = superior mesenteric artery.
Sources: [13–19].
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Table 14. Frequency and severity of adverse events in liver cancer (single-arm studies)
Author, year, country, study 
characteristics, grading 
system
Intervention 
mortality
Complications / adverse events Not graded Total
Major Minor
Grade V Grade IV Grade III Grade II Grade I
Fruhling, 2017, Sweden [20]
Prospective single-arm study, 
September 2011–September 2014
SIR grading system (30 days after 
IRE)
0 None related to 
IRE: pulmonary 
embolism (1 pt)
1 pt: bile duct dilatation and stricture of 
portal vein and bile duct
12:1 postprocedural pain (7 pts (1 
required morphine for chest pain)), 
haematoma (1 pt), shortness of breath 
(1 pt), tachycardia (1 pt), infection (1 
pt), increased blood pressure (1 pt)
Other changes: 
13 transient 
increase in liver 
transaminases
14 (among 30 
treated pts) 
Distelmaier, 2017, Germany [22]
Prospective single-arm study, 
February 2012–June 2015
SIR grading system
0 0 0 0 8: cholestasis (5 pts), arterioportal 
fistula (1 pt (periprocedural)), 
haematoma (2 pts (immediately after 
IRE))
8 (30.8%) needle 
tract seeding
8 (among 29 
pts)
Niessen, 2016, Germany [25]
Prospective single-arm study, 
December 2011–June 2013
SIR grading system
0 0 0 6: intraperitoneal 
bleeding (1 pt), 
partial thrombosis 
of portal vein (1 pt), 
abscess (4 pts)
0 8: haematoma (6 
pts), pneumothorax 
(2 pts)
14 (among 51 
procedures; 
27.5%)
Granata, 2016, Italy [24]
Prospective single-arm study, 
January 2012–July 2013
No grading system stated
0 0 2: peripheral arteriovenous shunt (1 
pt) 2, segmental dilation of intrahepatic 
biliary ducts (1 pt) 2
Capsular retraction 
(4 pts), changes in 
vascular perfusion 
during the arterial 
phase (6 pts)
2 (among 20 
pts)
Eller, 2015, Germany (23)
Prospective single-arm study, data 
collection period not reported
CTCAE version 2
0 1: severe 
abdominal 
bleeding 
requiring surgery
3: haemoperitoneum 
(1), haemothorax (2)
4 (among 14 
pts)
Cheung, 2013, Australia (21)
Prospective single-arm study, 
November 2008–December 2009
No grading system stated
0 0 0 0 11:1 transient urinary retention (4 pts), 
pain post procedure (7 pts)
1 Possible duplication of patients with complications.
2 Occurred along the needle tract
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; IRE = irreversible electroporation; pt = patient; SIR = Society of Interventional Radiology.
Sources: [12,20–25].
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
66Version 1.4, 18 May 2019
7 POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT AND 
SOCIAL, AND LEGAL ASPECTS (ETH, ORG, SOC, LEG)
7.1 Research questions
One specific question concerning ORG aspects was identified from the rapid REA checklist (Appendix 
3): Does the introduction of the new technology and its potential use/non-use instead of the defined, 
existing comparator(s) require organisational changes? Therefore, three critical issues were chosen 
from the ORG aspects of the HTA Core Model Application for Medical and Surgical Interventions 
(3.0).
Element ID Research question
G0003 What kind of process ensures proper education and training of staff?
G0006 What are the costs of processes related to acquisition and setting up of IRE?
G0007 What are the likely budget impacts of implementing IRE?
7.2 Results
[G0003] What kind of process ensures proper education and training of staff?
IRE can be carried out by existing professionals, but they must have acquired previous experience 
with the technique. The NanoKnife procedure is intended to be performed under the direction and 
supervision of a primary treating physician who has been thoroughly trained on advanced IRE pro-
cedures. The training to perform IRE includes determination of eligibility for IRE treatment, physical 
set-up for the procedure, establishing procedure protocols, monitoring the progress of procedures 
and stopping the procedure. Detailed physician and clinical support training are required for safe and 
effective use of the NanoKnife System. Training involves both didactic and animal laboratory training 
[26].
[G0006] What are the costs of processes related to acquisition and setting up IRE?
[G0007] What are the likely budget impacts of implementing IRE?
No information exists regarding the costs of the processes related to acquisition and setting up of 
IRE. However, given that IRE requires anaesthesia and radiological and/or surgical operating equip-
ment, it is deemed costlier in terms of resources than other ablative methods [5].
No information regarding the acquisition cost of the NanoKnife System was provided. According to 
Martin et al. [19] the probes cost approximately $2000 per unit.
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8 PATIENT INVOLVEMENT
Two patients aged ≥70 years with liver cancer agreed to participate and were interviewed in Hospital 
Clínico Universitario de Santiago de Compostela about their experiences and views regarding their 
clinical condition and the use of ablative methods and other treatments received. The patients were 
asked about their disease, diagnosis and treatment and were encouraged to discuss any issue 
they considered relevant. In addition, they were asked about the relevance of the patient-related 
outcomes included in the PICO question (health-related QoL and pain) and were invited to include 
any other outcomes they considered important.
Both patients had undergone MWA of their tumours. One of the patients had undergone one ablation 
procedure and received a transplant afterwards. The second patient received more than seven ab-
lation procedures and TACE. It was not possible to recruit patients who had undergone IRE as it is 
not authorized for this indication in this centre. The inclusion of LAPC patients was also not possible 
because clinicians were against interviewing these patients given their poor condition.
8.1 Views of patients
Benefits/risks ablative procedure
The patients highlighted that they did not experience any major complication or pain during or after 
MWA. The only AE noted was nausea related to sedation in one case. The patient that had to under-
go TACE twice because of the impossibility of MWA owing to the risk of the heat-sink effect stated 
that the TACE procedure was much more uncomfortable and did lead to pain. The transplant patient 
had a positive view of the MWA procedure as it did not require general anaesthesia and a hospital 
stay of only 1 day in hospital, but reported that he had feared the surgery. Both patients stated that 
they would certainly undergo an ablative procedure again, specifying that the only drawback was 
travelling to hospital and the hospital stay. One patient also mentioned the inconvenience of having 
to stop his medication for 2 days.
Patient reported outcomes
Neither of the patients experienced symptoms or pain before or after the procedure, except for the 
pain that occurred after TACE. Both stated that the disease and treatment had not notably affected 
their QoL. They also confirmed that they did not experience anxiety or depression as a result of the 
disease or treatment.
Relevancy of the outcomes
Patients highlighted the importance of the pain and QoL aspects and did not propose any additional 
items.
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9 DISCUSSION
IRE is an ablative modality that destroys soft-tissue tumours using low-energy electrical pulses to 
create nanoscale defects in cell membranes, resulting in loss of homeostasis and subsequent cell 
death. As the effect of IRE is supposed to be confined to the cell membrane, it is claimed that it could 
kill cancer cells while avoiding damage to surrounding structures, such as vessels, ducts and nerves 
[88]. Owing to this potential to spare critical structures, IRE has been proposed as an alternative 
option for solid tumours of the pancreas and liver that are not suitable for surgery or thermal ablation 
techniques because of vicinity to vulnerable tissue. The treatment of these cancers is very challeng-
ing and OS for these patients, especially those with pancreatic cancer, remains quite poor despite 
advances in systemic cancer therapies.
The exact mechanism of action of IRE is still unknown. While the ability of IRE to induce nanopores in 
perfused porcine liver has been demonstrated via electron microscopy [89], there are doubts regard-
ing the specific mechanism of cell death in practice. Some experimental studies revealed an increase 
in tissue temperature [90,91], raising the question of whether the effect of IRE could also be partly 
attributed to a thermal effect [56]. Likewise, it has also been suggested that IRE could contribute to 
cell death by inducing a type of immune response, although the connection between IRE and the 
immune system is still under investigation [15].
The performance of IRE is considered to be influenced by many technical factors, such as the elec-
trical current, the pulses, and the number and correct placement of electrode probes [24], for both 
the electrode distance and the parallelism of the insertion path have to remain exact [12]. We ob-
served that the studies included used different currents (20–50 A) and numbers of needles (ranging 
from 2 to 6) according to the size and location of the tumour. In several studies it was reported that 
needles needed to be repositioned or replaced according to radiological findings, highlighting the 
complexity of the procedure, which is further complicated by the fact that the patient requires general 
anaesthesia with deep sedation and complete muscle relaxation [18]. Patients who were interviewed 
considered this an important issue. Overall, the authors agree that IRE is more complicated and 
demanding than other thermoablative methods, but consider that it could represent a feasible option 
for patients for whom thermal ablation is not suitable [23].
However, the evidence from the studies included is not consistent regarding the effectiveness of IRE 
for achieving complete ablation. Information regarding success, defined as the ability to complete 
the IRE procedure as planned and the absence of any residual tumour, is lacking in many of the 
studies included, while those that do provide similar definitions show variable results. Regarding 
LAPC, we observed one study that claimed ablation success of close to 100% [19]. Other studies 
found that the tumour size remained unchanged [11]. For liver cancer, incomplete/similar definitions 
of success ranged from 54.5% to 93%. Commonly, studies attribute these differences in success 
and local recurrences to the different characteristics of the tumours ablated, prior treatments or how 
the surgical or IRE procedure was planned and performed [17]. For example, large tumour volumes 
were associated with incomplete ablation in the study by Cheung et al. [21], who reported a success 
rate of 93% for tumours <3 cm versus 0% for tumours <4 cm (p = 0.003). Paiella et al. [15], who 
found that the pancreatic tumour size initially increased by day 60 and then decreased by day 90, 
hypothesised that the initial increase might have being caused by local inflammation and that the lack 
of enhancement might have impeded discrimination of oedema from ablated tissue. Several other 
authors mentioned difficulty in assessing ablative success and local recurrence using conventional 
imaging modalities [19,20,24].
The available evidence is also insufficient to establish if IRE would be effective in improving OS 
for patients with pancreatic or liver cancer when compared to the standard of care. For LAPC, only 
one low-quality nonrandomised trial [11] complied with the eligibility criteria and found no significant 
difference in mean OS despite comparing IRE to noncurative surgery (10.03 months versus 9.3 
months). It should be noted that the internal validity of this trial was very limited, given that it was 
a nonrandomised study with a small sample size that compared patients who were not matched in 
terms of prior and post-IRE adjuvant treatments. The authors reported that some patients in the IRE 
group were given adjuvant therapy, but it is unknown how many in the control arm received this.
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The prospective single-arm observational trials on LAPC provided few relevant outcome data. Most 
studies reported on mean OS after IRE or time to local recurrence after IRE, but these are not valid 
outcome measures given that the times between diagnosis and IRE were different and the follow-up 
schemes varied greatly among studies. The most appropriate EFF-related survival outcome would 
be OS after diagnosis or PFS after diagnosis, but only three studies provided the OS or data to allow 
for its calculation using the Kaplan-Meier method. Only one trial reported on PFS after diagnosis. 
For pancreatic cancer, the trials reported mean OS after diagnosis in the range of 12.5–17.5 months, 
which is in the range found in the latest CHEMO trials [27], but no assumptions can be made given 
that the studies lack comparability. It should be noted that the patients included in the trials were 
treated with different CHEMO and/or CRT regimens before or concurrent with IRE, and it is not 
known how these might have contributed to OS or control rates. According to the results of Huang 
et al. [17], who noted that survival was significantly longer for patients who received TS-1 CHEMO 
(28.7 months) than those given gemcitabine (19.1 months), it seems reasonable to assume that the 
effect is not negligible. It was recently proposed that IRE combined with CHEMO could result in an 
additive effect. Given the potential to enhance CHEMO by disrupting the dense stroma of pancreatic 
tumours, IRE could be used in combination with first-line CHEMO [48,92].
The data for liver tumours are even more limited, as no comparative trials were identified and only 
one of the single-arm studies provided long-term survival data [20]. On the basis of these data 
we estimated that OS at 12, 18 and 24 months after IRE would be 89.76%, 69.05% and 65.21%, 
respectively, but these calculations are prone to important biases given that patient follow-up ranged 
from 2.5 to 55 months.
It is noteworthy that although it is one of the most relevant goals in the management of locally 
advanced cancers, only a few studies report on QoL. Results from the studies considered here, 
including the one non-RCT [11], do not support significant improvements with respect to the standard 
of care. On the contrary, one of the studies [15] found a decrease in the median QoL score of 36% 
at 2 weeks and 43% at 3 months after IRE. This study also reported increases in pain score in com-
parison to baseline values. Similarly, Scheffer et al. [16] observed that some of the pain items in the 
QoL domain deteriorated after IRE, although the clinical relevance of the results are uncertain given 
that the authors only provide p values. Further studies are required to elucidate how IRE affects QoL, 
especially in relation to symptom alleviation, because from an ethical point of view the benefits of a 
small increase in survival should always be weighed against QoL and AEs.
Overall, the safety of IRE is a concern. Although no intervention-specific mortality was reported, at 
least four (1.62%) of the patients recruited in LAPC studies suffered from IRE-related AEs that led 
to death (grade V) during the next 30–90 days. The frequency of other severe IRE-related com-
plications was also relatively high in several of the trials [13,16,25]. It appears that some of the 
severe complications are related to heating (portal vein thrombosis, duodenal and bile duct necrosis, 
penetrating/bleeding ulcers, cholangitis), reinforcing the idea that IRE does have a thermal effect. In 
addition, IRE might also be prone to more complications related to needle-tract seeding than thermal 
methods, since needle tract ablation is not possible with current IRE equipment [22]. However, no 
definitive conclusions can be drawn regarding comparison of these methods given the lack of com-
parative data.
The reporting of AEs was very heterogeneous in the studies included. These differences could be 
attributed in part to the use of different scales for defining AE severity, with some stricter than others, 
or the lack of clear consensus on the classification of IRE-related complications [16]. For instance, 
we observed that wound infection, abdominal and back pain and ascites were considered to be IRE-
related in some studies [16,20] but not in others [15,19]. It is possible that these types of complication 
were not reported in all studies, which would probably explain why Scheffer et al. [16] found a very 
high rate of gastrointestinal complications while others did not record any at all. Another problem we 
encountered is that complications were counted differently, with some providing the number of AEs 
[15,16] and others the number of patients who experienced major or minor AEs. To provide an overall 
estimate, we tried to calculate the number of patients affected in all studies. We cannot exclude the 
possibility of slight overestimation owing to duplication of patients with minor AEs. The studies that 
did not provide a grading of complications were not included in these calculations.
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9.1 Limitations of the present report
An important limitation of the present systematic review is that it was not possible to carry out a 
comparative analysis to assess how the tumour location and size and the approach could affect 
SAF outcomes. We observed that the overall frequency of IRE-related severe AEs was higher in 
the pancreatic studies that used a percutaneous approach in comparison to open surgery, although, 
as already noted, there are few studies available and these are not comparable in terms of other 
confounding factors. Nonetheless, it is important to note that some authors reported that the percu-
taneous approach was abandoned because of discouraging complications [11].
9.2 Quality of evidence
The quality of the evidence is very low for both indications. To date, there are no published RCTs 
and the only comparative trial included for LAPC is a small propensity-matched trial comparing IRE 
to noncurative surgery (laparotomy, nonradical resection, biopsy, etc.), with previous or concurrent 
treatments not taken into account [11]. The single-arm trials included to ascertain the effect on critical 
EFF or SAF outcomes were very limited by small size, short follow-up and highly selected popula-
tions, which had undergone different types of systemic therapy. Data for calculating OS and PFS 
from the time of diagnosis, as well as other critical EFF outcome measures such as QoL, were also 
missing in many of the trials, and this constituted an important impediment to drawing any conclu-
sion regarding the potential of IRE to treat these tumours. This was especially noticeable for liver 
cancer, for which most trials only reported local recurrence during follow-up. Among other important 
shortcomings are the lack of standardised definitions regarding success, the unclear classification of 
IRE-related complications and the possible underreporting of some types of AE.
9.3 Applicability
The applicability of the EFF and SAF results is also very doubtful. We observed that IRE application 
within the treatment algorithm was inconsistent across studies, raising uncertainties regarding the 
use of this technique in real practice. For example, whilst some studies restricted IRE to patients 
unresponsive to standard treatment [15], others only applied this technique when patients had a fa-
vourable survival profile [14] or when the disease did not progress after previous CHEMO treatment. 
The treatment protocols also varied substantially; some offered CHEMO before IRE and others of-
fered CRT or induction CHEMO and CRT before IRE; in addition, several applied CHEMO after IRE. 
Differences were also noted regarding the number of ablative sessions, imaging modalities and IRE 
technique, with no formal consensus regarding the considerations that should be taken into account 
to identify tumours for which IRE might be more beneficial.
It is essential that appropriately designed prospective comparative trials are carried out to be able 
to determine the comparative effectiveness and safety of IRE. Ideally, these would be randomised 
trials that would allow evaluation of whether there are additional benefits in terms of safety, survival, 
QoL and pain.
9.4 Ongoing studies
A search for ongoing studies identified 22 trials in pancreatic cancer, most of them single-arm trials. 
One of the studies is a patient registry. At least 16 are still recruiting patients. Two of the studies are 
comparative trials, one comparing the treatment arm with a historic control group and another with 
surgical resection. Another trial evaluated the effect of IRE when combined with natural killer cells. 
Further information is provided in Table A5. During the fact check, the manufacturer informed us 
that AngioDynamics is currently sponsoring a clinical study for pancreatic cancer. For liver cancer, 
16 trials were found, of which at least eight are still recruiting. Most of them are single-arm trials and 
some are complete but no publication was found. In addition, one trial compares IRE with microwave 
treatment and another evaluates the effect of IRE combined with natural killer cells. Further informa-
tion is provided in table A6.
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10 CONCLUSION
Pancreatic cancer
There is insufficient evidence to establish whether IRE is more effective than, or at least as effective 
as, the conventional standard of care (CHEMO, CRT or palliative therapy) for the treatment of unre-
sectable LAPC.
There is insufficient evidence to establish whether IRE is safer than, or at least as safe as, the 
conventional standard of care (CHEMO, CRT or palliative therapy) for the treatment of unresectable 
LAPC.
The existing evidence raises doubts regarding the efficacy of IRE for achieving complete ablation of 
unresectable LAPC.
The existing evidence raises doubts regarding the efficacy of IRE as a sole primary local treatment 
for LAPC. Currently, it is unclear whether IRE needs to be combined with CHEMO and, if so, which 
regimens are optimal.
There are uncertainties regarding the occurrence of severe AEs when IRE is used for the treatment 
of unresectable LAPC.
Liver cancer
There is a lack of data to establish whether IRE is more effective than, or at least as effective as, the 
conventional standard of care (TACE, sorafenib or palliative therapy) for the treatment of patients 
with primary or secondary unresectable liver cancer that is not suitable for thermal ablation.
There is a lack of evidence to establish whether IRE is safer than, or at least as safe as, the con-
ventional standard of care (TACE, sorafenib or palliative therapy) for the treatment of patients with 
primary or secondary unresectable liver cancer that is not suitable for thermal ablation.
The existing evidence raises doubts regarding the efficacy of IRE for achieving complete ablation of 
primary or secondary unresectable liver tumours that are not suitable for thermal ablation.
The existing evidence raises doubts regarding the efficacy of IRE as a sole primary local treatment 
for primary or secondary liver tumours that are not suitable for thermal ablation.
There are uncertainties regarding the occurrence of severe AEs when IRE is used for the treatment 
of liver tumours that are not suitable for thermal ablation.
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE 
USED
DOCUMENTATION OF THE SEARCH STRATEGIES
Search strategy for Medline on 26th September 2018
Search terms Nº
#1 ((((((Electropermeabilizat*[TIAB]) OR ((“Electroporation”[Mesh] OR 
electroporat*[TIAB] OR electro-porat*[TIAB]) AND irreversib*[TIAB])) OR 
(IRE[TIAB] OR Nanoknife[TIAB] OR “Nano knife”[TIAB] OR NTIRE[TIAB] OR 
“NT IRE”[TIAB]))) AND ((“Liver Neoplasms”[Mesh]) OR (((“Liver”[Mesh] OR 
liver[TIAB] OR hepatic*[TIAB] OR hepatocel*[TIAB] OR hepato-cel*[TIAB])) AND 
(“Neoplasms”[Mesh] OR neoplas*[TIAB] OR cancer*[TIAB] OR tumor*[TIAB] 
OR tumour*[TIAB] OR carcinom*[TIAB] OR hepatocarcinom*[TIAB] OR 
hepato-carcinom*[TIAB] OR metastas*[TIAB] OR malignanc*[TIAB]))))) OR 
((((((IRE[TIAB] OR Nanoknife[TIAB] OR “Nano knife”[TIAB] OR NTIRE[TIAB] 
OR “NT IRE”[TIAB])) OR ((“Electroporation”[Mesh] OR electroporat*[TIAB] OR 
electro-porat*[TIAB]) AND irreversib*[TIAB])) OR Electropermeabilizat*[TIAB])) 
AND ((“Pancreatic Neoplasms”[Mesh]) OR (((neoplas*[TIAB] OR cancer*[TIAB] OR 
tumor*[TIAB] OR tumour*[TIAB] OR carcinom*[TIAB] OR adenocarcinom*[TIAB] 
OR adeno-carcinom*[TIAB] OR “Neoplasms”[Mesh])) AND (“Pancreas”[Mesh] OR 
pancreas[TIAB] OR pancreat*[TIAB] OR hepatopancrea*[TIAB])))) Filters activated: 
English, French, Italian, Portuguese, Spanish
331
Search strategy for Embase on 26th September 2018
Search terms Nº
1 (“IRE” or “NT IRE” or NTIRE or “Nano knife” or Nanoknife).ti,ab. 2841
2 exp irreversible electroporation/ or (Electropermeabilization or ((Electroporation or 
electro-poration) and Irreversib*)).ti,ab.
1636
3 1 or 2 3647
4 (liver* or hepatic* or hepatocel* or hepato-cel*).ti,ab. 1134412
5 liver/ 401224
6 4 or 5 1218064
7 neoplasm/ 406306
8 (neoplas* or tumor* or tumour* or cancer* or hepatocarcinom* or hepato-carcinom* 
or malignanc* or metastas*).ti,ab.
3528418
9 7 or 8 3566545
10 6 and 9 277811
11 liver tumor/ 44723
12 10 or 11 294541
13 3 and 12 420
14 limit 13 to embase (english or french or italian or portuguese or spanish) 195
15 (IRE or Nanoknife or “Nano knife” or NTIRE or “NT IRE”).ab,ti. 2841
16 exp irreversible electroporation/ 479
17 (((electroporation or electro-poration) and irreversib*) or Electropermeabilization).
ab,ti.
1550
18 15 or 16 or 17 3647
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19 neoplasm/ 406306
20 (neoplas* or cancer* or tumor* or tumour* or carcinom* or adenocarcinom* or 
adeno-carcinom* or malignanc*).ab,ti.
3700523
21 19 or 20 3738245
22 (pancreas or pancreat* or hepatopancreat*).ab,ti. 341820
23 21 AND 22 136301
24 pancreas tumor/ 24324
25 23 OR 24 142721
26 18 AND 25 300
27 limit 26 to embase (english or french or italian or portuguese or spanish) 146
28 14 OR 27 286
Search strategy for Scopus on 26th September 2018
Search terms Nº
#1 ( ( TITLE-ABS-KEY ( liver OR hepatic* OR hepatocel* ) AND TITLE-ABS-
KEY ( neoplas* OR cancer* OR tumor* OR tumour* OR carcinom* OR 
hepatocarcinom* OR malignanc* OR metastas* ) AND TITLE-ABS-KEY ( ire OR 
nanoknife OR “Nano knife” OR ntire OR “NT IRE” OR “irreversible electroporation” 
OR “irreversible electro-poration” OR electropermeabilization ) ) ) OR ( TITLE-
ABS-KEY ( pancreas OR pancreat* OR hepatopancrea* ) AND TITLE-ABS-
KEY ( neoplas* OR cancer* OR tumor* OR carcinom* OR adenocarcinom* OR 
adeno-carcinom* OR malignanc* ) AND TITLE-ABS-KEY ( ire OR nanoknife OR 
“Nano knife” OR ntire OR “NT IRE” OR “irreversible electroporation” OR “irreversible 
electro-poration” OR electropermeabilization ) ) AND (LIMIT-TO (LANGUAGE , 
“English”) OR LIMIT-TO (LANGUAGE , “Spanish”) OR LIMIT-TO (LANGUAGE , 
“French”) OR LIMIT-TO (LANGUAGE , “Italian”)) 
593
Search strategy for Web of Science on 26th September 2018
Search terms Nº
# 1 TS = (liver or hepatic* or hepatocel* or hepato-cel*) OR TI = (liver or hepatic* or 
hepatocel* or hepato-cel*) AND LANGUAGE: (English OR French OR Italian OR 
Portuguese OR Spanish) Indexes = SCI-EXPANDED Timespan = All years
988789
# 2 TS = (neoplas* OR cancer* OR tumor* OR carcinom* OR tumour* OR 
hepatocarcinom* OR metastas* OR malignanc*) OR TI = (neoplas* OR cancer* 
OR tumor* OR carcinom* OR tumour* OR hepatocarcinom* OR metastas* OR 
malignanc*) AND LANGUAGE: (English OR French OR Italian OR Portuguese OR 
Spanish) Indexes = SCI-EXPANDED Timespan = All years
3258551 
# 3 TS = (ire OR nanoknife OR “Nano knife” OR ntire OR “NT IRE” OR “irreversible 
electroporation” OR “irreversible electro-poration” OR electropermeabilization) OR 
TI = (ire OR nanoknife OR “Nano knife” OR ntire OR “NT IRE” OR “irreversible 
electroporation” OR “irreversible electro-poration” OR electropermeabilization) 
AND LANGUAGE: (English OR French OR Italian OR Portuguese OR Spanish) 
Indexes = SCI-EXPANDED Timespan = All years
9371
# 4 #3 AND #2 AND #1 499
# 5 TS = (pancrea* OR hepatopancrea*) OR TI = (pancrea* OR hepatopancrea*) 
AND LANGUAGE: (English OR French OR Italian OR Portuguese OR Spanish) 
Indexes = SCI-EXPANDED Timespan = All years
308830
# 6 TS = (neoplas* OR cancer* OR tumor* OR carcinom* OR adenocarcinom* OR 
adeno-carcinom* OR tumour* OR malignanc*) OR TI = (neoplas* OR cancer* OR 
tumor* OR carcinom* OR adenocarcinom* OR adeno-carcinom* OR tumour* OR 
malignanc*) AND LANGUAGE: (English OR French OR Italian OR Portuguese OR 
Spanish) Indexes = SCI-EXPANDED Timespan = All years
3260225 
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# 7 TS = (ire OR nanoknife OR “Nano knife” OR ntire OR “NT IRE” OR “irreversible 
electroporation” OR “irreversible electro-poration” OR electropermeabilization) OR 
TI = (ire OR nanoknife OR “Nano knife” OR ntire OR “NT IRE” OR “irreversible 
electroporation” OR “irreversible electro-poration” OR electropermeabilization) 
AND LANGUAGE: (English OR French OR Italian OR Portuguese OR Spanish) 
Indexes = SCI-EXPANDED Timespan = All years
9402
# 8 #5 AND #6 AND #7 218
# 9 #4 OR #8 656
Search strategy for CRD on 26th September 2018
Search terms Nº
1 (Electroporation OR IRE OR Nanoknife OR “Nano knife”) AND (liver* OR hepat*):TI 6
2 (Electroporation OR IRE OR Nanoknife OR “Nano knife”) AND (pancrea*):TI 6
3 1 OR 2 9
Search strategy for Cochrane Library on 26th September 2018
Search terms Nº
#1 ((Electroporation or electro-poration) and Irreversible):ti,ab,kw (Word variations 
have been searched)
41
#2 (Electropermeabilization):ti,ab,kw (Word variations have been searched) 0
#3 IRE or (NT IRE) or NTIRE or (Nano knife) or Nanoknife:ti,ab,kw (Word variations 
have been searched)
101
#4 #1 OR #2 OR #3 114
#5 (liver or hepatic* or hepatocel* or hepato-cel*):ti,ab,kw (Word variations have been 
searched)
39325
#6 MeSH descriptor: [Neoplasms] explode all trees 67290
#7 neoplas* or cancer* or tumor* or tumour* or malignanc* or metastas* or 
carcinom*:ti,ab,kw (Word variations have been searched)
166941
#8 #6 OR #7 172135
#9 #5 AND #8 11884
#10 MeSH descriptor: [Liver Neoplasms] explode all trees 2576
#11 #9 OR #10 11884
#12 #4 AND #11 14
#13 MeSH descriptor: [Neoplasms] explode all trees 67290
#14 neoplas* or cancer* or tumor* or tumour* or carcinom* or adenocardinom* or 
adeno-carcinom* or malignanc*:ti,ab,kw (Word variations have been searched)
166829
#15 #13 OR #14 172010
#16 (pancrea* OR hepatopancrea*):ti,ab,kw (Word variations have been searched) 11976
#17 #15 AND #16 5146
#18 MeSH descriptor: [Pancreatic Neoplasms] explode all trees 1408
#19 #17 OR #18 5154
#20 #4 AND #19 14
#21 #12 OR #20 14
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Search strategy for identification of ongoing studies
clinicaltrials.gov, on 26th September 2018
Pancreatic cancer
Search terms
#1 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreas [DISEASE] AND Irreversible 
electroporation [TREATMENT]
#2 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreatic [DISEASE] AND Irreversible 
electroporation [TREATMENT]
#3 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND hepatopancreatic [DISEASE] AND 
Irreversible electroporation [TREATMENT]
#4 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND hepatopancreatic [DISEASE] AND 
nanoknife [TREATMENT]
#5 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreas [DISEASE] AND nanoknife 
[TREATMENT]
#6 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreatic [DISEASE] AND nanoknife 
[TREATMENT]
#7 neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor OR tumors 
OR tumour OR tumours OR carcinoma OR carcinomas OR adenocardinoma OR adenocarcinomas 
OR malignancy OR malignancies | pancreas | nanoknife
#8 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreas [DISEASE] AND “nano knife” 
[TREATMENT] 
#9 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND pancreatic [DISEASE] AND “nano knife” 
[TREATMENT]
#10 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies) AND hepatopancreatic [DISEASE] AND “nano 
knife” [TREATMENT]
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Liver cancer
Search terms
#1 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND 
liver[DISEASE] AND irreversible electroporation [TREATMENT]
#2 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND hepatic 
[DISEASE] AND irreversible electroporation [TREATMENT]
#3 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND 
hepatocellular [DISEASE] AND irreversible electroporation [TREATMENT] 
#4 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND liver 
[DISEASE] AND “nano knife” [TREATMENT]
#5 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND hepatic 
[DISEASE] AND “nano knife” [TREATMENT]
#6 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND 
hepatocellular [DISEASE] AND “nano knife” [TREATMENT]
#7 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND hepatic 
[DISEASE] AND nanoknife [TREATMENT]
#8 (neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor 
OR tumors OR tumour OR tumours OR carcinoma OR carcinomas OR adenocarcinoma OR 
adenocarcinomas OR malignancy OR malignancies OR metastases OR metastasis) AND liver 
[DISEASE] AND nanoknife [TREATMENT]
#9 neoplasm OR neoplasms OR neoplasia OR neoplasias OR cancer OR cancers OR tumor OR tumors 
OR tumour OR tumours OR carcinoma OR carcinomas OR adenocardinoma OR adenocarcinomas 
OR malignancy OR malignancies OR metastases OR metastais | hepatocellular | irreversible 
electroporation
International ClinicalTrials Registry Platform (ICTRP)
Pancreatic cancer
Search terms
#1 [search field condition]:Liver Neoplasms AND [Search field inetrvention]irreversible electroporation
#2 [search field condition]:Liver* OR hepat* AND [Search field inetrvention]:IRE or “NT IRE” or NTIRE or 
“Nano knife” or Nanoknife
Liver cancer
Search terms
#1 [search field condition]:Pancreatic Neoplasms AND [Search field inetrvention]:Irreversible 
electroporation
#2 [search field condition]:Pancrea* AND [Search field inetrvention]:IRE or “NT IRE” or NTIRE or “Nano 
knife” or Nanoknife
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EU clinical Registry
Pancreatic cancer
Search terms
#1 Pancreatic AND “Irreversible electroporation”
#2 Pancreas AND “Irreversible electroporation”
#3 hepatopancreatic AND “Irreversible electroporation”
#4 hepatopancreatic AND IRE 
#5 hepatopancreatic AND NT-IRE
#6 hepatopancreatic AND “Nano knife”
#7 hepatopancreatic AND Nanoknife
#8 pancreas AND Nanoknife
#9 pancreas AND “Nano knife”
#10 pancreas AND NT-IRE
#11 pancreas AND IRE
#12 pancreas AND electroporation
#13 pancreatic AND IRE 
#14 pancreatic AND NT-IRE
#15 pancreatic AND “Nano knife”
#16 pancreatic AND Nanoknife
Liver cancer
Search terms
#1 liver AND “Irreversible electroporation”
#2 hepatic AND “Irreversible electroporation”
#3 hepatocellular AND “Irreversible electroporation”
#4 liver AND IRE 
#5 liver AND NT-IRE
#6 liver AND “Nano knife”
#7 liver AND Nanoknife
#8 hepatic AND Nanoknife
#9 hepatic AND “Nano knife”
#10 hepatic AND NT-IRE
#11 hepatic AND IRE
#12 hepatocellular AND “Irreversible electroporation”
#13 hepatocellular AND IRE 
#14 hepatocellular AND NT-IRE
#15 hepatocellular AND “Nano knife”
#16 hepatocellular AND Nanoknife
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QUESTIONS FOR PATIENT INTERVIEWS
These are the set of questions that were defined for the two patients who were diagnosed with liver 
cancer and had undergone tumour ablation with a thermal ablative method.
1. What are the diagnosis you have had?
2. How was the diagnostic process?
3. How do you feel in relation to the diagnosis?
4. What was your experience with the disease and what treatments have you received?
5. What ablative treatment have you received? How many sessions did you receive? What was 
the approach? How long were you in the hospital? How was the recovery process? Did you 
have any complications after the ablation? How did the ablation affect your quality of life? How 
did ablation affect your pain?
6. Would you undergo another ablation treatment?
7. The included outcomes related to patients in the assessment are health related quality of life 
and pain. Do you agree with the included outcomes? Do you think we should consider any 
other outcome?
8. Is there anything else that you would like to say about your experience with the disease and 
the ablative treatment?
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DESCRIPTION OF THE EVIDENCE USED
Guidelines for diagnosis and management
Table A 1. Overview of guidelines
Name of society/
organisation 
issuing 
guidance
Date of 
issue
Country/
ies  
to which 
applicable
Summary of recommendation Level of 
evidence 
(A,B,C)/ class of 
recommendation 
(I, IIa, IIb, III)
Pancreatic cancer 
ESMO 2015 Europe Ablative techniques, such us IRE 
or other thermal techniques are not 
considered 
-
 KCE 2017 Belgium Ablative techniques, such us IRE 
or other thermal techniques are not 
considered 
-
NCCN 2017 USA Ablative techniques, such us IRE 
or other thermal techniques are not 
considered 
-
ASCO 2016 USA Ablative techniques, such us IRE 
or other thermal techniques are not 
considered 
-
NICE 2017 UK Little evidence was found on ablative 
therapies so the committee agreed 
not to make any recommendations 
for clinical practice about ablative 
techniques
-
SEOM 2016 Spain Ablative techniques, such us IRE 
or other thermal techniques are not 
considered 
-
Liver cancer 
EASL 2018 Europe IRE is a novel form of tissue ablation 
that could preserve sensible areas. 
However, delivery of IRE requires 
general anaesthesia with deep 
muscular blockade, given the 
muscular contraction induced by 
IRE stimuli, making its performance 
more demanding than RFA/MWA, 
and making it costlier in terms of 
resources.
No recommendations regarding IRE 
are made. 
-
BSG 2003 UK Ablative techniques as 
radiofrequency ablation may be a
good alternative ablative 
therapy but data are limited. No 
recommendations regarding IRE is 
made. 
-
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Name of society/
organisation 
issuing 
guidance
Date of 
issue
Country/
ies  
to which 
applicable
Summary of recommendation Level of 
evidence 
(A,B,C)/ class of 
recommendation 
(I, IIa, IIb, III)
ESMO-ESDO 2012 Europe Local ablation is an alternative for 
resection in some patients but no 
recommendations regarding IRE are 
made.
-
IKNL 2014 Netherlands It advises radiofrequency 
ablation in some patients, but no 
recommendations regarding IRE are 
made.
-
AISF 2013 Italy Percutaneous ablation is 
recommended in some patients. No 
recommendations regarding IRE are 
made. 
-
AASLD 2018 USA The comparative effectiveness of 
ablative strategies (other than RFA 
techniques) remain unclear. IRE is 
not considered. 
-
NCCN 2017 USA Ablation is recommended in some 
patients. No recommendations 
regarding IRE are made. 
-
Consensus 
Spanish 
Associations: 
AEEH, SEOM, 
SERAM, SERVEI 
and SETH
2016 Spain Ablation is recommended in some 
patients. No recommendations 
regarding IRE are made.
-
Abbreviations: AASLD = American Association for the Study of Liver Diseases; AEEH = Asociación Española para el Estudio 
del Hígado; AISF = Italian Association for the Study of the Liver; ASCO = American Society of Clinical Oncology; BSG = British 
Society Gastroenterology; EASL = European Association for the Study of the Liver; ESDO = European Society of Digestive 
Oncology; ESMO  =  European Society for Medical Oncology; IKNL  =  Integraal Kankercentrum Nederland; IRE  =  irre-
versible electroporation; KCE  =  Belgian Health Care Knowledge Centre; MWA  =  microwave ablation; NCCN  =  National 
Comprehensive Cancer Network; NICE = The National Institute for Health and Care Excellence; RFA = radiofrequency ablation; 
SEOM = Sociedad Española de Oncología Médica; SERAM = Sociedad Española de Radiología Médica; SERVEI = Sociedad 
Espanola de Radiología Vascular e Intervencionista; SETH = Sociedad Española de Trasplante Hepático.
Sources: (5, 27-29, 31, 32, 50, 74, 76, 81-85).
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Evidence tables of individual studies included for clinical effectiveness and safety
Table A 2. Characteristics of comparative studies for the effectiveness and safety for 
pancreatic cancer
Author, year, reference 
number
Lambert, 2016 (11)
Country Czech Republic
Centre NR
Funding IGA NT/13263-4 and the Ministry of Health No. RVO VFN 64 165. 
Conflict of interest NR 
Registration trial number NR 
Study Design Prospective non-RCT study (propensity score matched analysis)
Data collection period June 2012 – December 2014
Inclusion/exclusion criteria Inclusion:
• Unresectable pancreatic carcinoma Stage III (without metastatic disease)
• Tumour size ≤6.5 cm in axial plane
• Good performance status (Karnofsky performance status ≥80) 
Patient characteristics IRE 
Matched cohort (based on age 
and size of the tumour 1.5:1)
Number of patients: n 21 32
Age: years; mean ± SD 68 ± 8.4 65.2 ± 8.7 p = 0.22
Gender: n (%) Female: 11 (52.4%) Female: 10 
(31.3%)
p = 0.10
Clinical stage Stage III LAPC Stage III LAPC
Tumour type and location: 
n (%)
Type:
• Ductal adenocarcinoma: 16 (76%)
• Mucinous adenocarcinoma: 2 (10%)
• Acinary adenocarcinoma: 1 (5%)
• Dedifferentiated: 0
• Not specified: 2 (10%)
Location:
• Head: 17 (81%)
• Body: 3 (14%)
• Tail: 1 (5%)
Type:
• Ductal adenocarcinoma: 22 
(69%)
• Mucinous adenocarcinoma: 2 
(6%)
• Acinary adenocarcinoma: 1 (3%)
• Dedifferentiated: 5 (16%)
• Not specified: 2 (6%)
Location:
• Head: 24 (75%)
• Body: 5 (16%)
• Tail: 3 (10%)
Tumour size: cm; mean ± SD 3.82 ± 1.15 3.73 ± 1.39 p = 0.80
Treatments before IRE: n (%) Chemotherapy: 5 (23.8%)
Simultaneous treatments: 
n (%)
• Gastroenteroanastomosis (GEA): 1 
(4.8%)
• GEA and cholecystectomy: 1 (4.8%)
• Hepaticojejunoanastomosis (HJA): 
1 (4.8%)
• Cholecystectomy: 1 (4.8%)
 
Treatments after IRE: n (%) Chemotherapy: 7 (33.3%)
Intervention 
IRE device Nanoknife 
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Approach: n (%) Open surgery: 19 (90.5%)
Percutaneous: 2 (9.5%)
Imaging guidance NR 
Number and length 
of interventions: min; 
mean ± SD
Length:
• Open approach: 79 ± 23
• Percutaneous: 26 
IRE intention: ablation or 
margin accentuation
 Ablation 
Comparator Matched cohort: patients that had 
undergone surgery(explorative 
laparotomy, non-radical resection, 
bypass surgery, cholecystectomy, 
biopsy) or percutaneous biopsy only, 
with or without chemotherapy
Hospital stay: days; mean 
(range)
23 (6-150) 26 (2-166) p = 0.35
Length of follow-up: months; 
median (range) 
8.19 (1.25-26.84)
*Calculated with individual data 
provided by the author 
Effectiveness-related outcomes 
Success of the procedure 0%
[the size of the tumours after IRE did 
not change]
Overall survival: months; 
median (95% CI)
Survival at X months: 
10.03 (5.26, 15.39)
*calculated with individual data 
provided by the author. In the text: 
10.2
9.3 HR = 0.54
p = 0.053
At 3 months: 90.48 (67.00, 97.53)
At 6 months: 75.00 (49.81, 88.80)
At 12 months: 47.62 (24.37, 67.71)
At 18 months: 13.61 (2.33, 34.71)
*Calculated with individual data provided by the author
Cancer specific survival NR
Disease free survival NR
Progression free survival NR
Time to recurrence NR
Time to progression NR
[8/19 (42.1%) patients had disease 
progression]
Time to local recurrence NR
Health-related quality of life 81% of time after IRE KPS ≥70 (IQR 
65%-98%)
74% of time after 
surgery KPS ≥70 
(IQR: 14,88) 
p = 0.076 
Pain NR 
Safety-related outcomes 
Intervention specific 
mortality
0 (one month after IRE)
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Adverse events: n (%) 5 (23.8%) patients:
• Open surgery:
- Bleeding: 1
- Peripancreatic abscess: 1
- Fistula and abscess in the 
abdominal wall: 1
• Percutaneous approach:
- biliary peritonitis, cholangoitis, liver 
abscesses: 1
- Pancreatic fistula: 1
Other adverse events/
complications
Among 19 (90.5%) patients (who 
underwent computed tomography):
• Peripancreatic edema: 9
• Pancreatic or peripancreatic 
necrosis: 6
• Peripancreatic or supramesocolic 
inflammatory infiltrate: 4
• Enlarged lymph nodes: 4
• Carcinosis with ascites: 4
• Extension of the tumour into the 
liver: 1
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Table A 3. Characteristics of other relevant studies for the effectiveness and safety for 
pancreatic cancer
Author, year, reference number Huang, 2018 (17)
Country China
Centre Multicentre 
Funding No financial support or material support 
Conflict of interest None
Registration trial number 201210008DIC 
Study Design Prospective multicentre single-arm study
Data collection period 2012-2015
Inclusion/exclusion criteria Inclusion:
• confirmed LAPC
• induction chemotherapy without radiation and no 
disease progression
• tumour dimension maximum 4 cm
• tolerance to anaesthesia and complete muscle relaxant.
Exclusion criteria:
• history of heart problems or existing metallic implants. 
Patient characteristics 
Number of patients: n 70
Age NR
Gender NR
Clinical stage Stage III LAPC
Tumour type and location: n (%) Head: 24 (34.2%)
Body: 28 (40%)
Tail: 8 (11.4%)
Uncinate process: 10 (14.3%)
Tumour size: n (%) ≤3 cm: 37 (52.9%)
3-4 cm: 33 (47.1%)
Treatments before IRE: n (%) Gemcitabine: 42 (60%)
 TS-1 (Tegafur, Gimeracil and Oteracil): 28 (40%)
Simultaneous treatments NR
Treatments after IRE The same regime as before IRE (until evidence of tumour 
progression was noted)
Intervention 
IRE device Nanoknife 
Approach: n (%) Open surgery: 65 (92.9%)
Laparoscopic: 5 (7.1%)
Imaging guidance Ultrasound 
Number and length of interventions: n; min 
(median)
70 procedures
Length: 165 
IRE intention: ablation or margin accentuation Ablation
Comparator NA
Hospital stay: days; median Open surgery: 7.2
Laparoscopic: 5.6 
Length of follow-up: months; median 28.1 
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Effectiveness-related outcomes 
Success of the procedure: (%) NR
[No residual contras-enhanced tumour by dynamic 
imaging after 3 months: 100 %]
Overall survival: months; median (95% CI) 
[range]
Survival at X months:
Median 22.6 (19.60 - 25.60) [6.6-52.3]
Gemcitabine TS-1 p
19.1 months 28.7 months 0.04
At 3 months: 100%
At 6 months: 100%
At 12 months: 90%
At 24 months: 37%
*Data provided by the author. Only uncensored patients included. 
Cancer specific survival NR
Disease free survival NR
Progression free survival: months; median 
(range)
15.4 (5.3-52.3)
Gemcitabine TS-1 p
13.2 months 26.4 months 0.025
Time to recurrence NR
Time to progression NR
[Distant progression recurrence: 24/70 (34.2%)]
Time to local recurrence NR
[Local recurrence percentage: 6/70 (8.6%)]
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality  0
Adverse events: n (%)
Clavien-Dindo Classification:
• Major complications:
 3 Grade III in 3 patients (4.3%): pseudoaneurysm 
bleeding, pancreatic fistula and intra-abdominal 
abscess.
• Minor complications:
 27 Grade I-II in 13 patients: acute hepatitis, ascites 
accumulation, gastrointestinal bleeding and ileus.
Other adverse events/complications NR
Author, year, reference number Scheffer, 2016 (16)
Country Netherlands 
Centre NR 
Funding National Foundation Against Cancer (Amsterdam, the 
Netherlands)
Foundation for Image- guided Cancer Therapy (Diemen, 
The Netherlands)
Needle electrodes partially funded by AngioDynamics 
(Lathan, NY)
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Conflict of interest One of the authors is a paid consultant for AngioDynamics 
Registration trial number NCT01939665 (PANFIRE study)
Study Design Prospective single-arm study 
Data collection period January 2014 – June 2015
Inclusion/exclusion criteria Inclusion:
• radiologic confirmation
• maximum tumour size 5 cm
• histologic or cytologic confirmation
• written informed consent
• ASA classification 0-3
• age ≥18
• adequate bone narrow, liver and renal function
Exclusion:
• successful downstaging QT/RT from previous 
unresectable and/or borderline tumour to resectable 
tumour
• CHEMO/RT < = 6 weeks before
• allergy to contrast
• history of epilepsy
• implanted stimulation device
• ventricular arrhythmias
• compromised liver function
• metallic biliary stent 
Patient characteristics 
Number of patients 25
Age: years; median (range) 61 (41-78)
Gender: n (%) Female: 13 (52%)
Clinical stage LAPC (NCCN classification)
Tumour type and location: n (%) Location:
• Head: 18 (72%)
• Body: 2 (8%)
• Uncinate process: 5 (20%)
Tumour size (diameter): cm, median (range) 4.0 (3.3-5.0) 
Treatments before IRE: n Chemotherapy: 25 (100%)
• Gemcitabine: 2
• FOLFIRINOX: 10
• Gemcitabine + nab-paclitaxel: 1
Simultaneous treatments NR
Treatments after IRE NR
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Contrast-enhanced computed tomography
Number and length of interventions NR
IRE intention: ablation or margin accentuation Ablation 
Comparator NA
Hospital stay: days; median (range) 3 (2-20)
Length of follow-up: months; median (IQR) 12 (7-16) 
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Effectiveness-related outcomes 
Success of the procedure (%) NR
[A computed tomography scan was performed after IRE 
to confirm technical success (absence of any residual 
tumour enhancement) but no results were given
Needle placement and pulse delivery were successful in 
all patients.]
Overall survival: months; median (95% CI) 
[IQR]
From IRE: 11 months (9, 13) [8-17]
From diagnosis: 17 months (10, 24)
Cancer specific survival NR
Disease free survival NR
Progression free survival: months; median 
(95% CI)
From IRE: 8 (4, 12)
From diagnosis: 15 (10, 20)
[the study defined it as “event free survival”, as local or 
distant progression or death of disease
Time to recurrence NR
Time to progression NR
Time to local recurrence: months; median 
(95% CI)
12 (8, 16)
Health-related quality of life: QLQ-C30 and 
QLQ-PAN26
At 6 weeks:
• Reduced appetite (p = 0.048)
At 3 months:
• diminished general functioning at (p = 0.040)
At 6 months:
• diminished general functioning (p = 0.028)
• feeling or weak arms and/or legs (p = 0.0.31)
• indigestion problems (p = 0.007)
Pain • Day after IRE: median 2 (range 0-5)
• Deteriorated items at 6 weeks: the impact of pain on 
(a) gait (p = 0.016), (b) normal work (p = 0.039), and (c) 
daily activities (p = 0.023).
• Pain increased after 6 months and was more difficult to 
treat with analgesics (p = 0.039).
Safety-related outcomes 
Intervention specific mortality 0
Adverse events
CTCAE version 4.0:
23 adverse events in 10 patients [within 90 days]*
Grade IV: 2 p (pancreatitis, bleeding from duodenal ulcer)
Grade III: 9 p (pancreatitis, biliary obstruction, cholangitis 
and biloma, high-grade SMA stenosis, vomiting, loss of 
appetite/reduced intake)
Grade I/II: 12 p (abscess, pneumonia, nausea, vomiting, 
diarrhea, gastroparesis, abdominal pain)
*Discrepancies in the number of patients who experienced 23 
adverse events 
Other adverse events/complications Irregular vessel narrowing in 7 patients (resolved at 6 
weeks)
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Author, year, reference number Mansson, 2016 (14)
Country Sweden
Centre Uppsala University Hospital
Funding Grants from Uppsala University Hospital
Conflict of interest None
Registration trial number NR 
Study Design Prospective single-arm study 
Data collection period NR
Inclusion/exclusion criteria Inclusion:
• Patients over 18 years old
• Biopsy proven
• Unresectable LAPC
Exclusion:
• Implanted electronic devices
• ASA-score IV
• Expected survival <3 months
• Pregnancy
• Epilepsy
• Severe heart disease
• Tumour diameter >5.0 cm 
Patient characteristics 
Number of patients: n 24
Age: years; median (range) 65 (42-77)
Gender: n (%) Female: 12 (50%)
Clinical stage Unresectable LAPC (classification equivalent to NCCN 
criteria)
Tumour type and location: n (%) Location:
• Caput: 19 (79.2%)
• Corpus: 5 (20.8%)
Tumour size: volume; cm3 27 ± 15.5 cm3
Treatments before IRE: n (%) • Chemotherapy + radio-chemotherapy: 7 (29.2%)
• Radiochemotherapy alone: 3 (12.5%)
• Chemotherapy alone: 14 (58.3%)
Simultaneous treatments NR 
Treatments after IRE: n (%) Chemotherapy: 14 (58.3%)
Surgery:
• Pancreaticoduodenectomy with portal vein resection: 1 
(4.2%)
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Ultrasound guidance 
Number and length of interventions: n 24 procedures 
IRE intention: ablation or margin accentuation Ablation 
Comparator NA 
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Hospital stay: days; median (range) 5 (2-65)
*It is said that all patients were observed for at least 3 days in hos-
pital. According to the table, one patient was observed only 2 days 
Length of follow-up: months; median (range) 6.96 (1.12-18.75)
Effectiveness-related outcomes 
Success of the procedure NR 
Overall survival: months; mean (95% CI) 
[median (95% CI)]
Survival at X months:
From IRE: 7.66 (4.57-11.35) [8.95 (6.79-11.11)]
At 3 months: 95.83% (73.92-99.40)
At 6 months: 58.33% (36.45-74.99)
At 12 months: 29.55% (12.45-48.99)
From diagnosis:
17.52 months (13.18, 21.83) [calculated with individual 
data. In the article it is said 17.9]
At 3 months: 100%
At 6 months: 100%
At 12 months: 79.17% (56.98, 90.75)
At 18 months: 50% (29.10, 67.76)
At 24 months: 13.89% (3.54, 31.14)
*Kaplan-Meier Analysis, with individual data provided in the article
Cancer specific survival NR
Disease free survival NR 
Progression free survival: months; mean (95% 
CI) [median (95% CI)]
Progression free survival at X months:
4.51 (3.25-5.78) [3.19 (2.14-6.18)]
At 3 months: 58.33 (36.45-74.99)
At 6 months: 33.33 (15.90-51.87)
*Kaplan-Meier Analysis, with individual data provided in the article
Time to recurrence NR 
Time to progression: months; mean (95% CI) 
[median (95% CI)]
4.86 (3.53-6.19) [3.32 (2.30-6.38)]
*Kaplan-Meier Analysis, with individual data provided in the article
[Time to distant progression (median): 2.7 months]
[Distant progression percentage: 13 (54.2%)]
Time to local recurrence: months; mean (95% 
CI) [median (95% CI)]
7.25 (5.52-8.99) [6.81 (4.87-8.78)]
*Kaplan-Meier Analysis, with individual data provided in the article
[Local recurrence percentage: 14 (58.3%)]
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality 0
Adverse events: n (%)
Clavien-Dindo Classification:
24 (100%) patients [during the first 30 days after IRE]
• Minor (<3)
 Grade 1: 13 patients (no IRE related)
 Grade 2: 8 patients [infection, pancreatitis, portal vein 
thrombosis]
• Serious: 3 patients [thrombosis with bleeding (1), 
gastroenteroanastomosis (1), bleeding from a prior ulcer 
(1)]
• 1 patient died 2 weeks after IRE due to pneumonia (no 
IRE related)
[11/24 (45.8%) are considered IRE related complications]
*Discrepancies in the number of minor adverse events between 
the text and tables 
Other adverse events Bleeding: 1 [before discharge]
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Author, year, 
reference number
Kluger, 2016 (13)
Country United States 
Centre NewYork-Presbyterian/Columbia University Medical Center
Funding NR
Conflict of interest None
Registration trial number NR
Study Design Prospective single-arm study
Data collection period From October 2012 onwards
Inclusion/exclusion 
criteria 
Inclusion:
• at least 180º encasement of the celiac and/or superior mesenteric artery (T4 
according to the AJCC)
Exclusion:
• ECOG ≥3
• Atrial fibrillation
• M1 or distant N1 disease
•  Tumour size >3 cm
• Borderline resectable
Patient characteristics 
* data presented by number of procedures (n = 53)
All Ablative treatment Margin accentuation 
Number of patients: n 50 
Age*: years; median 
(range)
66.5 (60.2-72.0) 68.6 (63.4-73.8) 62.4 (56.1-68.6)
Gender*: n (%) Female: 22 (41.5%) Female: 14 (48.3%) Female: 8 (33.3%)
Clinical stage LAPC (NCCN)
Tumour type: n (%) Adenocarcinoma: 47 (94%)
Neuroendocrine: 3 (6%)
3 patients had recurrence 
and were treated with a 
second IRE (7,9,19 months 
after first IRE)
Adenocarcinoma: 24 
patients
Adenocarcinoma: 23 
patients
Tumour location*: n (%) Head: 32 (60.4%)
Neck/body: 21 (39.6%)
Head: 17 (58.6%)
Neck/body: 12 (41.4%)
Head: 15 (62.5%)
Neck/body: 9 (37.5%)
Tumour size*: cm; 
median (IQR)
3.0 (1.7-5.0) 2.7 (2.4-4.0) 3.2 (2.0-4.5)
Treatments before IRE
Chemotherapy: n (%) 46 (92%) patients:
GTX/GAX: 29 (63.0%)
FOLFIRINOX: 7 (15.2%)
Other: 10 (21.8%)
14 (58.3%)
3 (12.5%)
7 (29.2%) 
15 (68.2%)
4 (18.2%)
3 (13.6%)
Radiotherapy: n (%) 39 (78%) patients:
Intensity-modulated: 5 
(12.8%)
Stereotactic body: 34 
(87.2%)
3 (16.7%)
15 (83.3%)
2 (9.5%)
19 (90.5%)
Simultaneous 
treatments*: n (%)
Gastrojejunostomies: 2 
(6.9%)
Double-bypass 
operation: 2 (6.9%)
Wipple: 15 (63%)
Distal: 7 (29%)
Appleby: 2 (8%)
Venous reconstruction: 
12 patients (52%)
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Treatments after IRE NR 
Intervention All Ablative treatment Margin accentuation 
IRE device Nanoknife 
Approach NR
Imaging guidance NR
Number and length 
of interventions: n; 
minutes, median ± range
53 procedures; 42 min (26-
91)
29 procedures;
84 min (54-118)
24 procedures; 26.5 
min (17-33.5)
IRE intention: ablation 
or margin accentuation; 
n (%)
29 (55%) 24 (45%)
Comparator NA 
Hospital stay*: days, 
median (range)
6 (2-40) 4 (2-34) 8 (3-40)
Length of follow-up: 
months; median (IQR)
8.69 (0.26-16.26)
Effectiveness-related 
outcomes 
Data reported only 
for patients with 
adenocarcinoma 
Success of the 
procedure
NR
Overall survival: months; 
median (95% CI) 
12.03 (7.71-23.12) 7.71 (6.03-12.0) -
Cancer specific survival NR
Disease free survival NR
Progression free 
survival 
NR
Time to recurrence NR
Time to progression NR
[Percentage of progression 
(local + distant recurrence): 
58%]
[Time to distant recurrence: 
median of 90.2 months 
(95% CI, 6.66-16.98)]
Time to local 
recurrence: months, CI 
95%
8.6 (5.51- Not reached)
[Percentage of local 
recurrence: 11%]
Health-related quality 
of life
NR
Pain NR
Safety-related outcomes 
Intervention specific 
mortality
0
[6 patients died within 90 
days after IRE, median 
postoperative mortality: 26 
days (range 8-42)]
0
[5 postoperative 
mortality]
0
[1 postoperative 
mortality]
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Adverse events: n (%)
Clavien-Dindo 
classification:
30 days:
• Grade 3-4: 9 (16.9) (4 
IRE related)
• Grade 5: 4 (7.6) (1 IRE 
related: duodenal and 
bile duct necrosis)
90 days:
•  Grade 3-4: 1 (2.0)
•  Grade 5: 2 (3.8) (2 
IRE related: upper 
gastrointestinal 
bleeding, intraperitoneal 
haemorrhage)
*At 30 days: in the text 5 grade 
1 complication and 8 grade 2 
complications are mentioned.
*there were no statistically dif-
ferences in the incidence of 
adverse events adjusted by 
needle-placement, tumour size 
or primary treatment versus 
margin extension.
30 days:
• Grade 3-4: 4 (13.7)
• Grade 5: 3 (10.3)
90 days:
• Grade 3-4: 1 (3.4)
• Grade 5: 2 (6.9)
30 days:
• Grade 3-4: 5 (20.8)
• Grade 5: 1 (4.2)
90 days:
• Grade 3-4: 0 (0)
• Grade 5: 0 (0)
Other adverse events/
complications 
NR
Author, year, reference number Paiella, 2015 (15)
Country Italy 
Centre Single center: University of Verona Hospital Trust 
Funding None
Conflict of interest NR
Registration trial number NR
Study Design Prospective single-arm study
Data collection period June 2011-December 2011
Inclusion/exclusion criteria Inclusion:
• Male or female
• 18 years of age
• Meets criteria for locally advanced unresectable pancreatic 
adenocarcinoma
• Tumour size must be <4 cm (longest axis) and must be 
measurable
• Must have an INR <1.5
• Must be unresponsive to chemotherapy as demonstrated with 
either computed tomog-raphy or MRI imaging and not have 
taken any chemotherapy agents within 14 days of treatment 
with the NanoKnife LEDC System
• Are willing and able to comply with the protocol requirements
• Are able to comprehend and willing to sign an Informed 
Consent Form
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Exclusion:
• A baseline creatinine reported as >2.0 mg/dl
• Have any reported baseline lab values with a grade 3 or 4 
toxicity as defined by the CTCAE Version 3.0
• Inability to stop antiplatelet and Coumadin therapy for 7 days 
prior to and 7 days post treatment with the NanoKnife System
• Known history of contrast allergy that cannot be medically 
managed
• Known hypersensitivity to the metal in the electrodes (stainless 
steel 304L) that cannot be medically managed
• Unable to be treated with a muscle blockade agent (e.g., 
pancuronium bromide, atricurium, cisatricurium, etc.)
• Women who are pregnant or currently breast feeding
• Women of childbearing potential who are not utilizing an 
acceptable method of contraception
• Have taken an investigational agent within 30 days of visit 1
• Have implanted cardiac pacemakers or defibrillators
• Have implanted electronic devices or implants with metal parts 
in the immediate vicinity of a lesion
• Have a history of epilepsy or cardiac arrhythmia (atrial or 
ventricular fibrillation)
• Have a recent history of myocardial infarction (within the past 2 
months)
• Have Q-T intervals greater than 550 ms unless treated with 
an Accusync Model 72 synchronization system controlling the 
NanoKnife system’s output pulses
Patient characteristics 
Number of patients 10
Age: years; median 66
Gender: n (%) Female: 6 (60%)
* Discrepancies between the text and the tables: 5 females were 
included according to the abstract 
Clinical stage LAPC; any of the following features:
• Infiltration or thrombosis of one or more large arterious 
vessels surrounding the pancreas (celiac axis, and/or superior 
mesenteric artery and/or hepatic artery)
• Infiltration of the venous vessels wall (portal vein, and/or 
superior mesenteric vein)
• Contact >180º for more than 2 cm in length. 
Tumour type and location: n (%) Type: 10 adenocarcinoma (100%)
Location:
• Head: 7 (70%)
• Body: 3 (30%)
Tumour size: cm; median (range) 3 (2.5-3.9)
Treatments before IRE: n (%) Chemotherapy: 10 (100%)
• Gemcitabine: 2
• GEMOX: 5
• GEMOX first line, FOLFIRINOX second: 2
• PEXG: 1
Radiotherapy: 4 (40%)
Simultaneous treatments Double bypass (gastric and biliary) in one patient 
Treatments after IRE: n (%) Chemotherapy: 3 (30%)
Intervention 
IRE device Nanoknife 
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Approach Open surgery
Imaging guidance US 
Number and length of interventions: 
min; median (range)
79.5 (20-148)
IRE intention: ablation or margin 
accentuation
Ablation 
Comparator NA
Hospital stay: days; median (range) 9.5 (8-17)
Length of follow-up: months; median 7.6 
Effectiveness-related outcomes 
Success of the procedure NR
[IRE procedure 100% successful]
Overall survival: months; median (95% 
CI) [mean (95% CI)]
Survival at X months (95% CI): 
From IRE*: 4.3 m (2.9, 10.1) [Mean 7.5 (24.95,10.03)]
At 3 months: 90% (47.30, 98.53)
At 6 months: 50% (18.36, 75.32)
At 12 months: 20% (3.09, 47.47)
From diagnosis*: 12.5 months (95% CI: 8.5, 24.1) [16.79 (95% 
CI: 12.40, 21.18)]
At 3 months: 100%
At 6 months: 100%
At 12 months: 60% (25.27, 82.72)
At 18 months:50% (18.36, 75.32)
At 24 months: 30% (7.11, 57.79)
* Kaplan-Meier Analysis, with individual data provided in the article.
Important discrepancies between the text and the tables: in the text it is 
said that a patient died because of septic shock 2 weeks after IRE. 
Cancer specific survival NR
Disease free survival NR
Progression free survival NR
Time to recurrence NR
Time to progression NR
[One patient developed metastases 30 days after IRE]
Two patients developed metastases 60 days after IRE]
Time to local recurrence NR
Health-related quality of life: • EORTC QLQ 30/ PAN26:
Preoperatively: 58.3
2 weeks after IRE: 37.5
3 months:33.5
• KPS Performance status:
Baseline: 100
30 days after IRE: 80
60 days after IRE: 77.5
90 days after IRE: 70
Pain •  Visual Analogue Scale
Baseline: 0.5
30 days after IRE: 3
60 days after IRE: 4
90 days after IRE: 1
Safety-related outcomes 
Intervention specific mortality 0
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Adverse events: n (%)
MedDRA classification system; severity 
of toxicities according to the CTCAE, 
whenever possible
• Severe adverse events:
◊ Pulmonary embolism: 1
◊ Systemic candidiasis: 1
◊ Pneumonia: 1
◊ Sepsis: 1
◊ Pancreatic abscess and internal fistula: 1 (considered 
procedure-related abdominal complication)
• Non severe adverse events :
◊ Abdominal and back pain: 5
◊ Portal vein thrombosis: 1
◊ Onset ulcerative colitis: 1
◊ Peripheral oedema: 1
◊ Wound infection: 1
Other adverse events/complications • Intraoperativerly: 1 patient (10%) transient hypertensive 
episode 
Author, year, reference number Belfiore, 2015 (18)
Country Italy 
Centre Single center: S. Anna - S. Sebastiano Hospital 
Funding None
Conflict of interest None
Registration trial number NR
Study Design Prospective single-arm study 
Data collection period April 2013 - June 2014
Inclusion/exclusion criteria Inclusion:
• LAPC according to the NCCN guidelines
• Maximal axial diameter ≤6 cm
• No metastases
Exclusion:
• Moderate or severe cardio-pulmonary failure
• Coagulation disorders
• Contraindication to general anesthesia and/or chemotherapy
Patient characteristics 
Number of patients: n 20
Age: years; mean (range) [median] 69.2 (55-82) [70]
Gender: n (%) Female: 10 (50%)
Clinical stage LAPC (not reported if histologically confirmed)
Tumour type and location: n (%) Type: NR
Location:
• Head: 10 (50%)
• Body: 1 (5%)
• Body-tail: 5 (25%)
• Isthmus: 3 (15%)
• Isthmus-head: 1 (5%)
Tumour size (volume): cm³; mean 
(range) 
93 (39-170)
Treatments before IRE NR 
Simultaneous treatments NR 
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Treatments after IRE: n (%) 20 patients (100%): combination of gemcitabine (100mg/mq) + 
oxaliplatin (100 mg/mq) biweekly
3 (15%) patients underwent surgery because of lesions 
downstaging
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Computed tomography
Number and length of interventions: n 20
IRE intention: ablation or margin 
accentuation
Ablation 
Comparator NA 
Hospital stay NR 
Length of follow-up: months; mean 
(range)
8.55 (3-14)
Effectiveness-related outcomes 
Success of the procedure NR
[IRE procedure 100% successful. Residual tumour was observed 
in all patients after a 6 months of follow-up]
Overall survival: months; mean (CI 
95%)
Survival at X months (95% CI):
12.95 (11.57-14.33)
At 3 months: 95% (69.5 - 99.3)
At 6 months: 90% (65.6 - 97.4)
At 12 moths: 90% (65.6 - 97.4)
*Kaplan-Meier Analysis, with individual data provided in the article. 
Cancer specific survival NR
Disease free survival NR
Progression free survival NR
Time to recurrence NR
Time to progression NR
[No progression in 18/20 (90%) of patients at the last follow-up]
Time to local recurrence NR
[Local control at 6 months: 18/20 (90%)]
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality: n 0
Adverse events: n (%)
Not grading system stated
Minor complication: 2 (10%)
• Transient amylase increase in serum: 1
• Mild ascites: 1
Major complication: 0
Other adverse events/complications NR
Author, year, reference number Martin, 2012 (19)
Country United States 
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Centre Multicenter: Henry Ford Hospital and University of Louisville 
Funding Partial support of an educational grant from Angiodynamics 
Conflict of interest First author is a paid consultant for Angiodynamics 
Registration trial number NR
Study Design Prospective single-arm study 
Data collection period December 2009 - March 2011 
Inclusion/exclusion criteria Inclusion:
• Locally advanced pancreatic cancer (Stage III) by the AJCC 
staging system
Exclusion:
• Borderline resectable lesions
Patient characteristics 
Number of patients: n 27
Age: years; median (range) 61 (45-82)
*Discrepancies between the text and the table: in the abstract the range 
is 45-80
Gender: n (%) Female: 13 (48.1%)
Clinical stage LAPC Stage III (AJCC staging system) 
Tumour type and location: n (%) Location:
• Head: 15 (55.6%)
• Body/neck: 12 (44.4%)
Tumour size: cm; median (range) Axial: 3 (1-5.5)
Anterior to posterior: 2.8 (1-5.3)
Caudal to cranial: 2.6 (1-4.1)
Treatments before IRE: n (%) Previous treatment in 23 (85%) of patients:
• Chemotherapy:
◊ Gemzar: 8
◊ FOLFOX: 3
◊ FOLFIRI:1
◊ Oxaliplatin:1
◊ Avastin: 1
◊ Cisplatin: 2
◊ Taxol: 1
◊ FOLFIRINOX: 4
◊ Other: 15
• Radiotherapy:
◊ 5FU and radiation: 3
◊ Gemzar and radiation: 6
*FOLFIRI: folinic acid, fluorouracil and irinotecan
FOLFIRINOX: oxaliplatin, irinotecan, fluorouracil and leucovorin
FOLFOX: 5-FU, leucovorin and oxaliplatin
Simultaneous treatments • Resection + IRE: 8
◊ Whipple procedure: 4
◊ Subtotal pancreatectomy: 4
• Hepticojejunostomy: 4
• Gastrojejunostomy: 9
• Partial gastrectomy: 3
• Other: 17
Treatments after IRE NR 
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Intervention 
IRE device Nanoknife 
Approach: n (%) Open: 26 (96.3%)
Percutaneous: 1 (3.7%)
Imaging guidance Ultrasound 
Number and length of interventions: n; 
min; median (range)
27 procedures
Length of IRE: 10 (2-97)
Length of procedure: 160 (40-365)
IRE intention (ablation or margin 
accentuation): n (%)
Ablation: 19 (70.4%)
Margin accentuation: 8 (29.6%)
Comparator NA 
Hospital stay: days; median (range) 9 (1-58)
Length of follow-up: days 90 
Effectiveness-related outcomes 
Success of the procedure: % 96.3% (26/27)
[Definition: ability to deliver the planned therapy in the operative 
room and at 3 months to have no evidence of residual tumour]
[One patient died on day 70]
Overall survival At 3 months: 26 (100%) 
Cancer specific survival NR 
Disease free survival NR 
Progression free survival NR
Time to recurrence NR
Time to progression NR
Time to local recurrence NR
Health-related quality of life NR 
Pain Before IRE: 5 points (range 3-9)
Safety-related outcomes 
Intervention specific mortality 0
Adverse events: n (%)
Not grading system stated
9 (33%) patients, 17 adverse events:
• Grade 1: hematologic (1)
• Grade 2: hematologic (2), ileus(1), portal vein thrombosis (1), 
Deep venous thrombosis (2), wound infection (3)
• Grade 3: Bile leak (1), pulmonary (2), renal failure (1), ascites 
(1)
• Grade 4: bile leak(1)
• Grade 5: portal vein thrombosis (1)
[Possible IRE-related adverse events in 4 patients]
*Discrepancies between the text and the table: in the text 18 complications 
Other adverse events/complications NR
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Table A 4. Characteristics of other relevant studies for the effectiveness and safety for liver 
cancer
Author, year, reference number Frühling, 2017 (20)
Country Sweden 
Centre Single center: Uppsala University Hospital
Funding Non-industry sponsored 
Conflict of interest None
Registration trial number NR
Study Design Prospective single-arm study 
Data collection period September 2011 - September 2014
Inclusion/exclusion criteria Inclusion criteria:
• contraindicated for other ablation modalities
• size of <30 mm
• a maximum of 2 tumours
• performance, status according to Eastern Co-operative 
Oncology Group (ECOG) <2
Exclusion:
• American Society of Anaesthesiologists (ASA) 
classification score IV
• Pacemakers
• epilepsy
• severe cardiac disease
*A inclusion criteria is a tumour size <30 mm but they include 6 
patients with a marginally larger tumour.
Patient characteristics 
Number of patients: n 30 
Age: years; median (range) 63 (46-78)
Gender: n (%) Female: 9 (30%)
Clinical stage: n (%) NR
Tumour type and location: n (%) 38 tumours:
• Primary tumours:
◊ HCC: 8 (21.1%)
• Secondary tumours:
◊ CRLM: 23 (60.5%)
◊ Other metastases: 7 (18.4%)
Tumour size: cm; median (range) 2.4 (0.8-4)
Treatments before IRE: n Liver surgery: 18
MWA/RFA: 20
Simultaneous treatments NR
Treatments after IRE NR
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance CE-US
Number and length of interventions: n 38 treated tumours (2 patients were treated on two 
different occasions and 8 patients had 2 tumours)
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IRE intention: ablation or margin accentuation Ablation 
Comparator NA
Hospital stay: days; median (range) 2 (1-4)
Length of follow-up: months; median (range) 22.3 (2.5-55.6)
Effectiveness-related outcomes 
Success of the procedure NR
[Ablation success defined as acceptable ablation zone 
in the treated area and no evidence of residual tumour. 
Imaging techniques were performed 1 month after IRE but 
the results were not provided] 
Overall survival: months; mean (95% CI)
Survival at X months (95% CI): 
37.92 (30.28,45.57)
At 3 months: 96.67 (78.61, 99.52)
At 6 months: 96.67 (78.61, 99.52)
At 12 months: 89.76 (71.51, 96.58)
At 18 months: 69.05 (48.93, 82.54)
At 24 months: 65.21 (44.92, 79.58)
*Discrepancies between the text and the tables (number of deaths, 
range follow-up) were clarified by the author
*Kaplan-Meier Analysis, with individual data provided in the article.
Cancer specific survival NR
Disease free survival NR
Progression free survival NR 
Time to recurrence NR
Time to progression NR
Time to local recurrence NR
Local recurrence percentages:
3 months 6 months
All tumours 21.1% 34.2%
CRLM 26.1% 47.8%
HCC 0% 0%
Other metastases 28.6% 28.6%
Health-related quality of life NR
Pain Post-procedural pain: 7 patients
Safety-related outcomes 
Intervention specific mortality: n 0 (30 days after IRE)
Adverse events: n (%)
SIR grading system
(30 days after IRE)
• Major complication (2):
Grade V: pulmonary embolism (non-IRE related) (1)
Grade III-IV: bile duct dilatation and stricture of portal 
vein and bile duct (1)
• Minor complications (12):*
◊ Post-procedural pain: 7 patients (one patient required 
morphine for chest pain)
◊ Hematoma (1)
◊ Shortness of breath (1)
◊ Tachycardia (1)
◊ Infection (1)
◊ Increased blood pressure (1)
Other changes: 13 transient increase in liver 
transaminases
*Possible duplication of patients 
Other adverse events/complications NR
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Author, year, reference number Distelmaier, 2017 (22)
Country Germany 
Centre Single center: Academic comprehensive cancer centre 
Funding NR
Conflict of interest None
Registration trial number NR
Study Design Prospective single-arm study
Data collection period February 2012 to June 2015
Inclusion/exclusion criteria Inclusion criteria:
• not considered suitable for RFA or MWA because of the 
close proximity (<0.5 cm) to major hepatic or portal vein 
branches and bile duct structures
• no more than three malignant liver tumours, each 
smaller than 4 cm
Patient characteristics 
Number of patients: n 29
Age: years; mean ± SD 63 ± 12
Gender: n (%) Female: 14 (48.3%)
Clinical stage NR 
Tumour type and location Total 29 patients, 43 tumours:
Primary tumours (8 tumours):
• Hepatocellular carcinoma 2 patients, 4 target tumours
Secondary tumours (35 tumours):
• Breast cancer 4 patients, 4 target tumours
• Colorectal cancer 13 patients, 21 target tumours
• Cholangiocellular carcinoma 2 patients, 4 target 
tumours
• Pancreatic cancer 2 patients, 2 target tumours
• Melanoma 1 patient, 1 target tumour
• Mesothelioma 1 patient, 1 target tumour
• Esophageal carcinoma 2 patients, 2 target tumours
• Renal cell carcinoma 1 patient, 3 target tumours
• Gastrointestinal stromal tumour 1 patient, 1 target 
tumour
Tumour size: volume (mL); mean ± SD 6.4 ± 11.39
Treatments before IRE NR
Simultaneous treatments NR
Treatments after IRE NR
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Computed tomography
Number and length of interventions NR
IRE intention: ablation or margin accentuation Ablation 
Comparator NA
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Hospital stay NR
Length of follow-up: mean ± SD 24 ± 7
Effectiveness-related outcomes 
Success of the procedure: % (95% CI) [n] NR
[No residual tumour and the ablation zone cover the target 
tumour with an adequate safety margin:
By patients: 90% (95% CI: 73, 98) [26/29]
By tumours: 93% (95% CI: 85,100) [40/43]]
Overall survival NR
Cancer specific survival NR
Disease free survival NR
Progression free survival NR
Time to recurrence NR
[Recurrence (local + regional): by patient: 10/26 (38%; 
95% CI: 20,59) ]
Time to progression NR
[Distant progression: 5/29 (17.2%) patients (range: 8 
weeks-24 months)]
Time to local recurrence NR
Range: 2-18 months
[Local recurrence 7.70% (2/26)]
[Regional recurrence: 30.8% (8/26) (along the needle tract 
seeding)]
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality: n 0
Adverse events: n
SIR grading system:
• Minor: 8
◊ Cholestasis 2-6 weeks after IRE: 5
◊ Hematoma: 2 [inmmediate (within 24 hours after IRE)]
◊ Arterioportal fistula: 1 [periprocedural (within 30 days 
after IRE)]
Other adverse events/complications: n (%) 8/26 (30.8%) patients needle tract seeding 
Author, year, reference number Niessen, 2016 (25)
Country Germany 
Centre Single center: University Hospital Regensburg 
Funding NR
Conflict of interest None
Registration trial number NR
Study Design Prospective single-arm study 
Data collection period December 2011 - June 2013
EUnetHTA Joint Action 3 WP4
Irreversible electroporation for the treatment of liver and pancreatic cancer
109Version 1.4, 18 May 2019
Inclusion/exclusion criteria Inclusion:
• Diagnosis of primary or secondary liver cancer based 
on positive biopsy or noninvasive criteria (1 tumour 
<5cm, 3 tumours <3 cm)
• Noncandidacy for conventional thermal ablation
• Age 18-85
• Written informed consent
Exclusion:
• Resectable disease
• Severe coagulation disorders
• Vascular invasion, multifocal hepatic disease or 
extrahepatic spread on imaging
• Previous treatment of target nodule
• Patients who received systemic chemotherapy whiting 
30 days of IRE
• Severe heart failure, recent myocardial infarction, 
coronary artery disease, arrhythmia, implantable 
devices
• Pregnancy or women childbearing age not using 
contraception 
Patient characteristics 
Number of patients 34
Age: mean ± SD (range) 59.4 ± 11.2 (22-81)
Gender: n (%) Female: 7 (20.6%) 
Clinical stage NR
Tumour type and location: n 34 patients, 65 tumours:
• Primary tumours (33)
◊ Hepatocelular carcinoma: 15 p, 33 tumours
• Secondary tumours (32)
◊ Colorrectal liver metastases: 12 p, 22 tumours
◊ Cholangiocellular carcinoma: 4 p, 5 tumours
◊ Testicular metastases: 1 p, 2 tumours
◊ Neuroendocrine metastases: 2 p, 3 tumours
Tumour size (diameter): cm; median ± SD 
(range) 
2.4 ± 1.4 (0.2 – 7.1)
Treatments before IRE: n (%) Surgical treatment: 20 (58.8%)
Systemic therapy: 15 (44.1%)
RFA: 7 (20.6%)
Hepatic arterial therapy: 4 (11.8%)
Radiation therapy: 3 (8.8%)
Simultaneous treatments NR
Treatments after IRE NR 
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Computed tomography and US 
Number and length of interventions: n; 
minutes, mean ± range
51 procedures
Length: 163.5 min ± 59.5 (62-400)
IRE intention: ablation or margin accentuation Ablation 
Comparator NA
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Hospital stay NR
Length of follow-up: months; median (range) 13.9 (1.8-19.5)
Effectiveness-related outcomes 
Success of the procedure: n (%) NR
[Successful delivery of all planned pulses to the target 
volume as calculated by the IRE generator and complete 
tumour coverage (assessed by computed tomography 
or MR performed 6 weeks after ablation): 62/65 tumours 
(95.4%)].
[3 patients with incomplete ablation at 6 weeks and 9 
patients with recurrence at 3 or 6 months were retreated]
Overall survival NR
[One patient died 9.8 months after first IRE]
Cancer specific survival NR
Disease free survival NR
Progression free survival NR 
Time to recurrence NR
Time to progression: months; median 15.6 
Time to local recurrence: months; mean
 Local recurrence free survival at X months:
By tumour: 15.5
At 3 months: 87.4%
At 6 months: 79.8%
At 12 months:74.8%
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality NR 
Adverse events: n (%)
SIR grading system, graded according the 
CTCAE:
14/51 procedures (27.5%)
• Major complications: 6 (11.8%)
◊ Intraperitoneal bleeding: 1 (2.0%) [CTCAE 3]
◊ Partial thrombosis of portal vein 1(2.0%) [CTCAE 3]
◊ Abscess: 4 (7.8%) [CTCAE 3]
• Minor complications: 8 (15.7%)
◊ Hematoma: 6 (11.8%) [CTCAE 1]
◊ Pneumothorax: 2 (3.9%) [CTCAE 1]
Other complications/adverse events NR 
Author, year, reference number Granata, 2016 (24)
Country Italy 
Centre Single center: National Cancer Institute
Funding NR
Conflict of interest None
Registration trial number NR
Study Design Prospective single arm study 
Data collection period January 2012 - July 2013
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Inclusion/exclusion criteria Inclusion:
• Histologically proven diagnosis of HCC
• Not suitable for surgical resection with tumour sites 
unfavourable to radiofrequency ablation
• 3 HCC nodules or less
• Nodule size ≤3 cm
• Child-Pugh class A
• ECOG performance status of 0
• ASA score of 3
• Prothrombin time ratio >50%
• Platelets count >50 × 109/L
Exclusion:
• Distant metastases
• Tumour infiltration of the major liver vessels
• Recent myocardial infarction
• Cardiac arrhythmias, implanted pacemaker, renal failure
• Sepsis
• Poor life expectancy 
Patient characteristics 
Number of patients: n 20
Age: years; mean (range) 65 (48-80)
Gender: n (%) Female: 8 (40%)
Clinical stage BCLC classification: Stage A 
Tumour type and location: n (%) 24 primary tumours
Tumour type:
• Well-differentiated HCC: 20/24 (83.3%)
• Moderately differentiated nodule: 3/24 (12.5%)
• Poorly differentiated lesion: 1/24 (4.17%)
Tumour location:
• Location in difficult sites: 8/24 (33.3%)
• Non-difficult sites: 16/24 (66.7%)
Tumour size: cm; mean (range) 2 (1-3)
Treatments before IRE NR
Simultaneous treatments NR
Treatments after IRE NR
Intervention 
IRE device Nanoknife
Approach Percutaneous
Imaging guidance US
Number and length of interventions: n 22 procedures
IRE intention: ablation or margin accentuation Ablation
Comparator NA
Hospital stay NR
Length of follow-up: months 6
Effectiveness-related outcomes
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Success of the procedure: n (%) NR
[Complete response (disappearance of any enhancement 
in all target lesions): 22/24 (91.7%)]
[The two residual tumours underwent an additional single 
session of IRE achieving complete response]
Overall survival 100%
Cancer specific survival NR
Disease free survival NR
Progression free survival NR
Time to recurrence NR
Time to progression NR
Time to local recurrence NR
Health-related quality of life NR
Pain NR
Safety-related outcomes 
Intervention specific mortality 0
Adverse events Minor (2):
• Peripheral arteriovenous shunt: 1/20 (5%)*
• Segmental dilation of the intrahepatic biliary ducts: 1/20 
(5%)*
*Occurred along the needle tract
Other adverse events/complications: n (%) Capsular retraction: 4/24 (17%)
Alterations of vascular perfusion during the arterial phase: 
6/20 (30%)
Author, year, reference number Eller, 2015 (23)
Country Germany
Centre Single center: University Hospital Erlangen 
Funding NR
Conflict of interest None
Registration trial number NR 
Study Design Prospective single-arm study 
Data collection period NR
Inclusion/exclusion criteria Inclusion:
• Primary or secondary liver tumours in perivascular 
locations
• No surgical or thermo-ablative candidate 
Patient characteristics 
Number of patients: n 14
Age: years; mean ± SD (range) 58 ± 11 (36-73) 
Gender: n (%) Female: 3 (21.4%)
Clinical stage NR
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Tumour type and location: n (%) 14 patients, 18 tumours:
• Primary: 3/14 (21.4%)
◊ Hepatocellular carcinoma: 3/18
• Secondary: 11/14 (78.6%)
◊ Neuroendocrine: 1/14
◊ Squamous cell carcinoma: 1/14
◊ Colorrectal carcinoma: 9/14
Tumour size: cm; median (range) 2 ± 0.5 (1.1-3.7)
Treatments before IRE: n 1 patient treated with TACE 
Simultaneous treatments NR
Treatments after IRE: n 1 patient unsuccessful treated: RFA 4 weeks later
1 patient treated with MWA of further lesions
2 patients treated with RFA of recurrent lesions 
Intervention 
IRE device Nanoknife 
Approach Percutaneous 
Imaging guidance Computed tomography
Number and length of interventions: n; hours 14 procedures; range: 2-5 h
IRE intention: ablation or margin accentuation Ablation 
Comparator NA 
Hospital stay NR 
Length of follow-up: days; mean ± SD (range) 388 ± 160 (120-594) [among 10 patients without local 
recurrence]
Effectiveness-related outcomes 
Success of the procedure (%) NR
[Total inclusion in the devascularized area in the initial 
posinterventional computed tomography performed the 
first following day after IRE: 12/14 (86%)] 
Overall survival NR 
Cancer specific survival NR 
Disease free survival NR 
Progression free survival NR
Time to recurrence NR
Time to progression NR
• Progression percentage: 6/12 (50%)
Time to local recurrence: months; mean NR
Local recurrence percentage: 2/12 (17%)
Health-related quality of life NR 
Pain NR 
Safety-related outcomes
Intervention specific mortality 0
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Adverse events
Classified according CTCAE version 2:
• Major complications 4/14 (29%):
◊ Severe abdominal bleeding requiring surgery: 1 
[CTCAE 4]
◊ Hemoperitoneum:1 [CTCAE grade 3]
◊ Hematothorax: 2 [CTCAE grade 3]
No long-term complications 
Intervention specific mortality NR
Author, year, reference number Eisele, 2014 (12)
Country Germany 
Centre NR 
Funding None
Conflict of interest None 
Registration trial number NR 
Study Design Prospective single-arm study 
Data collection period NR
*10 months of recruitment 
Inclusion/exclusion criteria Inclusion:
• Unresectable tumour
• Small solitary tumour centrally sited in combination with a high 
probability for recurrent disease and/or not more than 3 tumours
• Abscense of coagulation disorders
• Normal blood cell count
• Tumours in the vicinity of larger vessels (predominantly portal or 
hepatic veins)
• Small tumours*
* Initially <2 cm. In the two most recent applications, tumour sizes were in-
creased up to 2.4 cm
Exclusion:
• Severe cardiac arrhythmia
• Inability to undergo general anaesthesia 
Patient characteristics 
Number of patients: n 13
Age: years; mean ± SD 63 ± 10
Gender: n (%) Female: 4 (30.8%)
Clinical stage NR
Tumor type and location: n (%) 14 tumours:
• Primary tumours: 8
◊ Hepatocellular carcinoma: 5 p, 5 tumours (35.7%)
◊ Intrahepatic recurrent cholangiocarcinoma: 2 p, 2 tumours 
(14.3%)
• Secondary tumours: 6
◊ Colorectal liver metastases: 6 p, 7 tumours (42.9%)
Tumour size: cm; mean ± SD 1.5 ± 0.5
Treatments before IRE: n Percutaneous Laparoscopic Open surgery
Intersticial 
brachytherapy: 
1 
NR NR
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Simultaneous treatments: n Hernia repair: 1 Hepatic 
resection: 2
Hepatic 
resection: 2
Treatments after IRE: n Brachytherapy: 
2
TACE: 1
Intervention Overall Percutaneous Laparoscopic Open surgery 
IRE device Nanoknife 
Approach: n (%) 7 (53.8%) 4 (30.8%) 2 (15.4%)
Imaging guidance US
Number and length of interventions: 
n; min, mean ± SD
Procedures: 7 4 2
Length: 62 ± 27 155 ± 75 240 ± 10
IRE intention: ablation or margin 
accentuation
Ablation 
Comparator NA 
Hospital stay: days; mean 2 4 9
Length of follow-up: months; median 
(range)
8 (3-12)
*Calculated with 
data from table II. 
In the text is stat-
ed 6 months
Effectiveness-related outcomes 
Success of the procedure: n (%) NR
[Complete 
ablation: By 
patient: 10/13 
(76.9%)
By tumour: 
11/14 (78.6)]
[One 
procedure was 
prematurely 
aborted due 
to technical 
failure of the 
generator]
NR
[4/7 (57.1%)]
NR
[4/4 (100%)]
NR
[2/2 (100%)]
Overall survival 100%
[No deaths 
occurred]
Cancer specific survival NR 
Disease free survival NR
Progression free survival NR
Time to recurrence NR
Time to progression NR
[Progression percentage: 2/10 (20%)]
Time to local recurrence NR
Health-related quality of life NR 
Pain NR 
Safety-related outcomes
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Intervention specific mortality: n 0
Adverse events NR
Other adverse events/complications NR
Author, year, reference number Cheung, 2013 (21)
Country Australia
Centre The Alfred Hospital. Melbourne. 
Funding Research equipment: AngioDynamics 
Conflict of interest Research equipment support for the Department of 
Radiology at The Alfred Hospital was received from 
AngioDynamics 
Registration trial number Australian New Zealand Clinical Trial Registry: #00083436
Study Design Prospective single-arm study 
Data collection period November 2008 - December 2009
Inclusion/exclusion criteria Inclusion:
• HCC histologically proven or stablished according to 
the American Association for the Study of Liver Disease 
practice guideline criteria
• No evidence of macrovascular invasion or extrahepatic 
metastases
• Unresectable (because of liver disease severity, portal 
hypertension and/or tumour location
• Tumour not amenable to RFA because of tumour 
proximity to essential tissue vulnerable to thermal injury 
or major blood vessels 
Patient characteristics 
Number of patients: n 11
Age: years; mean ± SD (range) 70 ± 8.7 (52-84)
Gender: n (%) Female: 3 (27.3%)
Clinical stage NR 
Tumour type and location 18 tumours 
Tumour size: cm; mean ± SD (range) 2.44 ± 0.99 (1.0 - 6.1)
Treatments before IRE NR 
Simultaneous treatments NR 
Treatments after IRE: n 4/5 incompletely ablated lesions: RFA
1/5 incompletely ablated lesions: TACE
1 patient: liver transplant
1 patients: Sorafenib for metastatic disease
1 patient: RFA for distant recurrence 
Intervention 
IRE device Nanoknife 
Approach Percutaneous
Imaging guidance Ultrasound/Computed tomography
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Number and length of interventions: n; hours, 
median (range)
154 procedures:
• Lesion <3 cm: median 4 procedures
• Lesion >3 cm: median 16 procedures
Length:
• Per treatment: 2.4 (1-3)
• Per tumour: 1.25 (0.6-2.75)
IRE intention: ablation or margin accentuation Ablation 
Comparator NA 
Hospital stay NR 
Length of follow-up: months; mean ± SD 
(range)
18 ± 4 (14-24)
Effectiveness-related outcomes 
Success of the procedure: n (%) NR
[Complete ablation: no recurrent or residual disease at 
or directly adjacent to the treated location after up to two 
ablation treatments and at least six months of follow-up
By tumour:
After 1st procedure: 12/18 (66.67%)
After 1st and 2nd procedure: 13/18 (72%) [after 6 months]
[4/5 (80%) incompletely ablated lesions were larger than 
3 cm]
By patient (1st and 2nd IRE): 6/11 (54.5%)]
Overall survival NR
Cancer specific survival NR 
Disease free survival NR 
Progression free survival NR 
Time to recurrence NR 
Time to progression: months; mean ± SD 
(range)
NR
[6 patients with complete response: time to distant 
recurrence 14 ± 6 (9-22)]
Time to local recurrence: months; mean ± SD NR
[Local recurrence percentage: 0/6 (0%), among 6 patients 
treated successfully]
Health-related quality of life NR 
Pain NR
Safety-related outcomes 
Intervention specific mortality 0
Adverse events Major complications: 0
Minor complications:
4 patients developed transient urinary retention (all had 
previous history of prostatic hypertrophy)
7 (64%) patients experienced pain post procedure
Other adverse events/complications NR
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List of ongoing and planned studies
Table A 5. List of ongoing studies with irreversible electroporation for pancreatic cancer
Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
2017-003775-62 Not available 
(ongoing)
Single-arm 
trial 
75 FOLFIRINOX 
followed by local 
therapy (resection, 
RT and/or IRE)
NA Inclusion criteria:
• LAPC (Karolinska Type B, C or D1)
• Cytologically or histologically verified adenocarcinoma/
carcinoma
• The patient is operable (i.e. no co-morbidity which can 
preclude anaesthesia or sur-gery)
• No sign of M1 disease
• WHO performance status 0-1
• Age ≥18 years
• Adequate hematological, renal, and hepatic function
• Patients with obstruction of bile duct or gut must be 
drained before start of therapy
• Oral and written informed consent must be obtained 
prior to registration with planned date of first treatment 
within 14 days from registration
Primary outcomes:
• 2 year survival for all patients starting 
chemotherapy
• Secondary outcomes:
• QoL (EORTC QLQ-PAN26)
• PFS
• OS
• Response rate (RECIST v1.1)
• Histological tumour regression
• Adverse events grade 2-5 (CTCAE 4.0)
• Surgical complications, including IRE 
(Clavien)
• Number of patients with progression during 
chemotherapy
• Number of patients with R0 resection
NCT03673137 November 
2021 (not yet 
recruiting)
Randomized 
controlled 
trial 
120 Synchronous 
treatment group: 
Gemcitabine was 
administered 
over 30 minutes 
immediately 
following 
percutaneous IRE
Traditional 
treatment 
group: 
gemcitabine 
administration 
on day 7 
following IRE 
treatment
Inclusion criteria:
• Histologically or cytologically confirmed pancreatic 
cancer
• Radiologic confirmation of AJCC stage III LAPC
• Histological or cytological confirmation of pancreatic 
adenocarcinoma
• The maximum diameter of tumour is less than 5 cm
• Biliary drainage in patients with biliary obstruction
• PS 0-1
• Written informed consent
Primary outcomes:
• OS
Secondary outcomes:
• Time to progression
• Time to local recurrence
• PFS
• Response rate
NCT03484299 December 
2023 
(recruiting)
Single-arm 
trial 
20 IRE and treatment 
with either 
FOLFIRINOX 
or Gemcitabine 
(based upon which 
chemotherapy 
regimen received 
prior to IRE)
NA Inclusion criteria:
• greater than or equal to 18 years of age
• diagnosed with stage III pancreatic cancer
• tumour is measurable
• GFR > m L/min/1.73 m2
• willing and able to comply with protocol requirements
• AST/ALT >3 times upper limit of normal
• stable surgical post-operative course as defined by 
operative surgeon
Primary outcomes:
• Incidence of Adverse and Serious Adverse 
events will be captured (safety and 
tolerability)
Secondary outcomes:
• PFS
EUnetHTA Joint Action 3 WP4 119Version 1.4, 18 May 2019
Irreversible electroporation for the treatment of liver and pancreatic cancer
Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT03614910 May 2023 
(recruiting)
Single-arm 30 IRE NA Inclusion criteria:
• age >18
• locally advanced unresectable pancreatic ductal 
adenocarcinoma as demonstrated by computed 
tomography or MRI
• must have received standard chemotherapy and 
completed at least four cycles of treatment at least 5 
weeks prior to therapy with Nanoknife
• INR <1.5
• able to tolerate laparotomy (medical/cardiac clearance 
as needed)
• able to comply with protocol requirements
• women of childbearing potential must have a negative 
serum pregnancy test and be practicing an effective 
form of birth control
Primary outcomes:
• OS
• Local progression-free survival
• Distant disease-free survival
• Tumour response
Secondary outcomes:
• Complications
• QoL
• Tumour markers
• Biliary obstruction
• Gastric outlet obstruction
• Cancer related pain
NCT02674100 January 2030 
(recruiting)
Prospective 
cohort 
(registry)
500 IRE NA Inclusion criteria:
• Adult patients (greater than 18 years of age) diagnosed 
with pancreatic cancer that are eligible for soft tissue 
ablation per the treating physician.
Primary outcomes:
• Adverse events (IRE related or non-IRE 
related)
Secondary outcomes:
• OS
NCT02952859 January 2024 
(recruiting)
Prospective 
cohort
36 IRE Historic control 
group 
Inclusion criteria:
• Patients with histology proven or highly suspected 
potentially resectable or borderline resectable 
pancreatic cancer will be included.
• Age ≥18 years
• Able to undergo general anesthesia (ASA ≤3)
• Performance status ECOG < = 2 (Eastern Cooperative 
Oncology Group)
• Life expectancy of at least 6 months
• Resectable or borderline resectable proven pancreatic 
adenocarcinoma of the pancreas
Primary outcomes:
• Time from diagnosis to death for any reason
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT03069599 January 2024 
(recruiting)
Prospective 
cohort 
30 IRE Surgical 
resection 
Inclusion Criteria:
•  Age ≥18 years
•  Able to undergo general anesthesia (ASA ≤4)
•  Performance status ECOG < = 2
•  Life expectancy of at least 6 months
•  Resectable, borderline resectable, or locally advanced 
pancreatic cancer
•  Patients who have locally advanced disease have 
to show no tumour progression after 3 month of 
neo-adjuvant chemotherapy+/-radiotherapy before 
undergoing in situ IRE
Primary outcomes:
•  Immunological outcome
Secondary outcomes:
•  Number of local tumour recurrences
•  Number of distant tumour recurrences
•  OS
•  Cancer specific survival 
NCT03080974 April 2022 
(recruiting) 
Single arm 
trial 
10 IRE and Nivolumab NA Inclusion Criteria:
• ≥18 years if age
•  Diagnosed with stage III pancreatic cancer
•  Tumour is measurable
•  Glomerular Filtration Rate >60 m/L/min/1.73 m(2)
•  Willing and able to comply with the protocol 
requirements
•  Able to comprehend and have signed the informed 
consent to participate
Primary outcomes:
•  Safety and Tolerability of combination IRE 
and Nivolumab treatment
Secondary outcomes:
•  PFS
•  OS
NCT03257150 September 
2021 
(recruiting)
Single arm 
trial 
47 IRE NA Inclusion Criteria:
•  Histologically proven pancreatic ductal adenocarcinoma
•  Age ≥18 years
•  Locally advanced unresectable primary tumour
•  Tumours ≤5 cm in largest dimension at the time of 
enrolment that is technically amenable to treatment with 
IRE
•  At least 4 months of combination chemotherapy
•  ECOG performance status of ≤2
•  Acceptable organ and bone marrow function
•  Life expectancy estimated ≥6 months
•  Ability and willingness to sign informed consent form
•  Have a measurable primary tumour at the time of study 
enrolment
•  Suitable and fit to undergo general anesthetic and 
laparotomy
•  Women of child-producing potential must agree to use 
effective contraceptive methods prior to study entry, 
during study participation, and for at least 30 days after 
the last administration of study medication.
Primary outcomes:
•  Adverse event rate
•  OS rate
Secondary outcomes:
•  PFS rate
•  OS rate of disease
•  PFS rate of disease 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02041936 December 
2019 
(recruiting)
Single-arm 
trial 
12 IRE NA Inclusion Criteria:
•  Male or female
•  18 years of age
•  Must be found to have locally advanced unresectable 
disease following standard chemotherapy ± 
radiotherapy as demonstrated with either computed 
tomography/MRI imaging and surgical evaluation, and 
not have taken any chemotherapy/radiotherapy within 5 
weeks of treatment with the NanoKnife IRE System
•  Must have an INR <1.5
•  Are willing and able to comply with the protocol 
requirements
•  Are able to comprehend and willing to sign an informed 
consent form
Primary outcomes:
•  Number of Participants with Adverse Events 
as a Measure of Safety and Tolerability
Secondary outcome
•  Pain Scores on the Visual Analogue Score
•  QoL on the EORTC QLQ-PAN26 and 
EORTC QLQ-C30 
NCT02898649 August 2019 
(recruiting)
Single-arm 
trial 
100 IRE NA Inclusion criteria:
•  Pathologically confirmed pancreatic cancer patients
•  LAPC patients. Vascular encasement by tumour was 
noted in radiological evaluation (computed tomography, 
MRI or PET-computed tomography)
•  Older than 19 years old and younger than 70 years old
•  Previously treated with systemic chemotherapy or 
chemoradiotherapy due to locally advanced pancreatic 
cancer.
Primary outcome
•  OS
•  Safety (frequency of procedure-related 
complication and death)
Secondary outcome
•  Time to progression
•  Tumour control
•  Pain control
•  Change in CA 19-9 
NCT02926040 September 
2023 
(recruiting)
Single-arm 
trial 
20 IRE NA Inclusion Criteria:
•  Age ≥18 years
•  Able to undergo general anesthesia (ASA ≤3)
•  Performance status ECOG < = 2 (Eastern Cooperative 
Oncology Group)
•  Locally advanced, unresectable, histology proven 
pancreatic adenocarcinoma
•  Partial response or stable disease after a minimum of 
3 months of (radio-) chemotherapy after diagnosis of 
pancreatic adenocarcinoma without signs of liver or 
lung metastases
•  Last chemo-/radiotherapy procedure >4 weeks ago
Primary outcomes
•  Change from baseline in Health related QoL 
measured by health questionnaire
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT03105921 June 2020 
(recruiting)
Single-arm 
trial 
20 IRE NA Inclusion Criteria:
•  Patients with histologically proven adenocarcinoma 
of the head of the pancreas (fine needle aspiration or 
biopsy)
•  Pancreatic adenocarcinoma locally advanced on 
imaging at diagnosis
•  Tumour of less than 7 cm in largest diameter
•  No chemotherapy or abdominal radiotherapy within five 
years before the inclusion in the study
Primary outcomes
•  R0 resection rate 
NCT02841436 October 
2018 (status 
unknown)
Single-arm 
trial
 40 IRE NA Inclusion Criteria:
•  LAPC
•  Biliary tract or intestine is compromised by tumour, 
palliative bypass operation (hepaticojejunostomy and/or 
gastrojejunostomy) is considered to be performed.
•  ECOG score of 0-1,
•  ASA score ≤3,
•  Adequate bone marrow, liver and renal function.
•  Prior Informed Consent Form
•  Life expectancy of at least 3 months.
Primary outcomes
•  Tumour response
•  Secondary outcomes
•  ECOG evaluation
•  Haematology test
•  Tumour marker measurement
•  Conduct computed tomography or MRI 
scans for tumour response evaluation
•  Review concomitant medications
•  Assess for presence of adverse event 
NCT03239184 September 
2018 
(completed)
Randomized 
trial (Parallel 
Assignment)
120 Ablation (IRE or 
cryosurgery)
• Life 
information 
rehabilitation 
therapy
• Combination 
therapy
• Control
Inclusion Criteria:
•  All standard therapies have failed according to NCCN 
guidelines or the patient refuses standard therapies
•  Body tumour 1-6, with at least one tumour length >2 cm
•  KPS ≥70, lifespan >6 months
•  Platelet count ≥80×109/L white blood cell count 
≥3×109/L, neutrophil count ≥2×109/L, hemoglobin ≥80 
g/L
Primary outcome
•  Relief degree of tumours
Secondary outcome
•  PFS
•  OS 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02981719 October 2020 
(recruiting)
Single arm 
trial 
20 IRE combined with 
chemotherapy 
(Gemcitabine)
NA Inclusion Criteria:
•  Radiologic confirmation of unresectable pancreatic 
cancer by at least computed tomography of chest and 
abdomen
•  Screening must be performed no longer than 2 weeks 
prior to study inclusion
•  Maximum tumour diameter ≤5 cm
•  Histological or cytological confirmation of pancreatic 
adenocarcinoma;
•  Age ≥18 years
•  ASA-classification 0-3
•  Life expectancy of at least 12 weeks
•  Adequate bone marrow, liver and renal function
•  Written informed consent
Primary outcome
•  Safety (adverse effects)
Secondary outcomes
•  Efficacy (percentage of lesions that show 
no sign of recurrence 12 months after
•  Voltage (A minimum and maximum range of 
voltage for safe and effective IRE)
•  OS
NCT02822716 June 2020 
(recruiting)
Single-arm 
trial 
35 IRE NA Inclusion criteria
•  Signed informed consent by patient
•  Age older than 18 years.
•  Any kind of histologically or radiologically diagnosed 
malignant pancreatic tumour.
•  Tumour size < = 3 cm in largest dimension
•  Surgical treatment is considered not an option because 
of patient factors or tumour factors, such as those 
with vascular encasement or regional lymph node 
metastasis
•  Locally recurrent pancreatic tumour after surgical 
resection
•  KPS of 50% or greater.
•  Life expectancy greater than 3 months.
•  Normal coagulation profile (INR <1.5; platelet count >50 
10^9/L).
•  Willingness and ability to complete follow-up interviews 
and imaging investigations following the treatment.
Primary outcome
•  Radiological assessment 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02514421 July 2017 
(status 
unknown)
Single-arm 
trial 
24 IRE combined with 
chemotherapy 
(Gemcitabine/nab-
paclitaxel)
NA Inclusion Criteria:
•  Histologically or cytologically proven pancreatic 
carcinoma which is safely accessible by percutaneous 
methods;
•  LAPC;
•  At least one measurable lesion according to RECIST 
criteria
•  WHO PS <2 or ECOG <2;
•  Age >18;
•  Life expectancy >3 months;
•  No history of gastric or esophageal varices;
•  No active, uncontrolled infection;
•  All patients must have adequate physiologic 
(hematologic, renal and hepatic) reserves
•  Pain and biliary obstruction controlled before the start of 
the study
•  Absence of psychological, familial, sociological, 
or geographical condition potentially hampering 
compliance with the study protocol and follow-up 
schedule;
•  Women of childbearing potential (defined as sexually 
mature woman who 1) has not undergone hysterectomy 
or bilateral oophorectomy or 2) has not been naturally 
post-menopausal for at last 24 consecutive months) 
must have a negative pregnancy test prior to starting 
therapy. Men and women of childbearing potential 
must be willing to use effective contraceptive while on 
treatment and for a reasonable period thereafter.
Primary outcome
•  Number of participants who experienced 
dose limiting toxicities
Secondary outcome
•  Number of participants who demonstrated 
no clinical change or clinical improvement 
in pancreatic adenocarcinoma outcome as 
assessed by time to progression
•  Number of participants who demonstrated 
no clinical change or clinical improvement 
in pancreatic adenocarcinoma outcome as 
assessed by one year survival
•  Number of participants who demonstrated 
no clinical change or clinical improvement 
in pancreatic adenocarcinoma outcome as 
assessed by tumour imaging
•  Number of participants who demonstrated 
diffusion weighted MRI changes
•  Number of participants who demonstrated 
MR changes
•  Number of groups of patients who have 
similar pancreatic tumour gene expression 
characteristics and associated imaging 
characteristics after electrochemotherapy
•  Number of groups of patients who have 
similar pancreatic tumour gene expression 
characteristics and associated clinical 
outcomes after electrochemotherapy 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02343835 January 2020 
(recruiting)
Single-arm 
trial 
20 IRE NA Inclusion criteria
•  Radiologic confirmation of unresectable pancreatic 
cancer by at least computed tomography of chest and 
abdomen
•  Screening must be performed no longer than 2 weeks 
prior to study inclusion
•  Maximum tumour diameter ≤5 cm;
•  Histological or cytological confirmation of pancreatic 
adenocarcinoma;
•  Age ≥8 years;
•  ASA-classification 0-3
•  Life expectancy of at least 12 weeks;
•  Adequate bone marrow, liver and renal function
•  Written informed consent
Primary outcome:
•  Characterization of the intra-tumoural 
and systemic immune response to IRE in 
unresectable pancreatic cancers
Secondary outcome:
•  Comparison immune response between 
non-ablated and ablated pancreatic cancer 
and pre-ablated and post ablated serum
Other outcomes:
•  OS and (local and distant) PFS
NCT02791503 May 2019 
(recruiting)
Randomized 
trial (parallel 
assignment)
138 Chemotherapy 
(FOLFIRINOX) and 
IRE 
Chemotherapy 
(FOLFIRINOX) 
with 
stereotactic 
ablative 
radiotherapy (a 
form of external 
beam radiation 
therapy)
Inclusion Criteria:
•  Radiologic confirmation of LAPC by at least computed 
tomography of chest and abdomen (with the upper 
abdomen scanned according to a dedicated 3mm slice 
multiphase pancreatic tumour protocol);
•  Maximum tumour diameter ≤5 cm;
•  Histological or cytological confirmation of pancreatic 
adenocarcinoma;
•  Age >18 years;
•  ASA-classification 0-3; WHO performance status 0-1 ;
•  Adequate bile drainage in case of biliary obstruction;
•  Written informed consent
Primary outcome
•  OS
Secondary outcome
•  PFS
•  Untreatable PFS
•  Number of participants with treatment-
related adverse events as assessed by 
CTCAE v4.0
•  Pain assessment
•  Cost-effectiveness analysis
•  QoL
•  Change in immune status and reactivity 
after the procedure (IRE/ stereotactic 
ablative radiation) by assessing the level of 
immune cells pre- and post-IRE
•  Tumour marker CA 19.9 
NCT02718859 March 2017 
(status 
unknown)
Randomized 
trial (parallel 
assignment)
60 IRE IRE and natural 
killer cells
Inclusion Criteria:
•  Age: 18-80
•  Advanced and active pancreatic cancer
•  The tumour is measurable
•  ECOG score : 0~2 : 3 but has no relationship with 
tumour
•  Vital organ function is normal
•  Non pregnant and lactating patients
•  Non allergic reactions to biological products
•  Informed and consent
Primary outcome
•  Relief degree
Secondary outcome
•  PFS
•  OS 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
JPRN-
UMIN000016423
Not available 
(status 
unknown) 
Single-arm 
trial 
6 IRE NA Inclusion criteria
•  It does not matter whether the pre-treatment but it 
is necessary that 4 weeks was passed from the pre- 
treatment
•  It has been confirmed pathologically is adenocarcinoma 
or adenosquamous carcinoma
•  Patient of unresectable LAPC
•  Major organs (heart, lung, kidney, liver, etc.) function 
are maintained
•  ECOG score 0 or 1
•  Life expectancy of at least 4 weeks
•  Written informed consent
Primary outcome:
•  Effectiveness of IRE for treatment of 
unresectable locally advanced pancreatic 
cancer according to local control rate using 
computed tomography or MRI performed 6 
months after treatment
Secondary outcome
•  Incidence and kind of adverse events of up 
to 1 month after treatment
Abbreviations: AJCC = American Joint Committee on Cancer; ALT = alanine aminotransferase; ASA = American Society of Anaesthesiologists; AST = Aspartate Aminotransferase; CT = computed tomography; 
CTCAE = Common Terminology Criteria for Adverse Events; ECOG = Eastern Cooperative Oncology Group; EORTC QLQ = European Organisation for Research and Treatment of Cancer- Quality of Life Questionnaire; 
GFR = glomerular filtration rate; INR = International Normalized Ratio; IRE = Irreversible electroporation; KPS = Karnofsky performance status; LAPC = locally advanced pancreatic cancer ; MRI = magnetic resonance 
imaging; NA = not applicable; NCCN = National Comprehensive Cancer Network; SGPT = serum glutamic-pyruvic transaminase; OS = overall survival; PET = Positron-emission tomography; PFS = progression free 
survival; PS = performance status; QoL = quality of life; RECIST = Response Evaluation Criteria In Solid Tumours; RT = radiotherapy; UPL = upper limit normal; WHO = world health organization .
Sources: Clinicaltrials.gov, Cochrane Central EU clinical trials, International ClinicalTrials Registry Platform (ICTRP), UK Clinical Trails gateway.
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Table A 6. List of ongoing studies with irreversible electroporation for liver cancer
Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
2017-004679-29 Not available 
(status: 
ongoing)
Single-arm 
trial
50 Nivolumab 
(neoadjuvant 
and adjuvant) 
in IRE treated 
patients 
NA •  Male or female patients superior or equal 18 years
•  Histological or cytological documentation of HCC or 
non-invasive diagnosis of HCC as per AASLD criteria 
in patients with a confirmed diagnosis of cirrhosis, 
BCLC stage Category B or C
•  Patients with HCC amenable for IRE as assessed by 
multidisciplinary board corresponding to the following 
extension:
◊  Uninodular HCC >3 cm and <5 cm
◊  Multinodular HCC
•  At least one uni-dimensional measurable lesion by 
computed tomography scan or MRI according to 
modified RECIST for HCC
•  Liver function status Child-Pugh Class A
•  ECOG Performance Status inferior or equal 2
•  Adequate bone marrow, liver and renal function
•  Life expectancy superior or equal 3 months
•  WOCBP need to accept one effective method of 
contraception until 5 months after the last Nivolumab 
infusion
•  Men who are sexually active with WOCBP 
partners need to accept one effective method of 
contraceptionuntil 7 months after the Nivolumab 
infusion and men must agree to use adequate 
contraception
•  Patients affiliated to a Social Security System
•  Written informed consent signed
Primary outcomes:
•  Local recurrence-free survival during a 
2-years follow-up
Secondary outcomes:
•  Changes of tumourous and non-tumourous 
perfusion parameters observed with 
compression ultrasound and MRI after one 
months of neoadjuvant treatments
•  Per nodule rates of early response (one 
month) after a single procedure of IRE
•  Incidences of intra segmental/extra 
segmental distant recurrence
•  OS at 2-years following IRE procedure
•  Compliance to neoadjuvant and adjuvant 
treatments
•  Tolerance of Nivolumab in the setting of 
neo- and adjuvant therapy to IRE
•  Tumoural and non tumoural assessment 
(histological and molecular study) of the 
effect of Nivolumab at 1 month
•  Peripheral blood approach of the effect of 
immunotherapy
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT03630640 September 
2020 
(recruiting)
Single-arm 
trial 
50 Nivolumab
up to 12 
months after 
IRE
NA Inclusion Criteria:
•  Male or female patients ≥18 years of age
•  Histological or cytological diagnosis of HCC
•  Patients with HCC eligible for IRE as assessed by 
multidisciplinary board
•  At least one uni-dimensional measurable lesion by 
computed tomography scan or MRI according to 
modified RECIST for HCC
•  Liver function status Child-Pugh Class A
•  ECOG Performance Status ≤2
•  Adequate bone marrow, liver and renal function
•  Life expectancy ≥3 months
•  Women of childbearing potential and men must agree 
to use adequate contraception
•  Patients affiliated to a Social Security System
•  Written informed consent signed
Primary outcomes:
•  Local recurrence-free survival
Secondary outcomes:
•  Changes of tumourous and non-tumourous 
perfusion parameters
•  Per nodule rates of early response
•  Incidences of intra segmental/ extra 
segmental distant recurrence
•  Assessment of OS
•  Assessment of tolerance of the 
immunotherapy treatment
•  Compliance to neoadjuvant treatments
•  Compliance to adjuvant treatments
•  Frequency of severe adverse events
•  Frequency of discontinuations treatment 
due to adverse events 
NCT02828865 October 2018 
(recruitment 
status 
unknown)
Single-arm 
trial
40 
participants
IRE NA Inclusion criteria:
•  HCC or metastatic liver cancers
•  Unsuitable for surgical resection but local ablation is 
indicated, however, the distance between tumour and 
vessels is smaller than 5 mm.
•  Have at least one, but less than or equal to 3 tumours,
•  Each tumour must be ≤5 cm in diameter,
•  Child-Pugh class A-B,
•  ECOG score of 0-1,
•  ASA score ≤3,
•  Adequate bone marrow, liver and renal function
•  Prior Informed Consent Form
•  Life expectancy of at least 3 months.
•  The disease status is not suitable to receive surgical 
resection, percutaneous alcohol injection, transarterial 
chemoembolization or other standard treatment.
Primary outcome:
•  Tumour response
Secondary outcome:
•  ECOG evaluation
•  Change of vital signs
•  Physical examination
•  Clinical laboratory assessments
•  Urinalysis
•  Conduct computed tomography or MR 
scans for tumour response evaluation
•  Review concomitant medications
•  Assess for presence of adverse events
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02333773 January 2020 
(recruiting)
Single-arm 
trial 
15 IRE NA Inclusion Criteria:
•  Liver cancer diagnosed by positive biopsy or non-
invasive criteria,
•  Liver cancer with Portal venous tumour emboli,
•  Not suitable for surgical resection or transplantation,
•  Child-Pugh class A,B
•  ECOG score of 0-1,
•  A prothrombin time ratio >50%,
•  Platelet count >80 × 10^9/L,
•  Ability of patient to stop anticoagulant and anti-platelet 
therapy for seven days prior to and seven days post 
NanoKnife procedure,
•  Able to comprehend and willing to sign the written 
informed consent form,
•  Have a life expectancy of at least 3 months.
Primary outcomes:
•  Safety (adverse effects)
Secondary outcomes:
•  Efficacy (percentage of lesions that show 
no sign of recurrence 12 months after IRE)
•  Voltage (A minimum and maximum range of 
voltage for safe and effective IRE)
•  Progress free disease
•  OS
NCT02329106 January 2020 
(recruiting)
Single arm 
trial 
30 IRE NA  Inclusion Criteria:
•  Liver cancer diagnosed by positive biopsy or non-
invasive criteria,
•  Tumours from diaphragm is <1 cm
•  not suitable for surgical resection or transplantation,
•  have at least one, but less than or equal to 3 tumours,
•  of the tumour(s) identified, each tumour must be ≤5 cm 
in diameter,
•  Child-Pugh class A, B
•  ECOG score of 0-1,
•  a prothrombin time ratio >50%,
•  platelet count >80 × 109/L,
•  ability of patient to stop anticoagulant and anti-platelet 
therapy for seven days prior to and seven days post 
NanoKnife procedure,
•  are able to comprehend and willing to sign the written 
informed consent form,
•  have a life expectancy of at least 3 months.
Primary outcomes:
•  Evaluate the safety of IRE for unresectable 
liver cancer close to diaphragmatic dome 
using CTCAE
Secondary outcomes:
•  Evaluate the efficacy of IRE for 
unresectable liver cancer close to 
diaphragmatic as measured by cell death 
of CRLM after IRE is demonstrated 
macroscopically by using vitality-staining 
with triphenyl-tetrazoliumchloride 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
JPRN-
UMIN000014522
Not available 
(status: 
recruiting) 
Single arm 
trial 
20 IRE NA Inclusion criteria:
•  Older than 20 years,
•  Male or female
•  Diagnosis of hepatocellular carcinoma, metastatic 
liver cancer or cholangiocarcinoma based on positive 
biopsy or noninvasive criteria
•  Not suitable for surgical resection and patients who 
are not willing ot surgical resection
•  Primary tumour is controlled
•  The target nodule must have a diammeter of < = 10 cm
•  Child-Pugh class A,
•  Liver lesion visible on US, computed tomography, or 
MRI
•  ECOG score 0, 1
•  ASA score < = 3
•  Life expectancy of at least 12 weeks
•  Written informed consent
Pimary outcome
•  Effectiveness of IRE for treatment of 
hepatic malignancies according to 
modified RECIST criteria using computed 
tomography or MRI performed 6 months 
after treatment.
Secondary outcomes
•  Safety within 30 days post-intervention. All 
adverse events will be classified according 
to CTCAE version 4.0 criteria
NCT01442324 September 
2012 (status 
unknown) 
Single arm 
trial 
5 IRE NA Inclusion Criteria:
•  older than 18 years,
•  male or female,
•  diagnosis of secondary liver cancer or 
cholangiocarcinoma based on positive biopsy or 
noninvasive criteria,
•  presence of at least one lesion untreatable by surgical 
resection or ablation for microwave or radio frequency,
•  the target nodule must have a diameter of ≤5 cm
•  ECOG score 0,
•  ASA score ≤3,
•  prothrombin time ratio >50%
•  platelet count >50 × 10^9/l,
•  patient’s ability to discontinue anticoagulant and 
antiplatelet therapy for seven days before and seven 
days after surgery with NanoKnife™,
•  ability to understand and willingness to sign the written 
informed consent form,
•  life expectancy of at least 3 months.
Primary outcome:
•  Effectiveness of IRE for the treatment 
of metastatic liver cancer or 
cholangiocarcinoma
Secondary outcomes:
•  Safety
•  Time to in situ recurrence
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02787954 Terminated 
(no publication 
found)
Cohort 10 IRE, TACE, 
Y-90 or MWA
NA Inclusion Criteria:
•  Diagnosis or suspicion of primary or metastatic liver 
cancer deemed eligible for TACE, Y-90, percutaneous 
ablation, and /or electroporation.
Primary Outcome:
•  Time to progression
Secondary Outcome Measures :
•  1 year survival 
NCT03040453 September, 
2018 (status 
unknown)
Non-
Randomized 
trial (parallel 
assignment)
40 IRE MWA Inclusion Criteria:
•  Hepatocellular carcinoma, maximum 3 lesions, 
maximum 30 mm in any cross section diameter
•  Physically fit to undergo general anaesthesia
•  Fully understand Swedish instructions regarding the 
study
Primary outcome:
•  Immunological response
Secondary outcome:
•  Number of participants with complete 
radiological response at follow-up 3, 6, 9 
and 12 months.
NCT03239158 Completed Randomized 
trial (Parallel 
Assignment)
120 Ablation (IRE 
or cryosurgery)
• Life 
information 
rehabilitation 
therapy
• Combination 
therapy
• Control 
Inclusion criteria:
•  All standard therapies have failed according to NCCN 
guidelines or the patient refuses standard therapies
•  Body tumour 1-6, with at least one tumour length >2 
cm
•  KPS ≥70, lifespan >6 months
•  Platelet count ≥80 × 109/L white blood cell count ≥3 × 
109/L, neutrophil count ≥2 × 109/L, hemoglobin ≥80 
g/L
Primary outcome:
•  Relief degree of tumours
Secondary outcome:
•  PFS
•  OS
NCT03008343 December 
2019 
(recruiting)
Randomized 
trial (Parallel 
Assignment)
20 IRE IRE and natural 
killer 
Inclusion criteria:
•  All standard therapies have failed according to NCCN 
guidelines or the patient refuses standard therapies 
after cancer recurrence
•  Body tumour 1-6, the maximum tumour length <5 cm
•  KPS ≥70, lifespan >6 months
•  Platelet count ≥80 ×109/L white blood cell count 
≥3×109/L, neutrophil count ≥2 × 109/L, hemoglobin 
≥80 g/L
Primary outcome:
•  Relief degree of tumours
Secondary outcome:
•  PFS
•  OS 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02332551 January 2020 
(recruiting)
Single-arm 
trial 
30 IRE NA Inclusion criteria:
•  Hepatic carcinoma diagnosed by positive biopsy or 
non-invasive criteria,
•  Tumour from gallbladder is <0.5 cm
•  not suitable for surgical resection or transplantation,
•  have at least one, but less than or equal to 3 tumours,
•  of the tumour(s) identified, each tumour must be ≤7 cm 
in diameter,
•  Child-Pugh class A,B
•  ECOG score of 0-1,
•  ASA score ≤3,
•  a prothrombin time ratio >50%,
•  platelet count >80 × 109/L,
•  ability of patient to stop anticoagulant and anti-platelet 
therapy for seven days prior to and seven days post 
NanoKnife procedure,
•  are able to comprehend and willing to sign the written 
informed consent form,
•  have a life expectancy of at least 3 months.
Primary outcome:
•  Treatment efficacy as measured by 
modified RECIST criteria by computed 
tomography or MRI
Secondary outcome:
•  Safety using CTCAE Version 3.0 criteria.
•  PFS
NCT02352935 January 2020 
(recruiting)
Single-arm 
trial
15 IRE NA Inclusion Criteria:
•  Hepatic carcinoma diagnosed by positive biopsy or 
non-invasive criteria,
•  not suitable for surgical resection or transplantation,
•  have at least one, but less than or equal to 3 tumours,
•  of the tumour(s) identified, each tumour must be ≤5 cm 
in diameter,
•  Child-Pugh class B or ≤12
•  ECOG score of 0-1,
•  ASA score ≤3,
•  a prothrombin time ratio >50%,
•  platelet count >80 × 109/L,
•  ability of patient to stop anticoagulant and anti-platelet 
therapy for seven days prior to and seven days post 
NanoKnife procedure,
•  are able to comprehend and willing to sign the written 
informed consent form,
•  have a life expectancy of at least 3 months.
Primary outcome:
•  Safety using CTCAE Version 3.0 criteria
Secondary outcome:
•  Treatment efficacy as measured by 
modified RECIST criteria by computed 
tomography or MRI
•  PFS
•  OS
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT02082782 May 2018 
(status 
unknown) 
Single-arm 
trial 
29 IRE NA Inclusion Criteria:
•  Histological or cytological documentation of primary 
colorectal tumour;
•  Previous induction chemotherapy due to 
unresectability; no intra- or extrahepatic disease 
progression under induction chemotherapy; OR
•  Previous chemotherapy for other CRLM, now 
presenting with renewed CRLM unsuitable for 
resection or thermal ablation;
•  Liver metastases PET avid and visible on computed 
tomography, size ≤3,5 cm and not eligible for resection 
or thermal ablation due to location close to a vessel or 
bile duct;
•  Age more than 18 years;
•  ASA classification 0-3;
•  Adequate bone marrow, liver and renal function
•  Written informed consent
Primary outcome:
•  Efficacy 
NCT02010801 December 
2013 
(completed)
Single-arm 
trial 
20 IRE NA Inclusion Criteria:
•  The diagnosis of HCC or other cancers with hepatic 
metastatic with pathologic proven.
•  The diagnosis of HCC will be made by pathology / 
cytology or according to the AASLD (2010) diagnostic 
criteria.
•  Suitable for surgical resection, but the distance 
between tumours and preserved vessels is less than 5 
mm. Adequate safe margin can not be obtained.
•  There are at least one tumour, but less than or equal to 
3 tumours,
•  Each tumour must be ≤5 cm in diameter,
•  Child-Pugh class A-B,
•  ECOG score of 0-1,
•  American Society of Anaesthesiologists (ASA) score 
≤3,
•  Platelet count ≥100 K/l
•  Total bilirubin ≤2 mg/dL
•  ALT and AST <5 × upper limit of normal
•  PT-INR ≤2.0, or PT <6 seconds above control
•  Serum creatinine ≤1.5 × upper limit of normal
•  Prior Informed Consent Form
•  Life expectancy of at least 3 months.
Primary outcome:
•  Complete treatment
Secondary outcome:
•  adverse effect 
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Study 
Identifier
Estimated 
completion 
date
Study 
type
Number  
of 
patients
Intervention Comparator Patient population Endpoints
NCT01078415 June 2013 
(completed)
Single-arm 
trial 
26 IRE NA Inclusion Criteria:
•  HCC diagnosed by positive biopsy or non-invasive 
criteria,
•  not suitable for surgical resection or transplantation,
•  have at least one, but less than or equal to 3 tumours,
•  of the tumour(s) identified, each tumour must be ≤3 cm 
in diameter,
•  Child-Pugh class A,
•  ECOG score of 0,
•  ASA score ≤3,
•  a prothrombin time ratio >50%,
•  platelet count >50 × 109/L,
•  ability of patient to stop anticoagulant and anti-platelet 
therapy for seven days prior to and seven days post 
NanoKnife procedure,
•  are able to comprehend and willing to sign the written 
informed consent form,
•  have a life expectancy of at least 3 months.
Primary outcome:
•  Treatment efficacy as measured by 
modified RECIST criteria by computed 
tomography or MRI.
Secondary outcome:
•  Safety using CTCAE Version 3.0 criteria. 
Abbreviations: AASLD = American Association for the Study of Liver Diseases; ALT = alanine aminotransferase; ASA = American Society of Anesthesiologists; BCLC = Barcelona Clínic Liver Cancer; CRLM = col-
orectal liver metastases ; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG = Eastern Cooperative Oncology Group; HCC = hepatocellular carcinoma; IRE = irreversible 
electroporation; KPS = Karnofsky performance status; LRFS = local recurrence free survival; MRI = magnetic resonance imaging; NA = not applicable; NCCN = National Comprehensive Cancer Network; OS = overall 
survival; PET = Positron-emission tomography; PT-INR = Prothrombin time-international normalized ratio; RECIST = Response Evaluation Criteria In Solid Tumours; TACE = Transarterial chemoembolisation; US = ul-
trasound; WOCBP = Women of childbearing potential.
Sources: Clinicaltrials.gov, Cochrane Central EU clinical trials, International ClinicalTrials Registry Platform (ICTRP), UK Clinical Trails gateway.
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Risk of bias tables
Table A 7. Risk of bias – study level-non-randomised study (matched analysis)
Study Lambert, 2016 (11)
Domain 1: Confounding Critical
(no details about the number of patients in the control 
group who received chemotherapy was given)
Domain 2: Selection Serious
(Inclusion criteria KPS>80; no details of exclusion criteria, 
no details about control group selection criteria)
Domain 3: Classification of intervention Critical
(intervention in the control group not clearly defined)
Domain 4: deviation from intervention Low
(no deviation)
Domain 5: missing data Low
(no missing data)
Domain 6: measurement of outcomes Moderate
(due to not blinding outcome assessors)
Domain 7: selection of reported result Serious
(no data provided about QoL (only graphical information); 
no information given about complications for patients in 
the control group)
Overall risk of Bias Critical
Abbreviations: KPS = Karnosfsky Performance Status; QoL = quality of life.
Sources: (11).
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Table A 8. Risk of bias – single-arm studies (IHE-20-Criteria checklist) in pancreatic cancer
Y/N/Partial/
Unclear
Huang, 
2018 (17)
Scheffer, 
2016 (16)
Mansson, 
2016 (14)
Kluger, 
2016 (13)
Paiella, 
2015 (15)
Belfiore, 
2015 (18)
Martin, 
2012 (19)
Study objective
1 Was the hypothesis/aim/objective of the study clearly stated? No Yes Yes Yes Yes Yes Yes
Study design
2 Was the study conducted prospectively? Unclear Yes Unclear Yes Yes Yes Unclear
3 Were the cases collected in more than one centre? Yes Unclear No No No No Yes
4 Were patients recruited consecutively? Unclear Unclear Unclear Yes Unclear Unclear Unclear
Study population
5
Were the characteristics of the patients included in the study 
described?
No Yes Partial Partial Yes Partial Yes
6
Were the eligibility criteria (i.e. inclusion and exclusion 
criteria) for entry into the study clearly stated?
Yes Yes Yes Yes Yes Yes Partial
7 Did patients enter the study at a similar point in the disease? Yes Yes Yes Yes Yes Yes Yes
Intervention and co-intervention
8 Was the intervention of interest clearly described? Yes Yes Yes Yes Yes Yes Yes
9
Were additional interventions (co-interventions) clearly 
described?
Yes Partial Yes Yes Yes Partial Yes
Outcome measure
10 Were relevant outcome measures established a priori? No Yes Yes Yes Yes Partial Yes
11
Were outcome assessors blinded to the intervention that 
patients received?
Unclear Unclear Unclear Unclear Unclear Unclear Yes
12
Were the relevant outcomes measured using appropriate 
objective/subjective methods?
Yes Yes Yes Yes Yes Yes Yes
13
Were the relevant outcome measures made before and after 
the intervention?
Yes Yes Yes Yes No Yes Yes
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Y/N/Partial/
Unclear
Huang, 
2018 (17)
Scheffer, 
2016 (16)
Mansson, 
2016 (14)
Kluger, 
2016 (13)
Paiella, 
2015 (15)
Belfiore, 
2015 (18)
Martin, 
2012 (19)
Statistical analysis 
14
Were the statistical tests used to assess the relevant 
outcomes appropriate?
Yes Yes Unclear Yes Yes Yes Unclear
Results and conclusions
15
Was follow-up long enough for important events and 
outcomes to occur? 
Yes Unclear Yes Unclear Yes No No
16 Were losses to follow-up reported? Unclear Unclear Yes Unclear Yes Yes Yes
17
Did the study provided estimates of random variability in the 
data analysis of relevant outcomes?
Partial Yes No Yes Yes Yes Partial
18 Were the adverse events reported? Yes Yes Yes Yes Yes Yes Yes
19 Were the conclusions of the study supported by results? No Yes No Yes Yes Yes No
Competing interests and sources of support
20
Were both competing interests and sources of support for the 
study reported?
Yes Yes Yes Partial Partial Yes Yes
Total 11/20 14/20 12/20 14/20 15/20 13/20 13/20
Overall risk of bias Serious Serious Serious Serious Serious Serious Serious
Sources: (13-19)
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Table A 9. Risk of bias – single-arm studies (IHE-20-Criteria checklist) in liver cancer
Y/N/Partial/Unclear
Fruhling, 
2017 (20) 
Distelmaier, 
2017 (22)
Niessen, 
2016 (25)
Granata, 
2016 (24)
Eller, 2015 
(23)
Eisele, 2014 
(12)
Cheung, 
2013 (21)
Study objective
1
Was the hypothesis/aim/objective of the study clearly 
stated?
Partial Yes Partial Yes Yes Yes Yes
Study design
2 Was the study conducted prospectively? Yes Yes Yes Yes Yes Yes Yes
3 Were the cases collected in more than one centre? No No No No No Unclear No
4 Were patients recruited consecutively? Unclear Yes Unclear No Yes Unclear Unclear
Study population
5
Were the characteristics of the patients included in the 
study described?
Yes Partial Partial Yes Partial Partial Partial
6
Were the eligibility criteria (i.e. inclusion and exclusion 
criteria) for entry into the study clearly stated?
Yes Partial Yes Yes Partial Yes Partial
7
Did patients enter the study at a similar point in the 
disease?
No No No Yes No No Unclear
Intervention and co-intervention
8 Was the intervention of interest clearly described? Yes Yes Yes Yes Yes Yes Yes
9
Were additional interventions (co-interventions) clearly 
described?
Partial No Partial No Yes Yes Partial
Outcome measure
10 Were relevant outcome measures established a priori? Yes Yes Yes Yes Partial No Yes
11
Were outcome assessors blinded to the intervention that 
patients received?
Unclear No Unclear Unclear Unclear Unclear Unclear
12
Were the relevant outcomes measured using appropriate 
objective/subjective methods?
Yes Yes Yes Yes Yes Yes Yes
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Y/N/Partial/Unclear
Fruhling, 
2017 (20) 
Distelmaier, 
2017 (22)
Niessen, 
2016 (25)
Granata, 
2016 (24)
Eller, 2015 
(23)
Eisele, 2014 
(12)
Cheung, 
2013 (21)
13
Were the relevant outcome measures made before and 
after the intervention?
Yes Yes Yes Yes Unclear Unclear Yes
Statistical analysis 
14
Were the statistical tests used to assess the relevant 
outcomes appropriate?
Yes Yes Yes Yes Unclear Yes Yes
Results and conclusions
15
Was follow-up long enough for important events and 
outcomes to occur? 
Yes Unclear Unclear No Yes Yes Unclear
16 Were losses to follow-up reported? Yes Yes Unclear Yes Yes Yes Yes
17
Did the study provided estimates of random variability in 
the data analysis of relevant outcomes?
Yes Yes Yes Partial Partial No Partial
18 Were the adverse events reported? Yes Yes Yes Yes Yes No Yes
19 Were the conclusions of the study supported by results? Unclear Yes Yes Yes Yes Unclear Yes
Competing interests and sources of support
20
Were both competing interests and sources of support 
for the study reported?
Partial Partial Partial Partial Partial Yes Partial 
Total 12/20 12/20 10/20 13/20 10/20 10/20 10/20
Overall risk of bias Serious Serious Serious Serious Serious Serious Serious
Sources: (12, 20-25)
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Table A 10. GRADE assessment of irreversible electroporation in pancreatic cancer (comparative study)
Quality assessment
Summary of findings Impor-
tance
Number of patients / Effect Effect Quality
Number  
of studies
Study design Risk of 
bias
Inconsis-
tency
Indirectness Imprecision Other con-
siderations 
ations
IRE Comparator Relative 
(95% CI)
Absolute 
(95% CI)
Effectiveness 
Success of the procedure 
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious4 0 Not available Not 
estimable
NA Very low Important
Overall survival 
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious6 10.03 months 9.3 months HR 0.54 
(p = 0.053)
NA Very low Critical 
Overall survival at 3 months 
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious7 90.48 (95% CI: 
67.0, 97.5)
Not available Not 
estimable 
NA Very low Critical
Overall survival at 6 months 
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious6 75.00 (95% CI 
49.81,88.80)
Not available Not 
estimable
NA Very low Critical
Overall survival at 12 months
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious6 47.62 (95% CI 
24.37,67.71
Not available Not 
estimable
NA Very low Critical
Overall survival at 18 months
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious6 13.61 (95% CI 
2.33, 34.71
Not available Not 
estimable
NA Very low Critical
Overall survival at 24 months: Not available 
Cancer specific survival: Not available
Disease free survival: Not available 
Progression free survival: Not available 
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Quality assessment
Summary of findings Impor-
tance
Number of patients / Effect Effect Quality
Number  
of studies
Study design Risk of 
bias
Inconsis-
tency
Indirectness Imprecision Other con-
siderations 
ations
IRE Comparator Relative 
(95% CI)
Absolute 
(95% CI)
Time to recurrence: Not available 
Time to progression: Not available 
Time to local recurrence: Not available
Health related quality of life (Karnofsky Performance Status)
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious5 Very serious6 81% of time after 
IRE KPS ≥70 
(IQR: 65,98)
74% of time after 
IRE KPS ≥70 
(IQR: 14,88)
Not 
available 
NA Very low Critical
Pain: Not available 
Safety 
Intervention specific mortality 
1 Observational 
(matched analysis)
Very 
serious1
NA2 Very serious3 Very serious4 0 Not available Not 
estimable
NA Very low Critical 
Major adverse events: Not available 
Minor adverse events: Not available
1 No randomization, patients received different adjuvant therapies, lack of information on patient selection, follow-up, and incomplete data from the control.
2 Only one trial
3 Heterogeneous treatments
4 Small sample size
5 Small sample size, no 95% CI available, p = 0.053
6 Small sample size, wide CI
Abbreviations: HR = hazard ratio; IQR = interquartile range; IRE = irreversible electroporation; NA = applicable; KPS = Karnofsky Performance Status
Sources: (11)
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Table A 11. GRADE assessment of irreversible electroporation in pancreatic cancer (single-arm studies)
Quality assessment
Summary of findings Impor-
tance
Number of patients/ Effect Effect Quality
Number  
of studies 
Study design Risk of 
bias
Inconsistency Indirectness Imprecision Other con-
siderations
Pre-IRE Post-IRE Relative 
(95% CI)
Absolute 
(95% CI)
Effectiveness 
Success of the procedure 
1 Observational 
(single-arm)
Very 
serious1
NA (oonly 
one trial)
Very serious2 Very serious4 -- 96.3% Not 
estimable
NA Very low Important
Overall survival 
6 Observational 
(single-arm)
Very 
serious1
Very serious 
(highly variable: 
4.3 vs 22.6)
Very serious2 Very serious4 -- 4.3-22.6 
months 
(Median)
Not 
estimable
NA Very low Critical 
Overall survival at 3 months
4 Observational 
(single-arm)
Very 
serious1
Not serious (95-
100)
Very serious2 Very serious4 -- 95%-100% Not 
estimable
NA Very low Critical
Overall survival at 6 months
4 Observational 
(single-arm)
Very 
serious1 
Very serious 
(highly variable: 
50 vs 100)
Very serious2 Serious4 -- 50%-100% Not 
estimable
NA Very low Critical
Overall survival at 12 months
4 Observational 
(single-arm)
Very 
serious1
Very serious 
(highly variable: 
20 vs 90)
Very serious2 Serious4 -- 20%-90% Not 
estimable
NA Very low Critical
Overall survival at 18 months: Not available
Overall survival at 24 months
1 Observational 
(single-arm)
Very 
serious1
NA5 Very serious2 Very serious6 -- 37% Not 
estimable
NA Very low Critical
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Quality assessment
Summary of findings Impor-
tance
Number of patients/ Effect Effect Quality
Number  
of studies 
Study design Risk of 
bias
Inconsistency Indirectness Imprecision Other con-
siderations
Pre-IRE Post-IRE Relative 
(95% CI)
Absolute 
(95% CI)
Cancer specific survival: Not available
Disease free survival: Not available
Progression free survival 
3 Observational 
(single-arm)
Very 
serious1
Very serious 
(highly variable: 
3.19 vs 15.4)
Very serious2 Serious4 -- 3.19-15.4 
months 
(median)
Not 
estimable
NA Very low Critical
Time to recurrence: NA
Time to progression 
1 Observational 
(single-arm)
Very 
serious1
NA5 Very serious2 Very serious4 -- 3.32 months 
(median)
Not 
estimable
NA Very low Critical
Time to local recurrence 
3 Observational 
(single-arm)
Very 
serious1
Serious (6.81 
vs 12)
Very serious2 Serious4 -- 6.81-12 
months 
(median)
Not 
estimable
NA Very low Critical 
Health related quality of life (QLQ C30/PAN26)
2 Observational 
(single-arm)
Very 
serious1
Not serious Very serious2 Very serious3 QoL 
decreased 
compared 
with baseline 
Not 
estimable
NA Very low Critical 
Pain 
2 Observational 
(single-arm)
Very 
serious1
Not serious Very serious2 Very serious3 Pain 
increased 
compared 
with baseline 
Not 
estimable
NA Very low Critical
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Quality assessment
Summary of findings Impor-
tance
Number of patients/ Effect Effect Quality
Number  
of studies 
Study design Risk of 
bias
Inconsistency Indirectness Imprecision Other con-
siderations
Pre-IRE Post-IRE Relative 
(95% CI)
Absolute 
(95% CI)
Safety 
Intervention specific mortality 
7 Observational 
(single-arm)
Very 
serious1
Not serious Very serious2 Very serious3 0/226 0/226 (0%) Not 
estimable
NA Very low Critical 
Major adverse events 
7 Observational 
(single-arm)
Very 
serious1 
Very serious (0% 
vs 50%)
Very serious2 Very serious3 0/226 44/226 
(19.47%)
Not 
estimable
NA Very low Critical
Minor adverse events 
7 Observational 
(single-arm)
Very 
serious1
Very serious 
(10% vs 87.5%)
Very serious2 Very serious3 0/226 74/226 
(32.74%)
Not 
estimable
NA Very low Important 
1 Single-arm studies, several bias and lack of information
2 No control group
3 Small sample size
4 Small sample size in most studies, wide CI
5 Only one trial
6 Small sample size, no CI available
Abbreviations: IRE = irreversible electroporation; NA = applicable; QoL = quality of life.
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Table A 12. GRADE assessment of irreversible electroporation in liver cancer (single-arm studies)
Quality assessment
Summary of findings Importance
Number of patients/Effect Effect Quality
Number  
of studies 
Study 
design
Risk of 
bias
Incon-
sistency
Indirectness Imprecision Other consid-
erations ations
Pre-IRE Post-IRE Relative 
(95% CI)
Absolute 
(95% CI)
Effectiveness 
Success of the procedure: Not available
Overall survival 
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 37.92 months 
95% CI: 30.28, 
45.57)
Not 
estimable 
NA Very low Critical 
Overall survival at 3 months
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 96.67% 
(78.61, 99.52)
Not 
estimable 
NA Very low Critical
Overall survival at 6 months
1 Observational 
(single-arm)
Very 
serious1
 NA2 Very serious3 Very serious4 -- 96.67% 
(78.61, 99.52)
Not 
estimable 
NA Very low Critical
Overall survival at 12 months
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 89.76% 
(71.51, 96.58)
Not 
estimable 
NA Very low Critical
Overall survival at 18 months
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 69.05% 
(48.93, 82.54)
Not 
estimable 
NA Very low Critical
Overall survival at 24 months
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 65.21% 
(44.92, 79.58)
Not 
estimable 
NA Very low Critical
Cancer specific survival: Not available
Disease free survival: Not available
Time to recurrence: Not available
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Quality assessment
Summary of findings Importance
Number of patients/Effect Effect Quality
Number  
of studies 
Study 
design
Risk of 
bias
Incon-
sistency
Indirectness Imprecision Other consid-
erations ations
Pre-IRE Post-IRE Relative 
(95% CI)
Absolute 
(95% CI)
Time to progression 
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 15.6 months 
(median)
Not 
estimable 
NA Very low Critical
Time to local recurrence 
1 Observational 
(single-arm)
Very 
serious1
NA2 Very serious3 Very serious4 -- 15.5 months 
(mean)
Not 
estimable 
NA Very low Critical
Health-related quality of life: Not available
Pain: Not available
Safety 
Intervention specific mortality 
6 Observational 
(single-arm)
Very 
serious1
Not 
serious
Very serious3 Very serious4 0/138 0/138 (0%) Not 
estimable
NA Very low Critical 
Major adverse events 
6 Observational 
(single-arm)
Very 
serious1
Very 
serious 
(0% vs 
28.6%)
Very serious3 Very serious4 0/138 12/138 (8.7%) Not 
estimable 
NA Very low Critical 
Minor adverse events 
5 Observational 
(single-arm)
Very 
serious1
Very 
serious 
(10% vs 
100%)
Very serious3 Very serious4 0/124 41/124 
(33.1%)
Not 
estimable 
NA Very low Important
1 Single-arm studies, several bias and lack of information
2 Only one trial
3 No control group
4 Small sample size
Abbreviations: IRE = irreversible electroporation; NA = applicable; QoL = quality of life.
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Applicability tables
Table A 13. Summary table characterising the applicability of a body of studies
Domain Description of applicability of evidence
Population Whilst irreversible electroporation (IRE) is intended to be used as the first line of 
treatment in histologically proven unresectable LAPC patients or patients with primary 
or secondary liver cancer that are not eligible for thermoablation. However, the 
enrolled population was highly heterogeneous in terms of theapplication of IRE. For 
LAPC, some studies restricted IRE to patients unresponsive to standard chemotherapy 
and/or radiochemotherapy treatment and others only applied this technique when 
patients had a favourable survival or when the disease did not progress after previous 
chemotherapy treatment. The majority of liver studies reported that patients had 
received several treatments before IRE, including surgical treatments, systematic 
therapy, radiofrequency/microwave ablation, brachytherapy, radiotherapy and 
transarterial chemoembolization, among others. These reduce the applicability of the 
evidence.
Intervention The Nanoknife System was used in all studies but the treatment algorithm was 
inconsistent across studies. Some studies offered chemotherapy prior IRE others 
chemoradiotherapy or induction chemotherapy and chemoradiotherapy prior to IRE 
and in addition, several applied chemotherapy after IRE. Differences were also noted 
regarding the number of ablative sessions, imaging modalities and IRE technique, not 
existing a formal consensus regarding the considerations that should be taken into 
account in order to identify the tumours for who IRE might be more beneficial. 
Comparators The only one comparative study compared IRE for pancreatic cancer with some 
type of non-curative surgery, including exploratory laparotomy, non-radical resection, 
bypass surgery, cholecystectomy or percutaneous biopsy only. No more information 
regarding the comparator was given. There were no other comparative studies.
Outcomes Included LAPC trials provided few relevant outcome data. Most studies reported on 
mean overall survival after IRE or time to local recurrence after IRE but these are 
not a valid outcome measures given that the time at which IRE was performed and 
the follow-up schemes varied greatly among studies. The definition of success of the 
procedure also differed among studies. With regard to complications/adverse events, 
it was often not stated over what time period they were reported. Some authors did 
not grade adverse events according to severity and the classification of IRE related 
complications was unclear in most of the studies. The follow-up period for these 
outcomes in some of the studies was commonly very short. Overall survival was not 
considered in most liver studies. Therefore, it was not possible to provide conclusions 
about safety or effectiveness of IRE. 
Setting Studies came from different countries from Europe and also from the United States, 
Asia and Australia. Therefore, there is no concern about the applicability of evidence 
related to this aspect. However, clinical settings were not described in the studies. 
Abbreviations: IRE = Irreversible electroporation; LAPC = locally advanced pancreatic cancer, MWA = microwave ablation
Sources: Evidence retrieved for the effectiveness and safety domains.
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS
Table A 14. Regulatory status
Country
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Europe CE mark (Notified 
Body)
Yes Cell membrane 
electroporation 
- March 10, 2010
Australia The Therapeutic 
Goods Administration 
Australian Department 
of Health 
Yes Cell membrane 
electroporation
- January 30, 2013
Canada Health Canada Yes Cell membrane 
electroporation
- May 29, 2009
China National Medical 
Product Administration 
(formerly CFCA)
Yes The intended use of this 
product is surgical ablation 
of liber and pancreatic 
cancer 
- June 18, 2015
Colombia Instituto Nacional 
de Vigilancia de 
Medicamentos y 
Alimentos (INVIMA)
Yes Cell membrane 
electroporation
- June 16, 2016
Costa 
Rica
Ministry of Health Yes Cell membrane 
electroporation
- June 14, 2016
Egypt Egyptian Drug 
Authority 
Yes Cell membrane 
electroporation
- February 12, 2013
Hong 
Kong 
Medical Device Control 
Office (MDCO)
Yes Cell membrane 
electroporation
- October 17, 2014
Israel Israeli Ministry of 
Health (AMAR)
Yes Cell membrane 
electroporation
- August 29, 2012
Mexico Comisión Federal para 
la Protección contra 
Riesgos Sanitarios 
(COFEPRIS)
Yes Cell membrane 
electroporation
- February 7, 2017
New 
Zealand
New Zealand 
Medicines and Medical 
Devices Safety 
Authority (Medsafe)
Yes Cell membrane 
electroporation
- November 17, 2014
Panama Ministry of Health 
of the Republic of 
Panama 
Yes The Nanoknife system with 
six outputs is indicated for 
the surgical ablation of soft 
tiussue 
- May 5, 2018
Peru General Directorate 
of Pharmaceuticals, 
Devices and Drugs 
Yes Cell membrane 
electroporation
- March 22, 2017
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Russia Federal Service 
on Surveillance in 
Healthcare and Social 
Development of the 
Russian Federation 
(ROSZDRAVNADZOR)
Yes Cell membrane 
electroporation
- October 30, 2014
Saudi 
Arabia 
Saudi Food and Drug 
Authority (SFDA)
Yes Cell membrane 
electroporation
- April 10, 2018
Singapore Health Sciences 
Authority (HSA)
Yes Cell membrane 
electroporation
- October 19, 2016
South 
Korea 
The Ministry of Food 
and Drug Safety 
(MFDS)
Yes Cell membrane 
electroporation
- May 24, 2013
Thailand Food and Drug 
Administration of 
Thailand (Thailand 
FDA)
Yes Cell membrane 
electroporation
- August 21, 2017
United 
States of 
America 
Food and Drug 
Administration (FDA)
Yes The Nanoknife System with 
six outputs is indicated for 
the surgical ablation of soft 
tissue 
- November 21, 2006
Abbreviations: CE = Conformité Européenne; FDA = Food and Drug Administration
Sources: (26)
Table A 15. Summary of (reimbursement) recommendations 
in European countries for the technology
Country and  
issuing organisation 
e.g. G-BA, NICE
Summary of (reimbursement)  
recommendations and 
restrictions
Summary of reasons for 
recommendations, rejections 
and restrictions
UK; NICE Negative; research context only 
Germany; Ministry of 
Health 
Positive coverage 2017 Pancreas G-DRG code (€):
• H09B (9,686€)
• H01B (16,320€)
2017 Liver G-DRG code (€):
• H09B (9,686€)
• H12B (5,398€)
Abbreviations: NICE = National Institute for Health and Care Excellence; UK = United Kingdom.
Sources: 
Reimbursement Guide Irreversible Electroporation for Liver and Pancreas. Angiodyamics, Inc. Published January 2017.
Germany Ministry of Health, G-DRG System 2017.
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APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, 
ORGANISATIONAL, PATIENT AND SOCIAL AND LEGAL ASPECTS
1 Ethical
1.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new ethical issues?
No 
1.2 Does comparing the new technology to the defined, existing comparators point to any 
differences that may be ethically relevant?
No 
2 Organisational
2.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) require organisational changes?
Yes
 Introduction of IRE could require some organisational changes as it is required the device 
and the training for the staff, and leads to increased costs
2.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be organisationally relevant?
No
3 Social
3.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new social issues?
No
3.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be socially relevant?
No
4 Legal
4.1 Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any legal issues?
No
4.2 Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be legally relevant?
No
For the purpose of transparency, a separate document with comments on the 2nd draft assess-
ment from external experts and the MAH/manufacturer(s) (fact check), as well as responses 
from authors, is available on the EUnetHTA website.
